data_1ibo_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1ibo _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.237 0 N-CA-C 110.169 -1.172 . . . . 1.0 110.169 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.2 tp -56.4 -47.96 77.92 Favored 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 124.442 1.097 . . . . 1.0 112.638 -170.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -63.58 -46.12 87.29 Favored 'General case' 0 C--N 1.33 -0.239 0 C-N-CA 124.406 1.082 . . . . 1.0 110.227 -177.016 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.33 -51.33 42.88 Favored Glycine 0 CA--C 1.53 1.025 0 CA-C-N 114.034 -1.439 . . . . 1.0 111.536 170.443 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.94 -39.09 90.88 Favored 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 117.953 0.877 . . . . 1.0 112.164 179.419 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.8 mt -63.57 -63.09 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.763 0 C-N-CA 127.568 2.347 . . . . 1.0 107.019 178.013 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.96 -29.44 63.21 Favored 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 112.537 0.569 . . . . 1.0 112.537 178.556 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.74 -53.43 34.73 Favored Glycine 0 CA--C 1.531 1.092 0 CA-C-N 119.447 1.021 . . . . 1.0 111.236 170.1 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -52.92 -30.77 36.39 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 124.955 1.302 . . . . 1.0 112.353 174.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -64.67 -14.04 15.46 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.846 0 C-N-CA 126.754 2.021 . . . . 1.0 111.456 -173.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -122.47 9.74 9.72 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 126.4 1.88 . . . . 1.0 110.749 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -140.37 -41.53 0.42 Allowed 'General case' 0 N--CA 1.465 0.323 0 O-C-N 121.096 -1.002 . . . . 1.0 113.522 -163.208 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -129.08 11.97 6.13 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 124.275 0.94 . . . . 1.0 112.046 175.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 54.0 t-105 -62.55 153.39 32.04 Favored 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 125.564 1.545 . . . . 1.0 113.405 -169.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -161.95 116.67 1.93 Allowed 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 127.391 2.276 . . . . 1.0 106.578 159.083 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 172.63 -3.36 0.03 OUTLIER Glycine 0 CA--C 1.529 0.936 0 C-N-CA 129.066 3.222 . . . . 1.0 111.11 171.457 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 11.8 ttt -144.44 12.08 1.51 Allowed 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 124.3 1.04 . . . . 1.0 113.058 176.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.542 0.647 0 CA-C-O 123.34 1.543 . . . . 1.0 108.34 167.26 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.324 0 N-CA-C 110.127 -1.189 . . . . 1.0 110.127 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.0 tp -56.0 -48.35 76.06 Favored 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 124.414 1.085 . . . . 1.0 112.576 -170.118 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -63.62 -46.73 84.38 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 124.456 1.103 . . . . 1.0 110.192 -176.79 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.68 -49.17 54.43 Favored Glycine 0 CA--C 1.53 1.004 0 CA-C-N 114.022 -1.445 . . . . 1.0 111.6 171.043 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -63.76 -39.81 95.18 Favored 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 118.198 0.999 . . . . 1.0 111.925 178.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.2 mt -63.63 -63.05 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.775 0 C-N-CA 127.434 2.294 . . . . 1.0 107.173 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.27 -34.13 68.34 Favored 'General case' 0 CA--C 1.542 0.641 0 CA-C-O 119.33 -0.367 . . . . 1.0 111.648 177.696 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -59.25 -50.67 65.33 Favored Glycine 0 CA--C 1.531 1.055 0 O-C-N 120.65 -1.281 . . . . 1.0 111.271 172.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -54.43 -33.04 58.68 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 124.186 0.994 . . . . 1.0 111.86 173.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -66.71 -14.65 18.21 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.916 0 C-N-CA 126.115 1.766 . . . . 1.0 110.065 -173.023 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -111.44 -1.17 16.01 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.331 1.452 . . . . 1.0 112.154 177.619 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 49.1 m-80 -138.05 -43.11 0.52 Allowed 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 119.623 1.101 . . . . 1.0 113.202 -159.186 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -121.29 8.92 10.26 Favored Glycine 0 CA--C 1.526 0.738 0 C-N-CA 124.133 0.873 . . . . 1.0 111.724 176.578 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.435 ' HE1' ' HB3' ' A' ' 17' ' ' MET . 55.1 t-105 -62.59 154.53 28.71 Favored 'General case' 0 N--CA 1.444 -0.726 0 C-N-CA 125.472 1.509 . . . . 1.0 113.028 -170.736 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -160.73 116.42 2.25 Favored 'General case' 0 N--CA 1.44 -0.95 0 C-N-CA 125.797 1.639 . . . . 1.0 106.977 159.048 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 175.38 -7.99 0.03 OUTLIER Glycine 0 CA--C 1.53 0.979 0 C-N-CA 128.98 3.181 . . . . 1.0 110.642 168.095 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' MET . . . . . 0.435 ' HB3' ' HE1' ' A' ' 14' ' ' TRP . 8.0 tpt -133.1 8.41 4.04 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 125.174 1.39 . . . . 1.0 113.451 177.59 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.6 mp . . . . . 0 CA--C 1.542 0.665 0 CA-C-O 123.123 1.44 . . . . 1.0 108.288 170.223 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.199 0 N-CA-C 109.956 -1.258 . . . . 1.0 109.956 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.4 tp -56.12 -48.83 75.46 Favored 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 124.519 1.128 . . . . 1.0 112.582 -171.153 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.2 t80 -63.62 -45.58 89.65 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 124.585 1.154 . . . . 1.0 109.988 -176.069 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.39 -50.27 53.38 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-N 114.026 -1.443 . . . . 1.0 111.648 170.525 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.83 -38.73 91.94 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 118.101 0.95 . . . . 1.0 112.134 178.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.2 mt -63.46 -63.18 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.774 0 C-N-CA 127.606 2.362 . . . . 1.0 106.877 178.268 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.68 -34.75 67.7 Favored 'General case' 0 CA--C 1.543 0.677 0 CA-C-O 119.263 -0.398 . . . . 1.0 111.809 178.375 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -60.6 -49.92 73.26 Favored Glycine 0 CA--C 1.531 1.047 0 O-C-N 120.667 -1.271 . . . . 1.0 111.348 172.691 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -55.39 -31.29 61.7 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 124.2 1.0 . . . . 1.0 112.064 173.191 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -67.59 -14.24 17.95 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.91 0 C-N-CA 125.761 1.624 . . . . 1.0 109.737 -173.799 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -110.08 -0.79 17.85 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 125.503 1.521 . . . . 1.0 111.94 177.592 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 50.3 m-80 -139.55 -41.68 0.45 Allowed 'General case' 0 N--CA 1.472 0.651 0 CA-C-N 119.74 1.155 . . . . 1.0 113.398 -159.259 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -124.45 9.05 8.29 Favored Glycine 0 CA--C 1.527 0.815 0 C-N-CA 124.222 0.915 . . . . 1.0 111.892 177.089 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 50.4 t-105 -60.21 154.68 19.19 Favored 'General case' 0 N--CA 1.446 -0.641 0 C-N-CA 125.789 1.636 . . . . 1.0 113.469 -171.393 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -160.83 116.56 2.23 Favored 'General case' 0 N--CA 1.44 -0.946 0 C-N-CA 125.703 1.601 . . . . 1.0 107.308 158.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 170.51 3.61 0.03 OUTLIER Glycine 0 CA--C 1.528 0.845 0 C-N-CA 128.554 2.978 . . . . 1.0 111.656 165.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 15.1 ttp -143.86 14.35 1.72 Allowed 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.017 1.327 . . . . 1.0 112.654 175.469 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.1 mp . . . . . 0 CA--C 1.537 0.462 0 CA-C-O 122.914 1.34 . . . . 1.0 108.095 167.542 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.313 0 N-CA-C 110.219 -1.152 . . . . 1.0 110.219 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.6 tp -56.39 -48.63 76.5 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 124.605 1.162 . . . . 1.0 112.57 -171.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.4 t80 -63.57 -45.86 88.53 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 124.348 1.059 . . . . 1.0 109.97 -177.129 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -51.67 -51.05 40.41 Favored Glycine 0 CA--C 1.531 1.038 0 CA-C-N 114.017 -1.447 . . . . 1.0 111.689 170.169 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.58 -39.45 93.74 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 118.26 1.03 . . . . 1.0 112.124 179.563 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.56 -63.05 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.763 0 C-N-CA 127.442 2.297 . . . . 1.0 106.969 178.23 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.04 -32.14 63.78 Favored 'General case' 0 CA--C 1.541 0.631 0 O-C-N 122.021 -0.424 . . . . 1.0 112.132 177.489 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -61.51 -52.84 48.54 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-N 119.951 1.251 . . . . 1.0 111.088 171.093 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -51.72 -33.67 35.47 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 124.192 0.997 . . . . 1.0 112.069 174.299 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -64.08 -13.96 14.55 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.907 0 C-N-CA 126.801 2.04 . . . . 1.0 111.333 -172.823 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -126.63 6.76 6.83 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 125.733 1.613 . . . . 1.0 111.711 178.517 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -139.23 -32.45 0.66 Allowed 'General case' 0 N--CA 1.471 0.61 0 O-C-N 121.231 -0.918 . . . . 1.0 112.805 -163.71 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -137.32 13.65 3.76 Favored Glycine 0 CA--C 1.526 0.735 0 C-N-CA 124.338 0.97 . . . . 1.0 111.627 174.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 56.8 t-105 -56.47 157.16 5.32 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 126.278 1.831 . . . . 1.0 113.648 -168.556 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -157.39 115.04 3.09 Favored 'General case' 0 N--CA 1.436 -1.171 0 N-CA-C 101.663 -3.458 . . . . 1.0 101.663 176.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 149.86 -4.01 0.62 Allowed Glycine 0 CA--C 1.531 1.045 0 C-N-CA 125.059 1.314 . . . . 1.0 114.866 167.637 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 15.7 ttt -130.75 9.72 5.02 Favored 'General case' 0 CA--C 1.54 0.576 0 CA-C-N 118.847 1.324 . . . . 1.0 111.961 172.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.2 mp . . . . . 0 CA--C 1.539 0.522 0 N-CA-C 107.51 -1.293 . . . . 1.0 107.51 -179.957 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.251 0 N-CA-C 109.917 -1.273 . . . . 1.0 109.917 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 8.4 tp -54.83 -50.49 68.46 Favored 'General case' 0 N--CA 1.467 0.388 0 C-N-CA 124.586 1.154 . . . . 1.0 112.76 -169.581 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.2 t80 -63.71 -46.79 83.84 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 124.17 0.988 . . . . 1.0 110.383 -175.129 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.16 -51.03 49.25 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-N 114.032 -1.44 . . . . 1.0 111.428 171.408 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -60.97 -40.63 94.13 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 123.682 0.793 . . . . 1.0 111.835 178.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.3 mt -63.43 -63.21 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.794 0 C-N-CA 127.511 2.324 . . . . 1.0 107.082 178.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.99 -33.22 66.91 Favored 'General case' 0 CA--C 1.542 0.65 0 CA-C-O 118.999 -0.524 . . . . 1.0 112.148 179.634 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.37 -50.92 58.71 Favored Glycine 0 CA--C 1.532 1.097 0 CA-C-N 120.062 1.301 . . . . 1.0 111.339 171.431 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -53.42 -30.63 41.35 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 124.457 1.103 . . . . 1.0 112.22 173.744 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -66.93 -13.72 16.97 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.921 0 C-N-CA 126.27 1.828 . . . . 1.0 110.546 -173.645 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -112.18 1.72 16.35 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 125.054 1.342 . . . . 1.0 111.905 176.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 12.5 t30 -139.09 -48.64 0.49 Allowed 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 119.353 0.978 . . . . 1.0 112.862 -159.547 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -118.71 9.86 12.61 Favored Glycine 0 CA--C 1.527 0.833 0 C-N-CA 124.303 0.954 . . . . 1.0 111.965 178.117 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 65.0 t-105 -56.93 164.93 1.38 Allowed 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 126.395 1.878 . . . . 1.0 114.55 -168.372 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -150.13 91.16 1.74 Allowed 'General case' 0 N--CA 1.442 -0.869 0 C-N-CA 125.054 1.342 . . . . 1.0 111.265 -175.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 165.94 -16.13 0.09 OUTLIER Glycine 0 CA--C 1.529 0.942 0 CA-C-N 115.405 -0.816 . . . . 1.0 114.734 165.053 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 1.3 mpt? -107.69 6.78 28.04 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 124.38 1.072 . . . . 1.0 111.766 175.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.6 mp . . . . . 0 CA--C 1.539 0.525 0 N-CA-C 106.844 -1.539 . . . . 1.0 106.844 -174.5 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.21 0 N-CA-C 110.155 -1.178 . . . . 1.0 110.155 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 8.7 tp -54.91 -49.05 72.22 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 124.522 1.129 . . . . 1.0 112.695 -169.147 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 12.2 t80 -63.76 -47.17 82.07 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 124.319 1.048 . . . . 1.0 110.538 -175.377 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.21 -51.11 48.96 Favored Glycine 0 CA--C 1.53 1.021 0 CA-C-N 114.072 -1.422 . . . . 1.0 111.287 171.187 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.19 -39.53 90.52 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 117.74 0.77 . . . . 1.0 111.952 179.28 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.47 -63.1 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.78 0 C-N-CA 127.654 2.381 . . . . 1.0 107.143 178.174 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.48 -29.93 64.67 Favored 'General case' 0 CA--C 1.539 0.543 0 N-CA-C 112.714 0.635 . . . . 1.0 112.714 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.58 -52.68 32.89 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-N 119.702 1.137 . . . . 1.0 111.206 170.094 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -52.43 -28.61 20.65 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 124.64 1.176 . . . . 1.0 112.3 174.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -64.83 -13.1 14.16 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.871 0 C-N-CA 125.98 1.712 . . . . 1.0 110.887 -175.568 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -126.82 6.94 6.71 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 126.357 1.863 . . . . 1.0 111.371 175.032 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 -147.69 90.61 1.87 Allowed 'General case' 0 C--N 1.341 0.196 0 O-C-N 120.956 -1.09 . . . . 1.0 109.291 -165.034 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 77.35 12.7 84.32 Favored Glycine 0 CA--C 1.532 1.124 0 CA-C-O 118.632 -1.094 . . . . 1.0 112.378 -169.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.412 ' HE1' ' CB ' ' A' ' 17' ' ' MET . 55.8 t-105 -51.99 156.15 1.62 Allowed 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.492 1.517 . . . . 1.0 112.967 176.62 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -159.1 101.92 1.6 Allowed 'General case' 0 N--CA 1.445 -0.711 0 C-N-CA 126.241 1.816 . . . . 1.0 106.327 -179.224 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 159.5 -5.79 0.12 Allowed Glycine 0 CA--C 1.53 1.03 0 CA-C-O 118.861 -0.966 . . . . 1.0 115.254 171.373 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' MET . . . . . 0.412 ' CB ' ' HE1' ' A' ' 14' ' ' TRP . 13.3 ttt -128.52 11.19 6.26 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 118.92 1.36 . . . . 1.0 111.947 174.095 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.7 mp . . . . . 0 CA--C 1.538 0.503 0 C-N-CA 124.977 1.311 . . . . 1.0 107.473 179.411 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.254 0 N-CA-C 110.165 -1.174 . . . . 1.0 110.165 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.5 tp -56.19 -48.63 76.01 Favored 'General case' 0 N--CA 1.468 0.449 0 C-N-CA 124.494 1.118 . . . . 1.0 112.659 -171.635 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -63.64 -45.42 90.32 Favored 'General case' 0 N--CA 1.455 -0.206 0 C-N-CA 124.18 0.992 . . . . 1.0 109.724 -178.11 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -50.74 -50.42 37.33 Favored Glycine 0 CA--C 1.532 1.13 0 CA-C-N 114.138 -1.392 . . . . 1.0 112.124 170.169 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -63.0 -41.53 99.61 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 118.143 0.972 . . . . 1.0 111.854 179.253 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.56 -63.01 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.843 0 C-N-CA 127.339 2.255 . . . . 1.0 106.695 179.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -54.25 -37.59 64.84 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.636 0.774 . . . . 1.0 111.814 177.332 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.34 -51.73 55.89 Favored Glycine 0 CA--C 1.531 1.049 0 CA-C-N 119.825 1.193 . . . . 1.0 111.42 173.346 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -58.46 -26.43 63.35 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 124.244 1.018 . . . . 1.0 112.712 174.031 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -68.91 -18.24 22.81 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.78 0 CA-C-N 119.776 1.171 . . . . 1.0 110.604 -172.123 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -109.53 0.73 19.35 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 125.873 1.669 . . . . 1.0 111.576 173.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 13.3 t-20 -152.05 95.84 2.12 Favored 'General case' 0 C--N 1.344 0.335 0 O-C-N 120.567 -1.333 . . . . 1.0 110.182 -159.287 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 74.94 11.16 83.92 Favored Glycine 0 CA--C 1.531 1.058 0 CA-C-O 118.583 -1.12 . . . . 1.0 112.414 -170.479 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.402 ' HE1' ' HB3' ' A' ' 17' ' ' MET . 59.3 t-105 -50.25 154.96 1.08 Allowed 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 125.513 1.525 . . . . 1.0 113.105 175.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -159.22 100.63 1.54 Allowed 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 106.045 -1.835 . . . . 1.0 106.045 -178.146 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 162.51 -6.84 0.08 OUTLIER Glycine 0 CA--C 1.532 1.133 0 CA-C-O 118.762 -1.021 . . . . 1.0 115.278 173.369 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' MET . . . . . 0.402 ' HB3' ' HE1' ' A' ' 14' ' ' TRP . 30.6 ttp -129.76 9.69 5.46 Favored 'General case' 0 CA--C 1.539 0.519 0 CA-C-N 119.128 1.464 . . . . 1.0 111.975 175.244 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.6 mp . . . . . 0 CA--C 1.538 0.506 0 N-CA-C 107.314 -1.365 . . . . 1.0 107.314 -178.02 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.329 0 N-CA-C 110.027 -1.229 . . . . 1.0 110.027 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.5 tp -57.98 -47.65 82.36 Favored 'General case' 0 N--CA 1.466 0.365 0 C-N-CA 124.25 1.02 . . . . 1.0 112.325 -172.212 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.6 t80 -63.59 -44.75 93.13 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 124.306 1.042 . . . . 1.0 109.759 -177.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -51.63 -50.64 41.9 Favored Glycine 0 CA--C 1.533 1.191 0 CA-C-N 114.241 -1.345 . . . . 1.0 112.044 170.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -63.1 -40.07 96.56 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 118.369 1.084 . . . . 1.0 112.147 179.667 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.0 mt -63.58 -62.93 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.773 0 C-N-CA 127.673 2.389 . . . . 1.0 106.433 178.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -53.85 -32.46 53.05 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 123.599 0.76 . . . . 1.0 112.278 175.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.57 -53.98 40.78 Favored Glycine 0 CA--C 1.53 0.992 0 CA-C-N 119.81 1.186 . . . . 1.0 111.158 171.614 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -56.04 -28.01 55.63 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 123.657 0.783 . . . . 1.0 112.443 174.406 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -69.0 -10.27 13.16 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.889 0 C-N-CA 124.798 1.239 . . . . 1.0 110.446 -174.163 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -123.81 8.53 8.78 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 126.972 2.109 . . . . 1.0 110.946 176.452 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -156.46 92.99 1.36 Allowed 'General case' 0 C--N 1.343 0.294 0 O-C-N 120.513 -1.367 . . . . 1.0 109.285 -169.436 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 85.16 6.49 84.48 Favored Glycine 0 CA--C 1.53 0.988 0 CA-C-O 118.749 -1.028 . . . . 1.0 112.663 -172.183 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 55.3 t-105 -55.79 155.14 6.22 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 124.739 1.216 . . . . 1.0 112.525 176.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -162.16 104.06 1.13 Allowed 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 105.421 -2.066 . . . . 1.0 105.421 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 162.07 -8.59 0.1 OUTLIER Glycine 0 CA--C 1.528 0.895 0 CA-C-O 118.939 -0.923 . . . . 1.0 115.048 174.581 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 31.7 ttm -132.09 8.34 4.38 Favored 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 118.913 1.356 . . . . 1.0 112.257 174.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.535 0.375 0 C-N-CA 124.695 1.198 . . . . 1.0 108.955 -179.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.245 0 N-CA-C 110.211 -1.155 . . . . 1.0 110.211 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.9 tp -56.12 -48.85 75.41 Favored 'General case' 0 N--CA 1.467 0.388 0 C-N-CA 124.613 1.165 . . . . 1.0 112.604 -170.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.5 t80 -63.63 -46.05 87.45 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 124.341 1.056 . . . . 1.0 110.068 -176.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.55 -50.05 49.98 Favored Glycine 0 CA--C 1.53 1.015 0 CA-C-N 114.194 -1.367 . . . . 1.0 111.667 170.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.0 -40.94 97.36 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 118.174 0.987 . . . . 1.0 111.944 178.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.2 mt -63.58 -63.18 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.782 0 C-N-CA 127.509 2.324 . . . . 1.0 107.251 179.267 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -58.13 -29.17 65.33 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 123.508 0.723 . . . . 1.0 112.484 178.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.62 -54.29 29.78 Favored Glycine 0 CA--C 1.529 0.951 0 CA-C-N 119.464 1.029 . . . . 1.0 110.832 170.038 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -52.24 -28.62 19.35 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 124.413 1.085 . . . . 1.0 112.42 174.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -65.99 -11.63 12.92 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.867 0 C-N-CA 125.825 1.65 . . . . 1.0 111.016 -175.213 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -126.81 8.25 6.84 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 126.663 1.985 . . . . 1.0 110.877 174.32 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -148.1 83.53 1.51 Allowed 'General case' 0 C--O 1.234 0.274 0 O-C-N 120.817 -1.177 . . . . 1.0 108.719 -166.69 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 88.33 7.38 72.91 Favored Glycine 0 CA--C 1.531 1.054 0 CA-C-O 118.992 -0.893 . . . . 1.0 112.587 -173.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 55.8 t-105 -52.87 155.23 2.46 Favored 'General case' 0 N--CA 1.452 -0.336 0 C-N-CA 125.655 1.582 . . . . 1.0 113.185 175.698 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -160.35 102.65 1.4 Allowed 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 126.275 1.83 . . . . 1.0 106.124 178.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 167.92 -17.44 0.08 OUTLIER Glycine 0 CA--C 1.529 0.94 0 CA-C-O 118.842 -0.977 . . . . 1.0 114.959 170.247 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -126.68 19.14 7.31 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-N 118.828 1.314 . . . . 1.0 112.662 175.607 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.4 mp . . . . . 0 CA--C 1.537 0.465 0 N-CA-C 106.853 -1.536 . . . . 1.0 106.853 172.736 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.238 0 N-CA-C 109.808 -1.317 . . . . 1.0 109.808 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 14.9 tp -55.45 -51.4 67.06 Favored 'General case' 0 N--CA 1.466 0.351 0 C-N-CA 124.836 1.254 . . . . 1.0 113.068 -169.064 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.5 t80 -63.8 -46.25 86.0 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 124.155 0.982 . . . . 1.0 110.136 -176.348 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.73 -49.18 54.69 Favored Glycine 0 CA--C 1.532 1.12 0 CA-C-N 114.02 -1.446 . . . . 1.0 111.723 171.046 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.81 -40.26 96.83 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 118.059 0.93 . . . . 1.0 111.751 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.55 -63.02 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.835 0 C-N-CA 127.318 2.247 . . . . 1.0 106.969 178.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -55.93 -34.39 65.57 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 122.991 0.516 . . . . 1.0 112.141 178.296 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -61.91 -50.96 60.48 Favored Glycine 0 CA--C 1.531 1.089 0 O-C-N 120.817 -1.177 . . . . 1.0 111.328 172.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -56.81 -25.03 54.85 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 124.505 1.122 . . . . 1.0 112.58 173.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -68.43 -16.32 20.82 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.948 0 C-N-CA 124.571 1.148 . . . . 1.0 110.415 -172.779 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -110.69 1.85 18.17 Favored 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 125.752 1.621 . . . . 1.0 111.439 172.553 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -150.32 81.97 1.36 Allowed 'General case' 0 C--O 1.235 0.337 0 O-C-N 120.969 -1.082 . . . . 1.0 108.95 -160.454 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 95.41 -0.18 63.4 Favored Glycine 0 CA--C 1.53 0.988 0 CA-C-O 118.947 -0.918 . . . . 1.0 112.789 -176.18 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 57.5 t-105 -54.61 154.47 4.86 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 125.06 1.344 . . . . 1.0 112.661 173.257 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -158.09 116.53 3.08 Favored 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 125.729 1.612 . . . . 1.0 107.065 159.08 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 173.19 4.11 0.03 OUTLIER Glycine 0 CA--C 1.527 0.816 0 C-N-CA 128.582 2.991 . . . . 1.0 111.829 165.162 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 22.0 ttp -143.67 10.05 1.59 Allowed 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 125.173 1.389 . . . . 1.0 112.995 178.145 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.4 mp . . . . . 0 CA--C 1.54 0.588 0 CA-C-O 122.723 1.249 . . . . 1.0 107.635 172.311 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.266 0 N-CA-C 110.112 -1.195 . . . . 1.0 110.112 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.3 tp -55.66 -49.13 73.73 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 124.656 1.182 . . . . 1.0 112.755 -170.506 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -63.63 -46.92 83.5 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 124.251 1.02 . . . . 1.0 110.134 -176.648 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.05 -50.06 46.81 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-N 114.083 -1.417 . . . . 1.0 111.61 171.16 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.26 -41.17 98.21 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 117.986 0.893 . . . . 1.0 111.928 178.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.2 mt -63.48 -63.24 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 C-N-CA 127.458 2.303 . . . . 1.0 107.196 179.606 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.87 -33.04 68.27 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 122.887 0.475 . . . . 1.0 111.98 179.014 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -61.0 -52.4 52.49 Favored Glycine 0 CA--C 1.53 1.004 0 CA-C-N 119.883 1.219 . . . . 1.0 111.09 171.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -54.4 -27.82 39.33 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 124.096 0.958 . . . . 1.0 112.396 173.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -68.38 -12.12 15.33 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.956 0 C-N-CA 125.199 1.399 . . . . 1.0 110.161 -174.595 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -117.11 1.77 12.57 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 125.92 1.688 . . . . 1.0 111.516 173.431 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -149.53 84.3 1.42 Allowed 'General case' 0 C--O 1.234 0.261 0 O-C-N 121.111 -0.993 . . . . 1.0 108.573 -160.167 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 87.68 6.73 76.31 Favored Glycine 0 CA--C 1.531 1.041 0 CA-C-O 118.725 -1.042 . . . . 1.0 112.613 -174.034 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 54.6 t-105 -53.68 152.49 5.2 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 124.878 1.271 . . . . 1.0 112.208 173.386 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -158.48 116.56 2.96 Favored 'General case' 0 N--CA 1.441 -0.924 0 C-N-CA 125.81 1.644 . . . . 1.0 107.042 159.147 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 172.4 5.28 0.03 OUTLIER Glycine 0 CA--C 1.528 0.882 0 C-N-CA 129.248 3.308 . . . . 1.0 111.747 168.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 23.2 ttm -147.91 10.77 0.93 Allowed 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 125.054 1.341 . . . . 1.0 113.329 178.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.1 mp . . . . . 0 CA--C 1.544 0.745 0 N-CA-C 106.581 -1.637 . . . . 1.0 106.581 172.225 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.313 0 N-CA-C 110.478 -1.049 . . . . 1.0 110.478 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.4 tp -55.83 -48.19 75.91 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 124.528 1.131 . . . . 1.0 112.578 -170.543 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -63.65 -45.51 89.85 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 124.567 1.147 . . . . 1.0 110.123 -176.424 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.01 -50.89 49.33 Favored Glycine 0 CA--C 1.531 1.087 0 CA-C-N 113.973 -1.467 . . . . 1.0 111.595 170.302 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.8 -38.6 91.3 Favored 'General case' 0 CA--C 1.535 0.396 0 CA-C-N 118.126 0.963 . . . . 1.0 112.072 179.22 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.7 mt -63.58 -62.96 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 C-N-CA 127.516 2.326 . . . . 1.0 106.717 178.376 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.66 -34.21 69.13 Favored 'General case' 0 CA--C 1.541 0.635 0 CA-C-O 119.134 -0.46 . . . . 1.0 111.793 179.124 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -60.0 -50.21 70.16 Favored Glycine 0 CA--C 1.532 1.14 0 CA-C-N 120.049 1.295 . . . . 1.0 111.235 172.36 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -54.75 -31.06 58.04 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 124.242 1.017 . . . . 1.0 112.143 173.845 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -68.21 -11.83 14.87 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.822 0 C-N-CA 126.463 1.905 . . . . 1.0 111.112 -172.189 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -121.1 6.65 10.28 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.788 1.635 . . . . 1.0 111.348 176.714 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 27.1 t-20 -138.84 -45.87 0.48 Allowed 'General case' 0 N--CA 1.466 0.336 0 O-C-N 121.312 -0.867 . . . . 1.0 113.29 -161.665 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.24 14.49 8.29 Favored Glycine 0 CA--C 1.528 0.863 0 C-N-CA 124.687 1.137 . . . . 1.0 111.477 175.806 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 57.7 t-105 -60.13 163.05 5.17 Favored 'General case' 0 N--CA 1.447 -0.582 0 C-N-CA 126.281 1.832 . . . . 1.0 113.845 -168.017 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -150.06 95.48 2.29 Favored 'General case' 0 N--CA 1.445 -0.715 0 C-N-CA 125.271 1.429 . . . . 1.0 108.127 177.131 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 166.72 -5.0 0.05 OUTLIER Glycine 0 CA--C 1.534 1.27 0 N-CA-C 117.085 1.594 . . . . 1.0 117.085 171.562 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' MET . . . . . 0.527 ' H ' HD11 ' A' ' 18' ' ' ILE . 4.0 ppp? -130.68 9.68 5.05 Favored 'General case' 0 N--CA 1.475 0.786 0 CA-C-N 119.541 1.67 . . . . 1.0 113.628 167.831 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.527 HD11 ' H ' ' A' ' 17' ' ' MET . 0.5 OUTLIER . . . . . 0 CA--C 1.541 0.621 0 N-CA-C 107.543 -1.28 . . . . 1.0 107.543 -176.615 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.225 0 N-CA-C 110.131 -1.188 . . . . 1.0 110.131 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.1 tp -55.04 -49.13 72.34 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 124.625 1.17 . . . . 1.0 112.582 -170.778 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -63.77 -46.75 83.83 Favored 'General case' 0 C--N 1.331 -0.199 0 C-N-CA 124.325 1.05 . . . . 1.0 110.327 -176.316 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.52 -49.3 57.84 Favored Glycine 0 CA--C 1.531 1.071 0 CA-C-N 114.168 -1.378 . . . . 1.0 111.48 171.703 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.58 -39.78 94.79 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-N 117.989 0.895 . . . . 1.0 111.932 178.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.6 mt -63.75 -63.05 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.801 0 C-N-CA 127.524 2.33 . . . . 1.0 106.866 178.578 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.44 -31.63 66.09 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 122.972 0.509 . . . . 1.0 112.256 179.009 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.72 -51.55 52.95 Favored Glycine 0 CA--C 1.53 1.0 0 CA-C-N 119.954 1.252 . . . . 1.0 111.018 171.09 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -54.12 -26.68 28.7 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 124.072 0.949 . . . . 1.0 112.36 173.671 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -67.76 -10.04 11.72 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.878 0 C-N-CA 125.175 1.39 . . . . 1.0 110.59 -175.372 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -127.16 6.76 6.48 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 126.524 1.93 . . . . 1.0 111.376 173.788 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 13.1 t-20 -148.51 93.36 2.13 Favored 'General case' 0 C--N 1.342 0.239 0 O-C-N 120.81 -1.181 . . . . 1.0 109.691 -164.384 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 76.93 10.84 85.99 Favored Glycine 0 CA--C 1.533 1.187 0 CA-C-O 118.979 -0.901 . . . . 1.0 112.199 -167.623 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 53.2 t-105 -53.82 161.09 1.22 Allowed 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 126.06 1.744 . . . . 1.0 113.228 176.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -152.49 98.08 2.33 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 125.579 1.552 . . . . 1.0 107.754 177.391 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 161.3 -4.44 0.09 OUTLIER Glycine 0 CA--C 1.531 1.074 0 N-CA-C 116.29 1.276 . . . . 1.0 116.29 170.026 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' MET . . . . . 0.456 ' H ' HD12 ' A' ' 18' ' ' ILE . 4.3 ppp? -116.65 -0.9 12.25 Favored 'General case' 0 N--CA 1.47 0.551 0 CA-C-N 119.17 1.485 . . . . 1.0 112.695 169.451 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.456 HD12 ' H ' ' A' ' 17' ' ' MET . 1.4 mp . . . . . 0 CA--C 1.543 0.69 0 CA-C-O 123.281 1.515 . . . . 1.0 107.54 -168.076 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.173 0 N-CA-C 110.186 -1.165 . . . . 1.0 110.186 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.7 tp -55.84 -50.25 71.08 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 124.89 1.276 . . . . 1.0 112.963 -170.225 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.2 t80 -63.53 -47.93 79.62 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 124.077 0.951 . . . . 1.0 110.241 -176.806 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -50.89 -50.46 38.05 Favored Glycine 0 CA--C 1.53 0.969 0 CA-C-N 114.087 -1.415 . . . . 1.0 111.485 171.338 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.01 -43.23 99.19 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 117.896 0.848 . . . . 1.0 111.722 178.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.4 mt -63.51 -63.31 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.673 0 C-N-CA 127.246 2.218 . . . . 1.0 107.55 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -60.73 -27.85 68.23 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 123.579 0.752 . . . . 1.0 112.524 -179.226 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.55 -55.16 21.95 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 110.655 -0.978 . . . . 1.0 110.655 169.697 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -51.22 -31.41 20.46 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 124.657 1.183 . . . . 1.0 112.297 176.124 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -60.07 -17.53 14.03 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.737 0 C-N-CA 126.631 1.973 . . . . 1.0 111.615 -174.263 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -129.58 9.84 5.56 Favored 'General case' 0 CA--C 1.545 0.767 0 C-N-CA 125.942 1.697 . . . . 1.0 110.391 177.36 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -147.6 78.91 1.47 Allowed 'General case' 0 C--O 1.234 0.279 0 C-N-CA 124.869 1.268 . . . . 1.0 108.905 -170.055 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 98.96 -3.16 58.48 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-O 119.198 -0.779 . . . . 1.0 112.875 -177.65 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 24.6 t-105 -55.17 155.76 4.59 Favored 'General case' 0 N--CA 1.456 -0.174 0 C-N-CA 124.795 1.238 . . . . 1.0 112.321 168.362 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -157.01 116.23 3.38 Favored 'General case' 0 N--CA 1.428 -1.572 0 C-N-CA 124.875 1.27 . . . . 1.0 108.156 158.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -160.61 -102.68 0.18 Allowed Glycine 0 CA--C 1.524 0.598 0 C-N-CA 125.557 1.551 . . . . 1.0 109.487 169.639 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 4.8 mpp? -71.03 6.75 1.43 Allowed 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 124.718 1.207 . . . . 1.0 113.242 -177.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.6 mt . . . . . 0 CA--C 1.533 0.3 0 N-CA-C 105.769 -1.937 . . . . 1.0 105.769 176.22 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.306 0 N-CA-C 110.225 -1.15 . . . . 1.0 110.225 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.1 tp -56.86 -49.18 76.24 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 124.57 1.148 . . . . 1.0 112.596 -171.268 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -63.65 -45.52 89.83 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 124.45 1.1 . . . . 1.0 110.128 -176.706 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.98 -50.16 56.07 Favored Glycine 0 CA--C 1.532 1.115 0 CA-C-N 114.031 -1.44 . . . . 1.0 111.497 171.097 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.08 -38.31 88.36 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 118.044 0.922 . . . . 1.0 112.095 179.145 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.9 mt -63.58 -63.22 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.694 0 C-N-CA 127.855 2.462 . . . . 1.0 107.299 176.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.8 -26.53 58.12 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 113.062 0.764 . . . . 1.0 113.062 177.773 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -67.32 -56.02 13.48 Favored Glycine 0 CA--C 1.531 1.073 0 CA-C-N 119.312 0.96 . . . . 1.0 111.066 168.35 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -47.98 -34.41 9.24 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 125.687 1.595 . . . . 1.0 112.193 175.058 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -57.29 -19.98 11.97 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.771 0 C-N-CA 127.336 2.254 . . . . 1.0 111.629 -175.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -132.15 15.09 4.66 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 126.783 2.033 . . . . 1.0 111.275 -178.355 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 21.4 t-20 -137.31 -33.45 0.74 Allowed 'General case' 0 N--CA 1.467 0.405 0 O-C-N 121.352 -0.842 . . . . 1.0 113.236 -170.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -139.42 9.21 3.2 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-O 119.017 -0.88 . . . . 1.0 112.53 174.647 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.417 ' HE1' HG13 ' A' ' 18' ' ' ILE . 35.3 t-105 -62.51 145.35 54.49 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 118.152 0.976 . . . . 1.0 113.271 -173.01 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 48.0 mt-10 -155.11 114.47 3.66 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 105.32 -2.104 . . . . 1.0 105.32 158.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -167.06 -24.79 0.02 OUTLIER Glycine 0 CA--C 1.53 0.982 0 N-CA-C 115.603 1.001 . . . . 1.0 115.603 168.738 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -133.74 -0.41 3.16 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 118.669 1.235 . . . . 1.0 112.962 172.235 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.417 HG13 ' HE1' ' A' ' 14' ' ' TRP . 59.8 mt . . . . . 0 CA--C 1.532 0.26 0 N-CA-C 105.147 -2.168 . . . . 1.0 105.147 -176.221 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.371 0 N-CA-C 109.89 -1.284 . . . . 1.0 109.89 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.3 tp -56.28 -48.58 76.34 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 124.419 1.088 . . . . 1.0 112.594 -170.552 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.1 t80 -63.7 -47.23 82.02 Favored 'General case' 0 N--CA 1.455 -0.206 0 C-N-CA 124.401 1.08 . . . . 1.0 110.105 -176.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -51.73 -50.61 42.61 Favored Glycine 0 CA--C 1.531 1.068 0 CA-C-N 114.178 -1.374 . . . . 1.0 111.538 171.156 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.18 -40.51 96.29 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 117.966 0.883 . . . . 1.0 112.031 179.197 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.9 mt -63.59 -63.18 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.704 0 C-N-CA 127.662 2.385 . . . . 1.0 107.061 178.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -58.84 -28.42 66.05 Favored 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 123.432 0.693 . . . . 1.0 112.513 179.261 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.1 -54.84 25.13 Favored Glycine 0 CA--C 1.528 0.894 0 CA-C-N 119.331 0.969 . . . . 1.0 110.762 169.782 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -51.92 -29.83 21.83 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 124.582 1.153 . . . . 1.0 112.478 175.443 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -61.98 -17.41 17.56 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.876 0 C-N-CA 126.055 1.742 . . . . 1.0 110.916 -175.432 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -123.17 6.45 9.16 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 127.04 2.136 . . . . 1.0 110.634 176.663 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -148.22 80.59 1.47 Allowed 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.596 1.159 . . . . 1.0 108.882 -167.265 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 96.29 -5.54 65.42 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 124.029 0.823 . . . . 1.0 113.049 -179.203 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.479 ' HE1' HG13 ' A' ' 18' ' ' ILE . 3.7 t-105 -60.03 155.24 17.34 Favored 'General case' 0 N--CA 1.456 -0.158 0 CA-C-N 118.027 0.913 . . . . 1.0 112.083 166.701 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -158.74 115.98 2.81 Favored 'General case' 0 N--CA 1.428 -1.534 0 C-N-CA 125.515 1.526 . . . . 1.0 107.784 158.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -168.79 -26.07 0.02 OUTLIER Glycine 0 CA--C 1.53 1.013 0 N-CA-C 115.57 0.988 . . . . 1.0 115.57 165.372 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 93.0 mtp -132.76 4.13 3.85 Favored 'General case' 0 N--CA 1.473 0.71 0 CA-C-N 118.947 1.374 . . . . 1.0 112.661 176.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.479 HG13 ' HE1' ' A' ' 14' ' ' TRP . 66.4 mt . . . . . 0 CA--C 1.534 0.342 0 N-CA-C 105.303 -2.11 . . . . 1.0 105.303 178.482 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.309 0 N-CA-C 110.294 -1.122 . . . . 1.0 110.294 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.4 tp -56.33 -47.39 78.89 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 124.506 1.123 . . . . 1.0 112.454 -171.779 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 7.8 t80 -63.55 -45.45 90.48 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 124.54 1.136 . . . . 1.0 110.06 -176.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.69 -51.9 41.55 Favored Glycine 0 CA--C 1.531 1.059 0 CA-C-N 114.096 -1.411 . . . . 1.0 111.474 170.197 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.48 -38.43 87.24 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 118.061 0.931 . . . . 1.0 112.175 179.611 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.8 mt -63.65 -62.99 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.706 0 C-N-CA 127.721 2.408 . . . . 1.0 106.963 177.38 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.65 -27.4 58.47 Favored 'General case' 0 CA--C 1.541 0.597 0 N-CA-C 113.077 0.769 . . . . 1.0 113.077 177.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -67.75 -55.15 15.28 Favored Glycine 0 CA--C 1.53 0.971 0 CA-C-N 119.748 1.158 . . . . 1.0 110.797 169.078 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -49.14 -30.05 6.19 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 125.096 1.359 . . . . 1.0 112.568 174.799 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -59.6 -20.9 19.74 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.848 0 C-N-CA 126.409 1.884 . . . . 1.0 111.074 -177.925 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -121.64 4.57 10.09 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 126.454 1.902 . . . . 1.0 111.048 175.111 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -141.34 76.87 1.57 Allowed 'General case' 0 C--N 1.339 0.13 0 O-C-N 120.363 -1.461 . . . . 1.0 107.971 -166.453 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 93.54 4.27 64.09 Favored Glycine 0 CA--C 1.528 0.898 0 CA-C-O 118.434 -1.203 . . . . 1.0 113.364 -179.029 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 11.9 t-105 -53.82 148.64 9.86 Favored 'General case' 0 C--N 1.34 0.162 0 CA-C-N 118.925 1.362 . . . . 1.0 112.466 170.121 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -166.34 116.32 0.96 Allowed 'General case' 0 N--CA 1.441 -0.917 0 C-N-CA 125.077 1.351 . . . . 1.0 108.476 158.285 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -168.39 8.24 0.05 OUTLIER Glycine 0 CA--C 1.53 0.971 0 C-N-CA 126.26 1.886 . . . . 1.0 115.2 163.466 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 9.1 ttp -167.92 7.78 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.411 1.484 . . . . 1.0 113.189 -174.208 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 41.1 mt . . . . . 0 CA--C 1.543 0.689 0 N-CA-C 104.485 -2.413 . . . . 1.0 104.485 -179.068 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.25 0 N-CA-C 110.382 -1.087 . . . . 1.0 110.382 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 15.0 tp -55.48 -48.77 74.03 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 124.822 1.249 . . . . 1.0 112.673 -172.574 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -63.44 -45.41 91.03 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 124.469 1.108 . . . . 1.0 110.01 -177.394 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.67 -49.86 51.52 Favored Glycine 0 CA--C 1.531 1.061 0 CA-C-N 114.126 -1.397 . . . . 1.0 111.796 170.211 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -63.6 -39.29 94.01 Favored 'General case' 0 CA--C 1.537 0.46 0 CA-C-N 118.298 1.049 . . . . 1.0 112.038 179.451 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.4 mt -63.39 -63.17 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.826 0 C-N-CA 127.586 2.354 . . . . 1.0 106.915 177.797 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -55.34 -32.63 62.68 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.033 0.533 . . . . 1.0 112.252 177.234 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -61.99 -52.24 51.54 Favored Glycine 0 CA--C 1.531 1.053 0 CA-C-N 119.879 1.218 . . . . 1.0 111.039 171.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -54.53 -26.84 34.25 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 124.196 0.998 . . . . 1.0 112.42 173.391 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -70.15 -9.41 12.4 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.043 0 C-N-CA 125.103 1.361 . . . . 1.0 109.653 -175.67 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -118.19 1.36 11.9 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 125.71 1.604 . . . . 1.0 111.468 171.738 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -151.96 81.19 1.27 Allowed 'General case' 0 C--O 1.234 0.261 0 O-C-N 121.072 -1.018 . . . . 1.0 108.707 -161.519 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 99.01 0.82 57.23 Favored Glycine 0 CA--C 1.531 1.075 0 CA-C-O 119.065 -0.853 . . . . 1.0 112.572 -173.366 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 62.4 t-105 -53.06 155.09 2.66 Favored 'General case' 0 N--CA 1.452 -0.356 0 C-N-CA 125.65 1.58 . . . . 1.0 112.728 174.576 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -141.79 -115.68 0.12 Allowed 'General case' 0 N--CA 1.442 -0.85 0 N-CA-C 105.047 -2.205 . . . . 1.0 105.047 -176.509 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 58.64 -75.58 0.01 OUTLIER Glycine 0 CA--C 1.531 1.086 0 C-N-CA 126.183 1.849 . . . . 1.0 113.437 -177.509 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.1 ttt -102.34 -10.6 19.34 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 125.35 1.46 . . . . 1.0 112.503 173.005 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.3 mp . . . . . 0 CA--C 1.543 0.689 0 C-N-CA 128.178 2.591 . . . . 1.0 106.126 176.749 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.271 0 N-CA-C 110.135 -1.186 . . . . 1.0 110.135 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.6 tp -56.65 -49.04 76.19 Favored 'General case' 0 N--CA 1.468 0.425 0 C-N-CA 124.51 1.124 . . . . 1.0 112.635 -170.478 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -63.71 -45.27 90.72 Favored 'General case' 0 C--O 1.225 -0.203 0 C-N-CA 124.358 1.063 . . . . 1.0 110.031 -176.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.83 -50.23 51.01 Favored Glycine 0 CA--C 1.532 1.145 0 CA-C-N 113.976 -1.465 . . . . 1.0 111.724 170.5 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.86 -39.05 93.2 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 118.258 1.029 . . . . 1.0 112.048 179.315 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.0 mt -63.73 -62.94 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 C-N-CA 127.384 2.274 . . . . 1.0 106.827 177.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.82 -31.74 65.03 Favored 'General case' 0 CA--C 1.542 0.644 0 N-CA-C 112.387 0.514 . . . . 1.0 112.387 178.326 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.66 -49.86 61.96 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-N 119.846 1.203 . . . . 1.0 111.329 172.018 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -54.24 -26.88 31.12 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 123.929 0.892 . . . . 1.0 112.241 172.478 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -68.84 -10.71 13.7 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.061 0 C-N-CA 124.878 1.271 . . . . 1.0 109.88 -174.523 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -118.71 2.51 11.68 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.027 1.731 . . . . 1.0 111.47 172.02 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -149.12 82.23 1.43 Allowed 'General case' 0 C--O 1.235 0.303 0 O-C-N 120.995 -1.066 . . . . 1.0 109.029 -164.167 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 97.23 -1.97 60.97 Favored Glycine 0 CA--C 1.532 1.094 0 CA-C-O 118.98 -0.9 . . . . 1.0 112.719 -175.783 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 56.1 t-105 -50.75 150.16 3.0 Favored 'General case' 0 C--O 1.233 0.202 0 C-N-CA 125.738 1.615 . . . . 1.0 113.055 173.326 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -123.94 -105.73 0.35 Allowed 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 126.827 2.051 . . . . 1.0 107.873 177.621 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 63.37 -68.91 0.03 OUTLIER Glycine 0 CA--C 1.534 1.24 0 CA-C-N 121.868 2.122 . . . . 1.0 114.683 174.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 67.5 mtt -123.56 -3.98 8.28 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 126.56 1.944 . . . . 1.0 112.937 172.627 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.2 mp . . . . . 0 CA--C 1.541 0.621 0 C-N-CA 128.327 2.651 . . . . 1.0 105.442 174.594 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.289 0 N-CA-C 110.132 -1.187 . . . . 1.0 110.132 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.9 tp -55.39 -48.28 74.57 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 124.424 1.09 . . . . 1.0 112.737 -169.374 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -63.47 -47.1 83.19 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 124.453 1.101 . . . . 1.0 110.659 -174.78 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.56 -51.55 47.47 Favored Glycine 0 CA--C 1.531 1.042 0 CA-C-N 113.918 -1.492 . . . . 1.0 111.026 170.701 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.91 -37.08 83.28 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 117.806 0.803 . . . . 1.0 112.489 179.506 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.53 -63.13 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 C-N-CA 127.771 2.429 . . . . 1.0 106.931 177.031 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -58.12 -27.79 64.06 Favored 'General case' 0 CA--C 1.539 0.547 0 N-CA-C 112.708 0.632 . . . . 1.0 112.708 179.417 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -67.48 -53.54 24.28 Favored Glycine 0 CA--C 1.531 1.055 0 CA-C-N 119.391 0.996 . . . . 1.0 111.302 169.502 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -51.44 -28.38 12.89 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 124.896 1.278 . . . . 1.0 112.397 174.338 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -65.98 -9.59 8.8 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.936 0 C-N-CA 126.161 1.784 . . . . 1.0 110.876 -175.858 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -130.13 8.9 5.2 Favored 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 126.723 2.009 . . . . 1.0 110.811 173.771 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -148.41 81.77 1.47 Allowed 'General case' 0 C--O 1.234 0.287 0 O-C-N 120.826 -1.171 . . . . 1.0 108.466 -166.47 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 91.89 7.26 64.58 Favored Glycine 0 CA--C 1.531 1.047 0 CA-C-O 119.023 -0.876 . . . . 1.0 112.393 -171.318 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . 0.436 ' HE1' ' CD1' ' A' ' 18' ' ' ILE . 60.4 t-105 -59.22 156.78 11.73 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 124.756 1.222 . . . . 1.0 112.098 175.684 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -140.02 -107.11 0.16 Allowed 'General case' 0 N--CA 1.449 -0.475 0 CA-C-N 115.433 -0.803 . . . . 1.0 108.883 167.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 65.79 -59.74 0.13 Allowed Glycine 0 CA--C 1.534 1.234 0 C-N-CA 126.839 2.162 . . . . 1.0 114.41 177.235 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 12.8 tmm? -128.81 -11.21 4.89 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 127.108 2.163 . . . . 1.0 112.666 175.537 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.436 ' CD1' ' HE1' ' A' ' 14' ' ' TRP . 2.5 mp . . . . . 0 CA--C 1.536 0.438 0 C-N-CA 128.687 2.795 . . . . 1.0 107.553 174.607 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.237 0 N-CA-C 110.169 -1.172 . . . . 1.0 110.169 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.2 tp -56.4 -47.96 77.92 Favored 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 124.442 1.097 . . . . 1.0 112.638 -170.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -63.58 -46.12 87.29 Favored 'General case' 0 C--N 1.33 -0.239 0 C-N-CA 124.406 1.082 . . . . 1.0 110.227 -177.016 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.33 -51.33 42.88 Favored Glycine 0 CA--C 1.53 1.025 0 CA-C-N 114.034 -1.439 . . . . 1.0 111.536 170.443 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.94 -39.09 90.88 Favored 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 117.953 0.877 . . . . 1.0 112.164 179.419 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.8 mt -63.57 -63.09 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.763 0 C-N-CA 127.568 2.347 . . . . 1.0 107.019 178.013 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.96 -29.44 63.21 Favored 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 112.537 0.569 . . . . 1.0 112.537 178.556 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.74 -53.43 34.73 Favored Glycine 0 CA--C 1.531 1.092 0 CA-C-N 119.447 1.021 . . . . 1.0 111.236 170.1 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -52.92 -30.77 36.39 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 124.955 1.302 . . . . 1.0 112.353 174.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -64.67 -14.04 15.46 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.846 0 C-N-CA 126.754 2.021 . . . . 1.0 111.456 -173.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -122.47 9.74 9.72 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 126.4 1.88 . . . . 1.0 110.749 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -140.37 -41.53 0.42 Allowed 'General case' 0 N--CA 1.465 0.323 0 O-C-N 121.096 -1.002 . . . . 1.0 113.522 -163.208 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -129.08 11.97 6.13 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 124.275 0.94 . . . . 1.0 112.046 175.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 54.0 t-105 -62.55 153.39 32.04 Favored 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 125.564 1.545 . . . . 1.0 113.405 -169.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -161.95 116.67 1.93 Allowed 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 127.391 2.276 . . . . 1.0 106.578 159.083 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 172.63 -3.36 0.03 OUTLIER Glycine 0 CA--C 1.529 0.936 0 C-N-CA 129.066 3.222 . . . . 1.0 111.11 171.457 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 11.8 ttt -144.44 12.08 1.51 Allowed 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 124.3 1.04 . . . . 1.0 113.058 176.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -103.37 33.42 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.647 0 CA-C-O 123.34 1.543 . . . . 1.0 108.34 167.26 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 23.6 t0 -74.3 91.04 2.15 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 126.649 1.98 . . . . 1.0 109.414 -172.23 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.968 0 C-N-CA 125.565 1.555 . . . . 1.0 112.894 -176.619 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.324 0 N-CA-C 110.127 -1.189 . . . . 1.0 110.127 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.0 tp -56.0 -48.35 76.06 Favored 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 124.414 1.085 . . . . 1.0 112.576 -170.118 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -63.62 -46.73 84.38 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 124.456 1.103 . . . . 1.0 110.192 -176.79 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.68 -49.17 54.43 Favored Glycine 0 CA--C 1.53 1.004 0 CA-C-N 114.022 -1.445 . . . . 1.0 111.6 171.043 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -63.76 -39.81 95.18 Favored 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 118.198 0.999 . . . . 1.0 111.925 178.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.2 mt -63.63 -63.05 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.775 0 C-N-CA 127.434 2.294 . . . . 1.0 107.173 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.27 -34.13 68.34 Favored 'General case' 0 CA--C 1.542 0.641 0 CA-C-O 119.33 -0.367 . . . . 1.0 111.648 177.696 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -59.25 -50.67 65.33 Favored Glycine 0 CA--C 1.531 1.055 0 O-C-N 120.65 -1.281 . . . . 1.0 111.271 172.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -54.43 -33.04 58.68 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 124.186 0.994 . . . . 1.0 111.86 173.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -66.71 -14.65 18.21 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.916 0 C-N-CA 126.115 1.766 . . . . 1.0 110.065 -173.023 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -111.44 -1.17 16.01 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.331 1.452 . . . . 1.0 112.154 177.619 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 49.1 m-80 -138.05 -43.11 0.52 Allowed 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 119.623 1.101 . . . . 1.0 113.202 -159.186 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -121.29 8.92 10.26 Favored Glycine 0 CA--C 1.526 0.738 0 C-N-CA 124.133 0.873 . . . . 1.0 111.724 176.578 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.435 ' HE1' ' HB3' ' A' ' 17' ' ' MET . 55.1 t-105 -62.59 154.53 28.71 Favored 'General case' 0 N--CA 1.444 -0.726 0 C-N-CA 125.472 1.509 . . . . 1.0 113.028 -170.736 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -160.73 116.42 2.25 Favored 'General case' 0 N--CA 1.44 -0.95 0 C-N-CA 125.797 1.639 . . . . 1.0 106.977 159.048 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 175.38 -7.99 0.03 OUTLIER Glycine 0 CA--C 1.53 0.979 0 C-N-CA 128.98 3.181 . . . . 1.0 110.642 168.095 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' MET . . . . . 0.435 ' HB3' ' HE1' ' A' ' 14' ' ' TRP . 8.0 tpt -133.1 8.41 4.04 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 125.174 1.39 . . . . 1.0 113.451 177.59 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.6 mp -103.27 34.02 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.665 0 CA-C-O 123.123 1.44 . . . . 1.0 108.288 170.223 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 17.7 t0 -76.61 95.75 4.01 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 125.977 1.711 . . . . 1.0 108.097 178.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.004 0 C-N-CA 125.148 1.356 . . . . 1.0 112.933 178.501 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.199 0 N-CA-C 109.956 -1.258 . . . . 1.0 109.956 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.4 tp -56.12 -48.83 75.46 Favored 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 124.519 1.128 . . . . 1.0 112.582 -171.153 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.2 t80 -63.62 -45.58 89.65 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 124.585 1.154 . . . . 1.0 109.988 -176.069 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.39 -50.27 53.38 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-N 114.026 -1.443 . . . . 1.0 111.648 170.525 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.83 -38.73 91.94 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 118.101 0.95 . . . . 1.0 112.134 178.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.2 mt -63.46 -63.18 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.774 0 C-N-CA 127.606 2.362 . . . . 1.0 106.877 178.268 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.68 -34.75 67.7 Favored 'General case' 0 CA--C 1.543 0.677 0 CA-C-O 119.263 -0.398 . . . . 1.0 111.809 178.375 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -60.6 -49.92 73.26 Favored Glycine 0 CA--C 1.531 1.047 0 O-C-N 120.667 -1.271 . . . . 1.0 111.348 172.691 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -55.39 -31.29 61.7 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 124.2 1.0 . . . . 1.0 112.064 173.191 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -67.59 -14.24 17.95 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.91 0 C-N-CA 125.761 1.624 . . . . 1.0 109.737 -173.799 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -110.08 -0.79 17.85 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 125.503 1.521 . . . . 1.0 111.94 177.592 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 50.3 m-80 -139.55 -41.68 0.45 Allowed 'General case' 0 N--CA 1.472 0.651 0 CA-C-N 119.74 1.155 . . . . 1.0 113.398 -159.259 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -124.45 9.05 8.29 Favored Glycine 0 CA--C 1.527 0.815 0 C-N-CA 124.222 0.915 . . . . 1.0 111.892 177.089 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 50.4 t-105 -60.21 154.68 19.19 Favored 'General case' 0 N--CA 1.446 -0.641 0 C-N-CA 125.789 1.636 . . . . 1.0 113.469 -171.393 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -160.83 116.56 2.23 Favored 'General case' 0 N--CA 1.44 -0.946 0 C-N-CA 125.703 1.601 . . . . 1.0 107.308 158.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 170.51 3.61 0.03 OUTLIER Glycine 0 CA--C 1.528 0.845 0 C-N-CA 128.554 2.978 . . . . 1.0 111.656 165.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 15.1 ttp -143.86 14.35 1.72 Allowed 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.017 1.327 . . . . 1.0 112.654 175.469 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.1 mp -103.31 37.3 0.27 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-O 122.914 1.34 . . . . 1.0 108.095 167.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 53.6 t0 -137.84 110.63 7.64 Favored 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 127.022 2.129 . . . . 1.0 107.432 170.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.035 0 C-N-CA 124.807 1.194 . . . . 1.0 111.546 165.463 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.313 0 N-CA-C 110.219 -1.152 . . . . 1.0 110.219 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.6 tp -56.39 -48.63 76.5 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 124.605 1.162 . . . . 1.0 112.57 -171.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.4 t80 -63.57 -45.86 88.53 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 124.348 1.059 . . . . 1.0 109.97 -177.129 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -51.67 -51.05 40.41 Favored Glycine 0 CA--C 1.531 1.038 0 CA-C-N 114.017 -1.447 . . . . 1.0 111.689 170.169 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.58 -39.45 93.74 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 118.26 1.03 . . . . 1.0 112.124 179.563 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.56 -63.05 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.763 0 C-N-CA 127.442 2.297 . . . . 1.0 106.969 178.23 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.04 -32.14 63.78 Favored 'General case' 0 CA--C 1.541 0.631 0 O-C-N 122.021 -0.424 . . . . 1.0 112.132 177.489 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -61.51 -52.84 48.54 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-N 119.951 1.251 . . . . 1.0 111.088 171.093 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -51.72 -33.67 35.47 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 124.192 0.997 . . . . 1.0 112.069 174.299 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -64.08 -13.96 14.55 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.907 0 C-N-CA 126.801 2.04 . . . . 1.0 111.333 -172.823 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -126.63 6.76 6.83 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 125.733 1.613 . . . . 1.0 111.711 178.517 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -139.23 -32.45 0.66 Allowed 'General case' 0 N--CA 1.471 0.61 0 O-C-N 121.231 -0.918 . . . . 1.0 112.805 -163.71 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -137.32 13.65 3.76 Favored Glycine 0 CA--C 1.526 0.735 0 C-N-CA 124.338 0.97 . . . . 1.0 111.627 174.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 56.8 t-105 -56.47 157.16 5.32 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 126.278 1.831 . . . . 1.0 113.648 -168.556 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -157.39 115.04 3.09 Favored 'General case' 0 N--CA 1.436 -1.171 0 N-CA-C 101.663 -3.458 . . . . 1.0 101.663 176.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 149.86 -4.01 0.62 Allowed Glycine 0 CA--C 1.531 1.045 0 C-N-CA 125.059 1.314 . . . . 1.0 114.866 167.637 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 15.7 ttt -130.75 9.72 5.02 Favored 'General case' 0 CA--C 1.54 0.576 0 CA-C-N 118.847 1.324 . . . . 1.0 111.961 172.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.2 mp -103.34 42.0 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.522 0 N-CA-C 107.51 -1.293 . . . . 1.0 107.51 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -124.7 99.68 6.28 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 126.503 1.921 . . . . 1.0 107.085 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.175 0 CA-C-O 119.273 -0.737 . . . . 1.0 114.787 -176.431 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.251 0 N-CA-C 109.917 -1.273 . . . . 1.0 109.917 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 8.4 tp -54.83 -50.49 68.46 Favored 'General case' 0 N--CA 1.467 0.388 0 C-N-CA 124.586 1.154 . . . . 1.0 112.76 -169.581 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.2 t80 -63.71 -46.79 83.84 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 124.17 0.988 . . . . 1.0 110.383 -175.129 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.16 -51.03 49.25 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-N 114.032 -1.44 . . . . 1.0 111.428 171.408 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -60.97 -40.63 94.13 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 123.682 0.793 . . . . 1.0 111.835 178.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.3 mt -63.43 -63.21 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.794 0 C-N-CA 127.511 2.324 . . . . 1.0 107.082 178.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.99 -33.22 66.91 Favored 'General case' 0 CA--C 1.542 0.65 0 CA-C-O 118.999 -0.524 . . . . 1.0 112.148 179.634 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.37 -50.92 58.71 Favored Glycine 0 CA--C 1.532 1.097 0 CA-C-N 120.062 1.301 . . . . 1.0 111.339 171.431 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -53.42 -30.63 41.35 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 124.457 1.103 . . . . 1.0 112.22 173.744 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -66.93 -13.72 16.97 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.921 0 C-N-CA 126.27 1.828 . . . . 1.0 110.546 -173.645 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -112.18 1.72 16.35 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 125.054 1.342 . . . . 1.0 111.905 176.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 12.5 t30 -139.09 -48.64 0.49 Allowed 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 119.353 0.978 . . . . 1.0 112.862 -159.547 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -118.71 9.86 12.61 Favored Glycine 0 CA--C 1.527 0.833 0 C-N-CA 124.303 0.954 . . . . 1.0 111.965 178.117 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 65.0 t-105 -56.93 164.93 1.38 Allowed 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 126.395 1.878 . . . . 1.0 114.55 -168.372 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -150.13 91.16 1.74 Allowed 'General case' 0 N--CA 1.442 -0.869 0 C-N-CA 125.054 1.342 . . . . 1.0 111.265 -175.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 165.94 -16.13 0.09 OUTLIER Glycine 0 CA--C 1.529 0.942 0 CA-C-N 115.405 -0.816 . . . . 1.0 114.734 165.053 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 1.3 mpt? -107.69 6.78 28.04 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 124.38 1.072 . . . . 1.0 111.766 175.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.6 mp -103.37 44.29 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.525 0 N-CA-C 106.844 -1.539 . . . . 1.0 106.844 -174.5 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 33.0 t0 -128.27 85.17 2.31 Favored 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 125.925 1.69 . . . . 1.0 107.982 -179.171 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 0.998 0 C-N-CA 125.209 1.385 . . . . 1.0 110.398 -175.394 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.21 0 N-CA-C 110.155 -1.178 . . . . 1.0 110.155 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 8.7 tp -54.91 -49.05 72.22 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 124.522 1.129 . . . . 1.0 112.695 -169.147 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 12.2 t80 -63.76 -47.17 82.07 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 124.319 1.048 . . . . 1.0 110.538 -175.377 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.21 -51.11 48.96 Favored Glycine 0 CA--C 1.53 1.021 0 CA-C-N 114.072 -1.422 . . . . 1.0 111.287 171.187 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.19 -39.53 90.52 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 117.74 0.77 . . . . 1.0 111.952 179.28 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.47 -63.1 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.78 0 C-N-CA 127.654 2.381 . . . . 1.0 107.143 178.174 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.48 -29.93 64.67 Favored 'General case' 0 CA--C 1.539 0.543 0 N-CA-C 112.714 0.635 . . . . 1.0 112.714 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.58 -52.68 32.89 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-N 119.702 1.137 . . . . 1.0 111.206 170.094 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -52.43 -28.61 20.65 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 124.64 1.176 . . . . 1.0 112.3 174.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -64.83 -13.1 14.16 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.871 0 C-N-CA 125.98 1.712 . . . . 1.0 110.887 -175.568 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -126.82 6.94 6.71 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 126.357 1.863 . . . . 1.0 111.371 175.032 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 -147.69 90.61 1.87 Allowed 'General case' 0 C--N 1.341 0.196 0 O-C-N 120.956 -1.09 . . . . 1.0 109.291 -165.034 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 77.35 12.7 84.32 Favored Glycine 0 CA--C 1.532 1.124 0 CA-C-O 118.632 -1.094 . . . . 1.0 112.378 -169.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.412 ' HE1' ' CB ' ' A' ' 17' ' ' MET . 55.8 t-105 -51.99 156.15 1.62 Allowed 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.492 1.517 . . . . 1.0 112.967 176.62 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -159.1 101.92 1.6 Allowed 'General case' 0 N--CA 1.445 -0.711 0 C-N-CA 126.241 1.816 . . . . 1.0 106.327 -179.224 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 159.5 -5.79 0.12 Allowed Glycine 0 CA--C 1.53 1.03 0 CA-C-O 118.861 -0.966 . . . . 1.0 115.254 171.373 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' MET . . . . . 0.412 ' CB ' ' HE1' ' A' ' 14' ' ' TRP . 13.3 ttt -128.52 11.19 6.26 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 118.92 1.36 . . . . 1.0 111.947 174.095 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.7 mp -103.31 42.13 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 C-N-CA 124.977 1.311 . . . . 1.0 107.473 179.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 31.6 t0 -142.37 100.28 3.67 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 126.255 1.822 . . . . 1.0 106.894 -179.549 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.723 0 C-N-CA 123.86 0.743 . . . . 1.0 112.38 175.128 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.254 0 N-CA-C 110.165 -1.174 . . . . 1.0 110.165 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.5 tp -56.19 -48.63 76.01 Favored 'General case' 0 N--CA 1.468 0.449 0 C-N-CA 124.494 1.118 . . . . 1.0 112.659 -171.635 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -63.64 -45.42 90.32 Favored 'General case' 0 N--CA 1.455 -0.206 0 C-N-CA 124.18 0.992 . . . . 1.0 109.724 -178.11 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -50.74 -50.42 37.33 Favored Glycine 0 CA--C 1.532 1.13 0 CA-C-N 114.138 -1.392 . . . . 1.0 112.124 170.169 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -63.0 -41.53 99.61 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 118.143 0.972 . . . . 1.0 111.854 179.253 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.56 -63.01 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.843 0 C-N-CA 127.339 2.255 . . . . 1.0 106.695 179.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -54.25 -37.59 64.84 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.636 0.774 . . . . 1.0 111.814 177.332 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.34 -51.73 55.89 Favored Glycine 0 CA--C 1.531 1.049 0 CA-C-N 119.825 1.193 . . . . 1.0 111.42 173.346 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -58.46 -26.43 63.35 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 124.244 1.018 . . . . 1.0 112.712 174.031 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -68.91 -18.24 22.81 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.78 0 CA-C-N 119.776 1.171 . . . . 1.0 110.604 -172.123 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -109.53 0.73 19.35 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 125.873 1.669 . . . . 1.0 111.576 173.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 13.3 t-20 -152.05 95.84 2.12 Favored 'General case' 0 C--N 1.344 0.335 0 O-C-N 120.567 -1.333 . . . . 1.0 110.182 -159.287 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 74.94 11.16 83.92 Favored Glycine 0 CA--C 1.531 1.058 0 CA-C-O 118.583 -1.12 . . . . 1.0 112.414 -170.479 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.402 ' HE1' ' HB3' ' A' ' 17' ' ' MET . 59.3 t-105 -50.25 154.96 1.08 Allowed 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 125.513 1.525 . . . . 1.0 113.105 175.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -159.22 100.63 1.54 Allowed 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 106.045 -1.835 . . . . 1.0 106.045 -178.146 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 162.51 -6.84 0.08 OUTLIER Glycine 0 CA--C 1.532 1.133 0 CA-C-O 118.762 -1.021 . . . . 1.0 115.278 173.369 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' MET . . . . . 0.402 ' HB3' ' HE1' ' A' ' 14' ' ' TRP . 30.6 ttp -129.76 9.69 5.46 Favored 'General case' 0 CA--C 1.539 0.519 0 CA-C-N 119.128 1.464 . . . . 1.0 111.975 175.244 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.6 mp -103.29 42.6 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.506 0 N-CA-C 107.314 -1.365 . . . . 1.0 107.314 -178.02 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 25.4 t0 -130.63 95.82 3.95 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 126.102 1.761 . . . . 1.0 107.934 -174.179 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.405 0 N-CA-C 109.259 -1.536 . . . . 1.0 109.259 177.663 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.329 0 N-CA-C 110.027 -1.229 . . . . 1.0 110.027 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.5 tp -57.98 -47.65 82.36 Favored 'General case' 0 N--CA 1.466 0.365 0 C-N-CA 124.25 1.02 . . . . 1.0 112.325 -172.212 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.6 t80 -63.59 -44.75 93.13 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 124.306 1.042 . . . . 1.0 109.759 -177.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -51.63 -50.64 41.9 Favored Glycine 0 CA--C 1.533 1.191 0 CA-C-N 114.241 -1.345 . . . . 1.0 112.044 170.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -63.1 -40.07 96.56 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 118.369 1.084 . . . . 1.0 112.147 179.667 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.0 mt -63.58 -62.93 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.773 0 C-N-CA 127.673 2.389 . . . . 1.0 106.433 178.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -53.85 -32.46 53.05 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 123.599 0.76 . . . . 1.0 112.278 175.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.57 -53.98 40.78 Favored Glycine 0 CA--C 1.53 0.992 0 CA-C-N 119.81 1.186 . . . . 1.0 111.158 171.614 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -56.04 -28.01 55.63 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 123.657 0.783 . . . . 1.0 112.443 174.406 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -69.0 -10.27 13.16 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.889 0 C-N-CA 124.798 1.239 . . . . 1.0 110.446 -174.163 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -123.81 8.53 8.78 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 126.972 2.109 . . . . 1.0 110.946 176.452 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -156.46 92.99 1.36 Allowed 'General case' 0 C--N 1.343 0.294 0 O-C-N 120.513 -1.367 . . . . 1.0 109.285 -169.436 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 85.16 6.49 84.48 Favored Glycine 0 CA--C 1.53 0.988 0 CA-C-O 118.749 -1.028 . . . . 1.0 112.663 -172.183 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 55.3 t-105 -55.79 155.14 6.22 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 124.739 1.216 . . . . 1.0 112.525 176.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -162.16 104.06 1.13 Allowed 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 105.421 -2.066 . . . . 1.0 105.421 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 162.07 -8.59 0.1 OUTLIER Glycine 0 CA--C 1.528 0.895 0 CA-C-O 118.939 -0.923 . . . . 1.0 115.048 174.581 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 31.7 ttm -132.09 8.34 4.38 Favored 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 118.913 1.356 . . . . 1.0 112.257 174.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -103.37 36.52 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.375 0 C-N-CA 124.695 1.198 . . . . 1.0 108.955 -179.476 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 32.4 t0 -146.09 97.74 2.99 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 125.398 1.479 . . . . 1.0 108.792 -175.023 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.789 0 CA-C-N 116.072 -0.513 . . . . 1.0 112.753 164.865 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.245 0 N-CA-C 110.211 -1.155 . . . . 1.0 110.211 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.9 tp -56.12 -48.85 75.41 Favored 'General case' 0 N--CA 1.467 0.388 0 C-N-CA 124.613 1.165 . . . . 1.0 112.604 -170.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.5 t80 -63.63 -46.05 87.45 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 124.341 1.056 . . . . 1.0 110.068 -176.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.55 -50.05 49.98 Favored Glycine 0 CA--C 1.53 1.015 0 CA-C-N 114.194 -1.367 . . . . 1.0 111.667 170.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.0 -40.94 97.36 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 118.174 0.987 . . . . 1.0 111.944 178.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.2 mt -63.58 -63.18 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.782 0 C-N-CA 127.509 2.324 . . . . 1.0 107.251 179.267 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -58.13 -29.17 65.33 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 123.508 0.723 . . . . 1.0 112.484 178.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.62 -54.29 29.78 Favored Glycine 0 CA--C 1.529 0.951 0 CA-C-N 119.464 1.029 . . . . 1.0 110.832 170.038 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -52.24 -28.62 19.35 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 124.413 1.085 . . . . 1.0 112.42 174.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -65.99 -11.63 12.92 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.867 0 C-N-CA 125.825 1.65 . . . . 1.0 111.016 -175.213 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -126.81 8.25 6.84 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 126.663 1.985 . . . . 1.0 110.877 174.32 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -148.1 83.53 1.51 Allowed 'General case' 0 C--O 1.234 0.274 0 O-C-N 120.817 -1.177 . . . . 1.0 108.719 -166.69 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 88.33 7.38 72.91 Favored Glycine 0 CA--C 1.531 1.054 0 CA-C-O 118.992 -0.893 . . . . 1.0 112.587 -173.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 55.8 t-105 -52.87 155.23 2.46 Favored 'General case' 0 N--CA 1.452 -0.336 0 C-N-CA 125.655 1.582 . . . . 1.0 113.185 175.698 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -160.35 102.65 1.4 Allowed 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 126.275 1.83 . . . . 1.0 106.124 178.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 167.92 -17.44 0.08 OUTLIER Glycine 0 CA--C 1.529 0.94 0 CA-C-O 118.842 -0.977 . . . . 1.0 114.959 170.247 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -126.68 19.14 7.31 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-N 118.828 1.314 . . . . 1.0 112.662 175.607 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.4 mp -103.26 43.63 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.465 0 N-CA-C 106.853 -1.536 . . . . 1.0 106.853 172.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -134.47 100.53 4.68 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 125.999 1.72 . . . . 1.0 107.749 -177.457 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.758 0 C-N-CA 124.925 1.25 . . . . 1.0 112.678 169.769 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.238 0 N-CA-C 109.808 -1.317 . . . . 1.0 109.808 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 14.9 tp -55.45 -51.4 67.06 Favored 'General case' 0 N--CA 1.466 0.351 0 C-N-CA 124.836 1.254 . . . . 1.0 113.068 -169.064 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.5 t80 -63.8 -46.25 86.0 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 124.155 0.982 . . . . 1.0 110.136 -176.348 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.73 -49.18 54.69 Favored Glycine 0 CA--C 1.532 1.12 0 CA-C-N 114.02 -1.446 . . . . 1.0 111.723 171.046 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.81 -40.26 96.83 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 118.059 0.93 . . . . 1.0 111.751 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.55 -63.02 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.835 0 C-N-CA 127.318 2.247 . . . . 1.0 106.969 178.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -55.93 -34.39 65.57 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 122.991 0.516 . . . . 1.0 112.141 178.296 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -61.91 -50.96 60.48 Favored Glycine 0 CA--C 1.531 1.089 0 O-C-N 120.817 -1.177 . . . . 1.0 111.328 172.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -56.81 -25.03 54.85 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 124.505 1.122 . . . . 1.0 112.58 173.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -68.43 -16.32 20.82 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.948 0 C-N-CA 124.571 1.148 . . . . 1.0 110.415 -172.779 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -110.69 1.85 18.17 Favored 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 125.752 1.621 . . . . 1.0 111.439 172.553 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -150.32 81.97 1.36 Allowed 'General case' 0 C--O 1.235 0.337 0 O-C-N 120.969 -1.082 . . . . 1.0 108.95 -160.454 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 95.41 -0.18 63.4 Favored Glycine 0 CA--C 1.53 0.988 0 CA-C-O 118.947 -0.918 . . . . 1.0 112.789 -176.18 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 57.5 t-105 -54.61 154.47 4.86 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 125.06 1.344 . . . . 1.0 112.661 173.257 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -158.09 116.53 3.08 Favored 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 125.729 1.612 . . . . 1.0 107.065 159.08 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 173.19 4.11 0.03 OUTLIER Glycine 0 CA--C 1.527 0.816 0 C-N-CA 128.582 2.991 . . . . 1.0 111.829 165.162 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 22.0 ttp -143.67 10.05 1.59 Allowed 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 125.173 1.389 . . . . 1.0 112.995 178.145 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.4 mp -103.14 40.73 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 CA-C-O 122.723 1.249 . . . . 1.0 107.635 172.311 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 30.2 t0 -132.5 101.44 5.33 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 126.955 2.102 . . . . 1.0 106.802 176.528 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.335 0.477 0 N-CA-C 109.927 -1.269 . . . . 1.0 109.927 -175.463 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.266 0 N-CA-C 110.112 -1.195 . . . . 1.0 110.112 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.3 tp -55.66 -49.13 73.73 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 124.656 1.182 . . . . 1.0 112.755 -170.506 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -63.63 -46.92 83.5 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 124.251 1.02 . . . . 1.0 110.134 -176.648 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.05 -50.06 46.81 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-N 114.083 -1.417 . . . . 1.0 111.61 171.16 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.26 -41.17 98.21 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 117.986 0.893 . . . . 1.0 111.928 178.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.2 mt -63.48 -63.24 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 C-N-CA 127.458 2.303 . . . . 1.0 107.196 179.606 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.87 -33.04 68.27 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 122.887 0.475 . . . . 1.0 111.98 179.014 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -61.0 -52.4 52.49 Favored Glycine 0 CA--C 1.53 1.004 0 CA-C-N 119.883 1.219 . . . . 1.0 111.09 171.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -54.4 -27.82 39.33 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 124.096 0.958 . . . . 1.0 112.396 173.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -68.38 -12.12 15.33 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.956 0 C-N-CA 125.199 1.399 . . . . 1.0 110.161 -174.595 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -117.11 1.77 12.57 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 125.92 1.688 . . . . 1.0 111.516 173.431 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -149.53 84.3 1.42 Allowed 'General case' 0 C--O 1.234 0.261 0 O-C-N 121.111 -0.993 . . . . 1.0 108.573 -160.167 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 87.68 6.73 76.31 Favored Glycine 0 CA--C 1.531 1.041 0 CA-C-O 118.725 -1.042 . . . . 1.0 112.613 -174.034 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 54.6 t-105 -53.68 152.49 5.2 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 124.878 1.271 . . . . 1.0 112.208 173.386 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -158.48 116.56 2.96 Favored 'General case' 0 N--CA 1.441 -0.924 0 C-N-CA 125.81 1.644 . . . . 1.0 107.042 159.147 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 172.4 5.28 0.03 OUTLIER Glycine 0 CA--C 1.528 0.882 0 C-N-CA 129.248 3.308 . . . . 1.0 111.747 168.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 23.2 ttm -147.91 10.77 0.93 Allowed 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 125.054 1.341 . . . . 1.0 113.329 178.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.1 mp -103.14 44.07 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.745 0 N-CA-C 106.581 -1.637 . . . . 1.0 106.581 172.225 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 17.6 t0 -123.4 96.61 5.05 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 127.458 2.303 . . . . 1.0 106.238 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.749 0 N-CA-C 109.527 -1.429 . . . . 1.0 109.527 -168.123 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.313 0 N-CA-C 110.478 -1.049 . . . . 1.0 110.478 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.4 tp -55.83 -48.19 75.91 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 124.528 1.131 . . . . 1.0 112.578 -170.543 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -63.65 -45.51 89.85 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 124.567 1.147 . . . . 1.0 110.123 -176.424 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.01 -50.89 49.33 Favored Glycine 0 CA--C 1.531 1.087 0 CA-C-N 113.973 -1.467 . . . . 1.0 111.595 170.302 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.8 -38.6 91.3 Favored 'General case' 0 CA--C 1.535 0.396 0 CA-C-N 118.126 0.963 . . . . 1.0 112.072 179.22 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.7 mt -63.58 -62.96 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 C-N-CA 127.516 2.326 . . . . 1.0 106.717 178.376 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.66 -34.21 69.13 Favored 'General case' 0 CA--C 1.541 0.635 0 CA-C-O 119.134 -0.46 . . . . 1.0 111.793 179.124 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -60.0 -50.21 70.16 Favored Glycine 0 CA--C 1.532 1.14 0 CA-C-N 120.049 1.295 . . . . 1.0 111.235 172.36 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -54.75 -31.06 58.04 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 124.242 1.017 . . . . 1.0 112.143 173.845 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -68.21 -11.83 14.87 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.822 0 C-N-CA 126.463 1.905 . . . . 1.0 111.112 -172.189 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -121.1 6.65 10.28 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.788 1.635 . . . . 1.0 111.348 176.714 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 27.1 t-20 -138.84 -45.87 0.48 Allowed 'General case' 0 N--CA 1.466 0.336 0 O-C-N 121.312 -0.867 . . . . 1.0 113.29 -161.665 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.24 14.49 8.29 Favored Glycine 0 CA--C 1.528 0.863 0 C-N-CA 124.687 1.137 . . . . 1.0 111.477 175.806 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 57.7 t-105 -60.13 163.05 5.17 Favored 'General case' 0 N--CA 1.447 -0.582 0 C-N-CA 126.281 1.832 . . . . 1.0 113.845 -168.017 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -150.06 95.48 2.29 Favored 'General case' 0 N--CA 1.445 -0.715 0 C-N-CA 125.271 1.429 . . . . 1.0 108.127 177.131 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 166.72 -5.0 0.05 OUTLIER Glycine 0 CA--C 1.534 1.27 0 N-CA-C 117.085 1.594 . . . . 1.0 117.085 171.562 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' MET . . . . . 0.527 ' H ' HD11 ' A' ' 18' ' ' ILE . 4.0 ppp? -130.68 9.68 5.05 Favored 'General case' 0 N--CA 1.475 0.786 0 CA-C-N 119.541 1.67 . . . . 1.0 113.628 167.831 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.527 HD11 ' H ' ' A' ' 17' ' ' MET . 0.5 OUTLIER -103.3 42.29 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 N-CA-C 107.543 -1.28 . . . . 1.0 107.543 -176.615 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 11.3 p-10 -113.38 -0.97 14.33 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 126.172 1.789 . . . . 1.0 112.899 -160.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.085 0 N-CA-C 110.426 -1.07 . . . . 1.0 110.426 166.19 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.225 0 N-CA-C 110.131 -1.188 . . . . 1.0 110.131 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.1 tp -55.04 -49.13 72.34 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 124.625 1.17 . . . . 1.0 112.582 -170.778 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -63.77 -46.75 83.83 Favored 'General case' 0 C--N 1.331 -0.199 0 C-N-CA 124.325 1.05 . . . . 1.0 110.327 -176.316 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.52 -49.3 57.84 Favored Glycine 0 CA--C 1.531 1.071 0 CA-C-N 114.168 -1.378 . . . . 1.0 111.48 171.703 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.58 -39.78 94.79 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-N 117.989 0.895 . . . . 1.0 111.932 178.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.6 mt -63.75 -63.05 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.801 0 C-N-CA 127.524 2.33 . . . . 1.0 106.866 178.578 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.44 -31.63 66.09 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 122.972 0.509 . . . . 1.0 112.256 179.009 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.72 -51.55 52.95 Favored Glycine 0 CA--C 1.53 1.0 0 CA-C-N 119.954 1.252 . . . . 1.0 111.018 171.09 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -54.12 -26.68 28.7 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 124.072 0.949 . . . . 1.0 112.36 173.671 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -67.76 -10.04 11.72 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.878 0 C-N-CA 125.175 1.39 . . . . 1.0 110.59 -175.372 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -127.16 6.76 6.48 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 126.524 1.93 . . . . 1.0 111.376 173.788 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 13.1 t-20 -148.51 93.36 2.13 Favored 'General case' 0 C--N 1.342 0.239 0 O-C-N 120.81 -1.181 . . . . 1.0 109.691 -164.384 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 76.93 10.84 85.99 Favored Glycine 0 CA--C 1.533 1.187 0 CA-C-O 118.979 -0.901 . . . . 1.0 112.199 -167.623 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 53.2 t-105 -53.82 161.09 1.22 Allowed 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 126.06 1.744 . . . . 1.0 113.228 176.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -152.49 98.08 2.33 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 125.579 1.552 . . . . 1.0 107.754 177.391 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 161.3 -4.44 0.09 OUTLIER Glycine 0 CA--C 1.531 1.074 0 N-CA-C 116.29 1.276 . . . . 1.0 116.29 170.026 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' MET . . . . . 0.456 ' H ' HD12 ' A' ' 18' ' ' ILE . 4.3 ppp? -116.65 -0.9 12.25 Favored 'General case' 0 N--CA 1.47 0.551 0 CA-C-N 119.17 1.485 . . . . 1.0 112.695 169.451 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.456 HD12 ' H ' ' A' ' 17' ' ' MET . 1.4 mp -103.03 34.88 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.69 0 CA-C-O 123.281 1.515 . . . . 1.0 107.54 -168.076 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 24.1 t0 -91.38 93.1 8.87 Favored 'General case' 0 N--CA 1.454 -0.257 0 C-N-CA 125.8 1.64 . . . . 1.0 109.146 -171.376 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.962 0 C-N-CA 125.094 1.331 . . . . 1.0 112.952 174.435 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.173 0 N-CA-C 110.186 -1.165 . . . . 1.0 110.186 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.7 tp -55.84 -50.25 71.08 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 124.89 1.276 . . . . 1.0 112.963 -170.225 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.2 t80 -63.53 -47.93 79.62 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 124.077 0.951 . . . . 1.0 110.241 -176.806 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -50.89 -50.46 38.05 Favored Glycine 0 CA--C 1.53 0.969 0 CA-C-N 114.087 -1.415 . . . . 1.0 111.485 171.338 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.01 -43.23 99.19 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 117.896 0.848 . . . . 1.0 111.722 178.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.4 mt -63.51 -63.31 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.673 0 C-N-CA 127.246 2.218 . . . . 1.0 107.55 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -60.73 -27.85 68.23 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 123.579 0.752 . . . . 1.0 112.524 -179.226 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.55 -55.16 21.95 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 110.655 -0.978 . . . . 1.0 110.655 169.697 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -51.22 -31.41 20.46 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 124.657 1.183 . . . . 1.0 112.297 176.124 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -60.07 -17.53 14.03 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.737 0 C-N-CA 126.631 1.973 . . . . 1.0 111.615 -174.263 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -129.58 9.84 5.56 Favored 'General case' 0 CA--C 1.545 0.767 0 C-N-CA 125.942 1.697 . . . . 1.0 110.391 177.36 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -147.6 78.91 1.47 Allowed 'General case' 0 C--O 1.234 0.279 0 C-N-CA 124.869 1.268 . . . . 1.0 108.905 -170.055 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 98.96 -3.16 58.48 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-O 119.198 -0.779 . . . . 1.0 112.875 -177.65 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 24.6 t-105 -55.17 155.76 4.59 Favored 'General case' 0 N--CA 1.456 -0.174 0 C-N-CA 124.795 1.238 . . . . 1.0 112.321 168.362 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -157.01 116.23 3.38 Favored 'General case' 0 N--CA 1.428 -1.572 0 C-N-CA 124.875 1.27 . . . . 1.0 108.156 158.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -160.61 -102.68 0.18 Allowed Glycine 0 CA--C 1.524 0.598 0 C-N-CA 125.557 1.551 . . . . 1.0 109.487 169.639 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 4.8 mpp? -71.03 6.75 1.43 Allowed 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 124.718 1.207 . . . . 1.0 113.242 -177.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 48.6 mt -104.03 56.9 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.3 0 N-CA-C 105.769 -1.937 . . . . 1.0 105.769 176.22 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -133.1 102.14 5.48 Favored 'General case' 0 N--CA 1.453 -0.276 0 C-N-CA 125.596 1.558 . . . . 1.0 107.646 179.225 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.595 0 C-N-CA 125.096 1.331 . . . . 1.0 110.725 175.75 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.306 0 N-CA-C 110.225 -1.15 . . . . 1.0 110.225 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.1 tp -56.86 -49.18 76.24 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 124.57 1.148 . . . . 1.0 112.596 -171.268 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -63.65 -45.52 89.83 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 124.45 1.1 . . . . 1.0 110.128 -176.706 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.98 -50.16 56.07 Favored Glycine 0 CA--C 1.532 1.115 0 CA-C-N 114.031 -1.44 . . . . 1.0 111.497 171.097 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.08 -38.31 88.36 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 118.044 0.922 . . . . 1.0 112.095 179.145 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.9 mt -63.58 -63.22 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.694 0 C-N-CA 127.855 2.462 . . . . 1.0 107.299 176.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.8 -26.53 58.12 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 113.062 0.764 . . . . 1.0 113.062 177.773 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -67.32 -56.02 13.48 Favored Glycine 0 CA--C 1.531 1.073 0 CA-C-N 119.312 0.96 . . . . 1.0 111.066 168.35 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -47.98 -34.41 9.24 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 125.687 1.595 . . . . 1.0 112.193 175.058 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -57.29 -19.98 11.97 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.771 0 C-N-CA 127.336 2.254 . . . . 1.0 111.629 -175.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -132.15 15.09 4.66 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 126.783 2.033 . . . . 1.0 111.275 -178.355 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 21.4 t-20 -137.31 -33.45 0.74 Allowed 'General case' 0 N--CA 1.467 0.405 0 O-C-N 121.352 -0.842 . . . . 1.0 113.236 -170.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -139.42 9.21 3.2 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-O 119.017 -0.88 . . . . 1.0 112.53 174.647 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.417 ' HE1' HG13 ' A' ' 18' ' ' ILE . 35.3 t-105 -62.51 145.35 54.49 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 118.152 0.976 . . . . 1.0 113.271 -173.01 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 48.0 mt-10 -155.11 114.47 3.66 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 105.32 -2.104 . . . . 1.0 105.32 158.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -167.06 -24.79 0.02 OUTLIER Glycine 0 CA--C 1.53 0.982 0 N-CA-C 115.603 1.001 . . . . 1.0 115.603 168.738 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -133.74 -0.41 3.16 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 118.669 1.235 . . . . 1.0 112.962 172.235 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.417 HG13 ' HE1' ' A' ' 14' ' ' TRP . 59.8 mt -104.1 53.19 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.26 0 N-CA-C 105.147 -2.168 . . . . 1.0 105.147 -176.221 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -138.78 97.17 3.27 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 126.539 1.936 . . . . 1.0 106.683 -174.519 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.122 0 C-N-CA 123.898 0.761 . . . . 1.0 114.399 178.617 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.371 0 N-CA-C 109.89 -1.284 . . . . 1.0 109.89 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.3 tp -56.28 -48.58 76.34 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 124.419 1.088 . . . . 1.0 112.594 -170.552 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.1 t80 -63.7 -47.23 82.02 Favored 'General case' 0 N--CA 1.455 -0.206 0 C-N-CA 124.401 1.08 . . . . 1.0 110.105 -176.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -51.73 -50.61 42.61 Favored Glycine 0 CA--C 1.531 1.068 0 CA-C-N 114.178 -1.374 . . . . 1.0 111.538 171.156 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.18 -40.51 96.29 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 117.966 0.883 . . . . 1.0 112.031 179.197 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.9 mt -63.59 -63.18 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.704 0 C-N-CA 127.662 2.385 . . . . 1.0 107.061 178.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -58.84 -28.42 66.05 Favored 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 123.432 0.693 . . . . 1.0 112.513 179.261 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.1 -54.84 25.13 Favored Glycine 0 CA--C 1.528 0.894 0 CA-C-N 119.331 0.969 . . . . 1.0 110.762 169.782 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -51.92 -29.83 21.83 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 124.582 1.153 . . . . 1.0 112.478 175.443 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -61.98 -17.41 17.56 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.876 0 C-N-CA 126.055 1.742 . . . . 1.0 110.916 -175.432 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -123.17 6.45 9.16 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 127.04 2.136 . . . . 1.0 110.634 176.663 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -148.22 80.59 1.47 Allowed 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.596 1.159 . . . . 1.0 108.882 -167.265 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 96.29 -5.54 65.42 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 124.029 0.823 . . . . 1.0 113.049 -179.203 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.479 ' HE1' HG13 ' A' ' 18' ' ' ILE . 3.7 t-105 -60.03 155.24 17.34 Favored 'General case' 0 N--CA 1.456 -0.158 0 CA-C-N 118.027 0.913 . . . . 1.0 112.083 166.701 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -158.74 115.98 2.81 Favored 'General case' 0 N--CA 1.428 -1.534 0 C-N-CA 125.515 1.526 . . . . 1.0 107.784 158.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -168.79 -26.07 0.02 OUTLIER Glycine 0 CA--C 1.53 1.013 0 N-CA-C 115.57 0.988 . . . . 1.0 115.57 165.372 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 93.0 mtp -132.76 4.13 3.85 Favored 'General case' 0 N--CA 1.473 0.71 0 CA-C-N 118.947 1.374 . . . . 1.0 112.661 176.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.479 HG13 ' HE1' ' A' ' 14' ' ' TRP . 66.4 mt -104.18 54.05 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 N-CA-C 105.303 -2.11 . . . . 1.0 105.303 178.482 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 21.7 t0 -144.7 97.07 2.97 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 126.097 1.759 . . . . 1.0 107.617 -176.164 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.84 0 N-CA-C 110.598 -1.001 . . . . 1.0 110.598 177.351 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.309 0 N-CA-C 110.294 -1.122 . . . . 1.0 110.294 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.4 tp -56.33 -47.39 78.89 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 124.506 1.123 . . . . 1.0 112.454 -171.779 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 7.8 t80 -63.55 -45.45 90.48 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 124.54 1.136 . . . . 1.0 110.06 -176.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.69 -51.9 41.55 Favored Glycine 0 CA--C 1.531 1.059 0 CA-C-N 114.096 -1.411 . . . . 1.0 111.474 170.197 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.48 -38.43 87.24 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 118.061 0.931 . . . . 1.0 112.175 179.611 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.8 mt -63.65 -62.99 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.706 0 C-N-CA 127.721 2.408 . . . . 1.0 106.963 177.38 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.65 -27.4 58.47 Favored 'General case' 0 CA--C 1.541 0.597 0 N-CA-C 113.077 0.769 . . . . 1.0 113.077 177.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -67.75 -55.15 15.28 Favored Glycine 0 CA--C 1.53 0.971 0 CA-C-N 119.748 1.158 . . . . 1.0 110.797 169.078 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -49.14 -30.05 6.19 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 125.096 1.359 . . . . 1.0 112.568 174.799 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -59.6 -20.9 19.74 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.848 0 C-N-CA 126.409 1.884 . . . . 1.0 111.074 -177.925 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -121.64 4.57 10.09 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 126.454 1.902 . . . . 1.0 111.048 175.111 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -141.34 76.87 1.57 Allowed 'General case' 0 C--N 1.339 0.13 0 O-C-N 120.363 -1.461 . . . . 1.0 107.971 -166.453 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 93.54 4.27 64.09 Favored Glycine 0 CA--C 1.528 0.898 0 CA-C-O 118.434 -1.203 . . . . 1.0 113.364 -179.029 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 11.9 t-105 -53.82 148.64 9.86 Favored 'General case' 0 C--N 1.34 0.162 0 CA-C-N 118.925 1.362 . . . . 1.0 112.466 170.121 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -166.34 116.32 0.96 Allowed 'General case' 0 N--CA 1.441 -0.917 0 C-N-CA 125.077 1.351 . . . . 1.0 108.476 158.285 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -168.39 8.24 0.05 OUTLIER Glycine 0 CA--C 1.53 0.971 0 C-N-CA 126.26 1.886 . . . . 1.0 115.2 163.466 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 9.1 ttp -167.92 7.78 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.411 1.484 . . . . 1.0 113.189 -174.208 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 41.1 mt -123.12 43.01 0.68 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 N-CA-C 104.485 -2.413 . . . . 1.0 104.485 -179.068 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 10.4 p-10 -98.84 -5.35 31.21 Favored 'General case' 0 N--CA 1.462 0.17 0 C-N-CA 128.011 2.525 . . . . 1.0 113.948 -158.814 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.706 0 C-N-CA 125.176 1.37 . . . . 1.0 109.843 178.566 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.25 0 N-CA-C 110.382 -1.087 . . . . 1.0 110.382 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 15.0 tp -55.48 -48.77 74.03 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 124.822 1.249 . . . . 1.0 112.673 -172.574 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -63.44 -45.41 91.03 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 124.469 1.108 . . . . 1.0 110.01 -177.394 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.67 -49.86 51.52 Favored Glycine 0 CA--C 1.531 1.061 0 CA-C-N 114.126 -1.397 . . . . 1.0 111.796 170.211 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -63.6 -39.29 94.01 Favored 'General case' 0 CA--C 1.537 0.46 0 CA-C-N 118.298 1.049 . . . . 1.0 112.038 179.451 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.4 mt -63.39 -63.17 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.826 0 C-N-CA 127.586 2.354 . . . . 1.0 106.915 177.797 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -55.34 -32.63 62.68 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.033 0.533 . . . . 1.0 112.252 177.234 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -61.99 -52.24 51.54 Favored Glycine 0 CA--C 1.531 1.053 0 CA-C-N 119.879 1.218 . . . . 1.0 111.039 171.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -54.53 -26.84 34.25 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 124.196 0.998 . . . . 1.0 112.42 173.391 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -70.15 -9.41 12.4 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.043 0 C-N-CA 125.103 1.361 . . . . 1.0 109.653 -175.67 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -118.19 1.36 11.9 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 125.71 1.604 . . . . 1.0 111.468 171.738 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -151.96 81.19 1.27 Allowed 'General case' 0 C--O 1.234 0.261 0 O-C-N 121.072 -1.018 . . . . 1.0 108.707 -161.519 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 99.01 0.82 57.23 Favored Glycine 0 CA--C 1.531 1.075 0 CA-C-O 119.065 -0.853 . . . . 1.0 112.572 -173.366 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 62.4 t-105 -53.06 155.09 2.66 Favored 'General case' 0 N--CA 1.452 -0.356 0 C-N-CA 125.65 1.58 . . . . 1.0 112.728 174.576 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -141.79 -115.68 0.12 Allowed 'General case' 0 N--CA 1.442 -0.85 0 N-CA-C 105.047 -2.205 . . . . 1.0 105.047 -176.509 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 58.64 -75.58 0.01 OUTLIER Glycine 0 CA--C 1.531 1.086 0 C-N-CA 126.183 1.849 . . . . 1.0 113.437 -177.509 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.1 ttt -102.34 -10.6 19.34 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 125.35 1.46 . . . . 1.0 112.503 173.005 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.3 mp -103.3 41.68 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 C-N-CA 128.178 2.591 . . . . 1.0 106.126 176.749 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 42.6 t0 -76.19 96.41 3.9 Favored 'General case' 0 C--O 1.234 0.249 0 C-N-CA 125.129 1.372 . . . . 1.0 109.026 176.643 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.245 0 CA-C-O 118.174 -1.348 . . . . 1.0 114.535 177.158 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.271 0 N-CA-C 110.135 -1.186 . . . . 1.0 110.135 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.6 tp -56.65 -49.04 76.19 Favored 'General case' 0 N--CA 1.468 0.425 0 C-N-CA 124.51 1.124 . . . . 1.0 112.635 -170.478 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -63.71 -45.27 90.72 Favored 'General case' 0 C--O 1.225 -0.203 0 C-N-CA 124.358 1.063 . . . . 1.0 110.031 -176.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.83 -50.23 51.01 Favored Glycine 0 CA--C 1.532 1.145 0 CA-C-N 113.976 -1.465 . . . . 1.0 111.724 170.5 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.86 -39.05 93.2 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 118.258 1.029 . . . . 1.0 112.048 179.315 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.0 mt -63.73 -62.94 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 C-N-CA 127.384 2.274 . . . . 1.0 106.827 177.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.82 -31.74 65.03 Favored 'General case' 0 CA--C 1.542 0.644 0 N-CA-C 112.387 0.514 . . . . 1.0 112.387 178.326 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.66 -49.86 61.96 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-N 119.846 1.203 . . . . 1.0 111.329 172.018 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -54.24 -26.88 31.12 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 123.929 0.892 . . . . 1.0 112.241 172.478 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -68.84 -10.71 13.7 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.061 0 C-N-CA 124.878 1.271 . . . . 1.0 109.88 -174.523 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -118.71 2.51 11.68 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.027 1.731 . . . . 1.0 111.47 172.02 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -149.12 82.23 1.43 Allowed 'General case' 0 C--O 1.235 0.303 0 O-C-N 120.995 -1.066 . . . . 1.0 109.029 -164.167 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 97.23 -1.97 60.97 Favored Glycine 0 CA--C 1.532 1.094 0 CA-C-O 118.98 -0.9 . . . . 1.0 112.719 -175.783 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 56.1 t-105 -50.75 150.16 3.0 Favored 'General case' 0 C--O 1.233 0.202 0 C-N-CA 125.738 1.615 . . . . 1.0 113.055 173.326 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -123.94 -105.73 0.35 Allowed 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 126.827 2.051 . . . . 1.0 107.873 177.621 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 63.37 -68.91 0.03 OUTLIER Glycine 0 CA--C 1.534 1.24 0 CA-C-N 121.868 2.122 . . . . 1.0 114.683 174.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 67.5 mtt -123.56 -3.98 8.28 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 126.56 1.944 . . . . 1.0 112.937 172.627 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.2 mp -103.59 47.12 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 C-N-CA 128.327 2.651 . . . . 1.0 105.442 174.594 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 22.1 t0 -139.13 102.01 4.41 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 126.718 2.007 . . . . 1.0 106.532 173.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.748 0 N-CA-C 109.729 -1.348 . . . . 1.0 109.729 -171.765 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.289 0 N-CA-C 110.132 -1.187 . . . . 1.0 110.132 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.9 tp -55.39 -48.28 74.57 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 124.424 1.09 . . . . 1.0 112.737 -169.374 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -63.47 -47.1 83.19 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 124.453 1.101 . . . . 1.0 110.659 -174.78 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.56 -51.55 47.47 Favored Glycine 0 CA--C 1.531 1.042 0 CA-C-N 113.918 -1.492 . . . . 1.0 111.026 170.701 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.91 -37.08 83.28 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 117.806 0.803 . . . . 1.0 112.489 179.506 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.53 -63.13 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 C-N-CA 127.771 2.429 . . . . 1.0 106.931 177.031 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -58.12 -27.79 64.06 Favored 'General case' 0 CA--C 1.539 0.547 0 N-CA-C 112.708 0.632 . . . . 1.0 112.708 179.417 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -67.48 -53.54 24.28 Favored Glycine 0 CA--C 1.531 1.055 0 CA-C-N 119.391 0.996 . . . . 1.0 111.302 169.502 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -51.44 -28.38 12.89 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 124.896 1.278 . . . . 1.0 112.397 174.338 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -65.98 -9.59 8.8 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.936 0 C-N-CA 126.161 1.784 . . . . 1.0 110.876 -175.858 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -130.13 8.9 5.2 Favored 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 126.723 2.009 . . . . 1.0 110.811 173.771 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -148.41 81.77 1.47 Allowed 'General case' 0 C--O 1.234 0.287 0 O-C-N 120.826 -1.171 . . . . 1.0 108.466 -166.47 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 91.89 7.26 64.58 Favored Glycine 0 CA--C 1.531 1.047 0 CA-C-O 119.023 -0.876 . . . . 1.0 112.393 -171.318 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . 0.436 ' HE1' ' CD1' ' A' ' 18' ' ' ILE . 60.4 t-105 -59.22 156.78 11.73 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 124.756 1.222 . . . . 1.0 112.098 175.684 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -140.02 -107.11 0.16 Allowed 'General case' 0 N--CA 1.449 -0.475 0 CA-C-N 115.433 -0.803 . . . . 1.0 108.883 167.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 65.79 -59.74 0.13 Allowed Glycine 0 CA--C 1.534 1.234 0 C-N-CA 126.839 2.162 . . . . 1.0 114.41 177.235 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 12.8 tmm? -128.81 -11.21 4.89 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 127.108 2.163 . . . . 1.0 112.666 175.537 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.436 ' CD1' ' HE1' ' A' ' 14' ' ' TRP . 2.5 mp -114.41 44.26 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.438 0 C-N-CA 128.687 2.795 . . . . 1.0 107.553 174.607 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -68.62 66.56 0.13 Allowed 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 128.792 2.837 . . . . 1.0 112.499 -176.353 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.073 0 C-N-CA 125.971 1.748 . . . . 1.0 114.758 -179.152 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.237 0 N-CA-C 110.169 -1.172 . . . . 1.0 110.169 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.2 tp -56.4 -47.96 77.92 Favored 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 124.442 1.097 . . . . 1.0 112.638 -170.538 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -63.58 -46.12 87.29 Favored 'General case' 0 C--N 1.33 -0.239 0 C-N-CA 124.406 1.082 . . . . 1.0 110.227 -177.016 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.33 -51.33 42.88 Favored Glycine 0 CA--C 1.53 1.025 0 CA-C-N 114.034 -1.439 . . . . 1.0 111.536 170.443 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.94 -39.09 90.88 Favored 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 117.953 0.877 . . . . 1.0 112.164 179.419 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.8 mt -63.57 -63.09 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.763 0 C-N-CA 127.568 2.347 . . . . 1.0 107.019 178.013 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.96 -29.44 63.21 Favored 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 112.537 0.569 . . . . 1.0 112.537 178.556 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.74 -53.43 34.73 Favored Glycine 0 CA--C 1.531 1.092 0 CA-C-N 119.447 1.021 . . . . 1.0 111.236 170.1 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -52.92 -30.77 36.39 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 124.955 1.302 . . . . 1.0 112.353 174.932 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -64.67 -14.04 15.46 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.846 0 C-N-CA 126.754 2.021 . . . . 1.0 111.456 -173.87 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -122.47 9.74 9.72 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 126.4 1.88 . . . . 1.0 110.749 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -140.37 -41.53 0.42 Allowed 'General case' 0 N--CA 1.465 0.323 0 O-C-N 121.096 -1.002 . . . . 1.0 113.522 -163.208 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -129.08 11.97 6.13 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 124.275 0.94 . . . . 1.0 112.046 175.173 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.559 ' CD1' HD11 ' A' ' 18' ' ' ILE . 54.0 t-105 -62.55 153.39 32.04 Favored 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 125.564 1.545 . . . . 1.0 113.405 -169.77 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -161.95 116.67 1.93 Allowed 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 127.391 2.276 . . . . 1.0 106.578 159.083 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 172.63 -3.36 0.03 OUTLIER Glycine 0 CA--C 1.529 0.936 0 C-N-CA 129.066 3.222 . . . . 1.0 111.11 171.457 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 11.8 ttt -144.44 12.08 1.51 Allowed 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 124.3 1.04 . . . . 1.0 113.058 176.877 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.559 HD11 ' CD1' ' A' ' 14' ' ' TRP . 0.9 OUTLIER . . . . . 0 CA--C 1.542 0.647 0 CA-C-O 123.34 1.543 . . . . 1.0 108.34 167.26 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.324 0 N-CA-C 110.127 -1.189 . . . . 1.0 110.127 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.0 tp -56.0 -48.35 76.06 Favored 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 124.414 1.085 . . . . 1.0 112.576 -170.118 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -63.62 -46.73 84.38 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 124.456 1.103 . . . . 1.0 110.192 -176.79 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.68 -49.17 54.43 Favored Glycine 0 CA--C 1.53 1.004 0 CA-C-N 114.022 -1.445 . . . . 1.0 111.6 171.043 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -63.76 -39.81 95.18 Favored 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 118.198 0.999 . . . . 1.0 111.925 178.951 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.2 mt -63.63 -63.05 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.775 0 C-N-CA 127.434 2.294 . . . . 1.0 107.173 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.27 -34.13 68.34 Favored 'General case' 0 CA--C 1.542 0.641 0 CA-C-O 119.33 -0.367 . . . . 1.0 111.648 177.696 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -59.25 -50.67 65.33 Favored Glycine 0 CA--C 1.531 1.055 0 O-C-N 120.65 -1.281 . . . . 1.0 111.271 172.168 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -54.43 -33.04 58.68 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 124.186 0.994 . . . . 1.0 111.86 173.88 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -66.71 -14.65 18.21 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.916 0 C-N-CA 126.115 1.766 . . . . 1.0 110.065 -173.023 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -111.44 -1.17 16.01 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.331 1.452 . . . . 1.0 112.154 177.619 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 49.1 m-80 -138.05 -43.11 0.52 Allowed 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 119.623 1.101 . . . . 1.0 113.202 -159.186 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -121.29 8.92 10.26 Favored Glycine 0 CA--C 1.526 0.738 0 C-N-CA 124.133 0.873 . . . . 1.0 111.724 176.578 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.535 ' CD1' HD11 ' A' ' 18' ' ' ILE . 55.1 t-105 -62.59 154.53 28.71 Favored 'General case' 0 N--CA 1.444 -0.726 0 C-N-CA 125.472 1.509 . . . . 1.0 113.028 -170.736 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -160.73 116.42 2.25 Favored 'General case' 0 N--CA 1.44 -0.95 0 C-N-CA 125.797 1.639 . . . . 1.0 106.977 159.048 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 175.38 -7.99 0.03 OUTLIER Glycine 0 CA--C 1.53 0.979 0 C-N-CA 128.98 3.181 . . . . 1.0 110.642 168.095 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' MET . . . . . 0.463 ' HB3' ' HE1' ' A' ' 14' ' ' TRP . 8.0 tpt -133.1 8.41 4.04 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 125.174 1.39 . . . . 1.0 113.451 177.59 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.535 HD11 ' CD1' ' A' ' 14' ' ' TRP . 1.6 mp . . . . . 0 CA--C 1.542 0.665 0 CA-C-O 123.123 1.44 . . . . 1.0 108.288 170.223 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.199 0 N-CA-C 109.956 -1.258 . . . . 1.0 109.956 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.4 tp -56.12 -48.83 75.46 Favored 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 124.519 1.128 . . . . 1.0 112.582 -171.153 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.2 t80 -63.62 -45.58 89.65 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 124.585 1.154 . . . . 1.0 109.988 -176.069 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.39 -50.27 53.38 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-N 114.026 -1.443 . . . . 1.0 111.648 170.525 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.83 -38.73 91.94 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 118.101 0.95 . . . . 1.0 112.134 178.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.2 mt -63.46 -63.18 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.774 0 C-N-CA 127.606 2.362 . . . . 1.0 106.877 178.268 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.68 -34.75 67.7 Favored 'General case' 0 CA--C 1.543 0.677 0 CA-C-O 119.263 -0.398 . . . . 1.0 111.809 178.375 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -60.6 -49.92 73.26 Favored Glycine 0 CA--C 1.531 1.047 0 O-C-N 120.667 -1.271 . . . . 1.0 111.348 172.691 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -55.39 -31.29 61.7 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 124.2 1.0 . . . . 1.0 112.064 173.191 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -67.59 -14.24 17.95 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.91 0 C-N-CA 125.761 1.624 . . . . 1.0 109.737 -173.799 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -110.08 -0.79 17.85 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 125.503 1.521 . . . . 1.0 111.94 177.592 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 50.3 m-80 -139.55 -41.68 0.45 Allowed 'General case' 0 N--CA 1.472 0.651 0 CA-C-N 119.74 1.155 . . . . 1.0 113.398 -159.259 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -124.45 9.05 8.29 Favored Glycine 0 CA--C 1.527 0.815 0 C-N-CA 124.222 0.915 . . . . 1.0 111.892 177.089 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.509 ' CD1' HD11 ' A' ' 18' ' ' ILE . 50.4 t-105 -60.21 154.68 19.19 Favored 'General case' 0 N--CA 1.446 -0.641 0 C-N-CA 125.789 1.636 . . . . 1.0 113.469 -171.393 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -160.83 116.56 2.23 Favored 'General case' 0 N--CA 1.44 -0.946 0 C-N-CA 125.703 1.601 . . . . 1.0 107.308 158.959 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 170.51 3.61 0.03 OUTLIER Glycine 0 CA--C 1.528 0.845 0 C-N-CA 128.554 2.978 . . . . 1.0 111.656 165.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 15.1 ttp -143.86 14.35 1.72 Allowed 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.017 1.327 . . . . 1.0 112.654 175.469 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.509 HD11 ' CD1' ' A' ' 14' ' ' TRP . 2.1 mp . . . . . 0 CA--C 1.537 0.462 0 CA-C-O 122.914 1.34 . . . . 1.0 108.095 167.542 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.313 0 N-CA-C 110.219 -1.152 . . . . 1.0 110.219 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.6 tp -56.39 -48.63 76.5 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 124.605 1.162 . . . . 1.0 112.57 -171.391 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.4 t80 -63.57 -45.86 88.53 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 124.348 1.059 . . . . 1.0 109.97 -177.129 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -51.67 -51.05 40.41 Favored Glycine 0 CA--C 1.531 1.038 0 CA-C-N 114.017 -1.447 . . . . 1.0 111.689 170.169 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.58 -39.45 93.74 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 118.26 1.03 . . . . 1.0 112.124 179.563 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.56 -63.05 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.763 0 C-N-CA 127.442 2.297 . . . . 1.0 106.969 178.23 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.04 -32.14 63.78 Favored 'General case' 0 CA--C 1.541 0.631 0 O-C-N 122.021 -0.424 . . . . 1.0 112.132 177.489 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -61.51 -52.84 48.54 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-N 119.951 1.251 . . . . 1.0 111.088 171.093 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -51.72 -33.67 35.47 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 124.192 0.997 . . . . 1.0 112.069 174.299 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -64.08 -13.96 14.55 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.907 0 C-N-CA 126.801 2.04 . . . . 1.0 111.333 -172.823 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -126.63 6.76 6.83 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 125.733 1.613 . . . . 1.0 111.711 178.517 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -139.23 -32.45 0.66 Allowed 'General case' 0 N--CA 1.471 0.61 0 O-C-N 121.231 -0.918 . . . . 1.0 112.805 -163.71 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -137.32 13.65 3.76 Favored Glycine 0 CA--C 1.526 0.735 0 C-N-CA 124.338 0.97 . . . . 1.0 111.627 174.865 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.478 ' CD1' HD11 ' A' ' 18' ' ' ILE . 56.8 t-105 -56.47 157.16 5.32 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 126.278 1.831 . . . . 1.0 113.648 -168.556 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -157.39 115.04 3.09 Favored 'General case' 0 N--CA 1.436 -1.171 0 N-CA-C 101.663 -3.458 . . . . 1.0 101.663 176.948 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 149.86 -4.01 0.62 Allowed Glycine 0 CA--C 1.531 1.045 0 C-N-CA 125.059 1.314 . . . . 1.0 114.866 167.637 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' MET . . . . . 0.42 ' CB ' ' HE1' ' A' ' 14' ' ' TRP . 15.7 ttt -130.75 9.72 5.02 Favored 'General case' 0 CA--C 1.54 0.576 0 CA-C-N 118.847 1.324 . . . . 1.0 111.961 172.916 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.478 HD11 ' CD1' ' A' ' 14' ' ' TRP . 1.2 mp . . . . . 0 CA--C 1.539 0.522 0 N-CA-C 107.51 -1.293 . . . . 1.0 107.51 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.251 0 N-CA-C 109.917 -1.273 . . . . 1.0 109.917 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 8.4 tp -54.83 -50.49 68.46 Favored 'General case' 0 N--CA 1.467 0.388 0 C-N-CA 124.586 1.154 . . . . 1.0 112.76 -169.581 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.2 t80 -63.71 -46.79 83.84 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 124.17 0.988 . . . . 1.0 110.383 -175.129 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.16 -51.03 49.25 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-N 114.032 -1.44 . . . . 1.0 111.428 171.408 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -60.97 -40.63 94.13 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 123.682 0.793 . . . . 1.0 111.835 178.899 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.3 mt -63.43 -63.21 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.794 0 C-N-CA 127.511 2.324 . . . . 1.0 107.082 178.873 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.99 -33.22 66.91 Favored 'General case' 0 CA--C 1.542 0.65 0 CA-C-O 118.999 -0.524 . . . . 1.0 112.148 179.634 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.37 -50.92 58.71 Favored Glycine 0 CA--C 1.532 1.097 0 CA-C-N 120.062 1.301 . . . . 1.0 111.339 171.431 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -53.42 -30.63 41.35 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 124.457 1.103 . . . . 1.0 112.22 173.744 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -66.93 -13.72 16.97 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.921 0 C-N-CA 126.27 1.828 . . . . 1.0 110.546 -173.645 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -112.18 1.72 16.35 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 125.054 1.342 . . . . 1.0 111.905 176.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 12.5 t30 -139.09 -48.64 0.49 Allowed 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 119.353 0.978 . . . . 1.0 112.862 -159.547 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -118.71 9.86 12.61 Favored Glycine 0 CA--C 1.527 0.833 0 C-N-CA 124.303 0.954 . . . . 1.0 111.965 178.117 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.403 ' CD1' HD11 ' A' ' 18' ' ' ILE . 65.0 t-105 -56.93 164.93 1.38 Allowed 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 126.395 1.878 . . . . 1.0 114.55 -168.372 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -150.13 91.16 1.74 Allowed 'General case' 0 N--CA 1.442 -0.869 0 C-N-CA 125.054 1.342 . . . . 1.0 111.265 -175.716 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 165.94 -16.13 0.09 OUTLIER Glycine 0 CA--C 1.529 0.942 0 CA-C-N 115.405 -0.816 . . . . 1.0 114.734 165.053 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 1.3 mpt? -107.69 6.78 28.04 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 124.38 1.072 . . . . 1.0 111.766 175.825 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.479 HD12 ' N ' ' A' ' 18' ' ' ILE . 1.6 mp . . . . . 0 CA--C 1.539 0.525 0 N-CA-C 106.844 -1.539 . . . . 1.0 106.844 -174.5 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.21 0 N-CA-C 110.155 -1.178 . . . . 1.0 110.155 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 8.7 tp -54.91 -49.05 72.22 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 124.522 1.129 . . . . 1.0 112.695 -169.147 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 12.2 t80 -63.76 -47.17 82.07 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 124.319 1.048 . . . . 1.0 110.538 -175.377 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.21 -51.11 48.96 Favored Glycine 0 CA--C 1.53 1.021 0 CA-C-N 114.072 -1.422 . . . . 1.0 111.287 171.187 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.19 -39.53 90.52 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 117.74 0.77 . . . . 1.0 111.952 179.28 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.47 -63.1 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.78 0 C-N-CA 127.654 2.381 . . . . 1.0 107.143 178.174 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.48 -29.93 64.67 Favored 'General case' 0 CA--C 1.539 0.543 0 N-CA-C 112.714 0.635 . . . . 1.0 112.714 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.58 -52.68 32.89 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-N 119.702 1.137 . . . . 1.0 111.206 170.094 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -52.43 -28.61 20.65 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 124.64 1.176 . . . . 1.0 112.3 174.415 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -64.83 -13.1 14.16 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.871 0 C-N-CA 125.98 1.712 . . . . 1.0 110.887 -175.568 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -126.82 6.94 6.71 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 126.357 1.863 . . . . 1.0 111.371 175.032 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 -147.69 90.61 1.87 Allowed 'General case' 0 C--N 1.341 0.196 0 O-C-N 120.956 -1.09 . . . . 1.0 109.291 -165.034 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 77.35 12.7 84.32 Favored Glycine 0 CA--C 1.532 1.124 0 CA-C-O 118.632 -1.094 . . . . 1.0 112.378 -169.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.449 ' CD1' HD11 ' A' ' 18' ' ' ILE . 55.8 t-105 -51.99 156.15 1.62 Allowed 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.492 1.517 . . . . 1.0 112.967 176.62 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -159.1 101.92 1.6 Allowed 'General case' 0 N--CA 1.445 -0.711 0 C-N-CA 126.241 1.816 . . . . 1.0 106.327 -179.224 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 159.5 -5.79 0.12 Allowed Glycine 0 CA--C 1.53 1.03 0 CA-C-O 118.861 -0.966 . . . . 1.0 115.254 171.373 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' MET . . . . . 0.44 ' CB ' ' HE1' ' A' ' 14' ' ' TRP . 13.3 ttt -128.52 11.19 6.26 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 118.92 1.36 . . . . 1.0 111.947 174.095 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.449 HD11 ' CD1' ' A' ' 14' ' ' TRP . 1.7 mp . . . . . 0 CA--C 1.538 0.503 0 C-N-CA 124.977 1.311 . . . . 1.0 107.473 179.411 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.254 0 N-CA-C 110.165 -1.174 . . . . 1.0 110.165 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.5 tp -56.19 -48.63 76.01 Favored 'General case' 0 N--CA 1.468 0.449 0 C-N-CA 124.494 1.118 . . . . 1.0 112.659 -171.635 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -63.64 -45.42 90.32 Favored 'General case' 0 N--CA 1.455 -0.206 0 C-N-CA 124.18 0.992 . . . . 1.0 109.724 -178.11 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -50.74 -50.42 37.33 Favored Glycine 0 CA--C 1.532 1.13 0 CA-C-N 114.138 -1.392 . . . . 1.0 112.124 170.169 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -63.0 -41.53 99.61 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 118.143 0.972 . . . . 1.0 111.854 179.253 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.56 -63.01 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.843 0 C-N-CA 127.339 2.255 . . . . 1.0 106.695 179.663 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -54.25 -37.59 64.84 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.636 0.774 . . . . 1.0 111.814 177.332 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.34 -51.73 55.89 Favored Glycine 0 CA--C 1.531 1.049 0 CA-C-N 119.825 1.193 . . . . 1.0 111.42 173.346 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -58.46 -26.43 63.35 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 124.244 1.018 . . . . 1.0 112.712 174.031 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -68.91 -18.24 22.81 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.78 0 CA-C-N 119.776 1.171 . . . . 1.0 110.604 -172.123 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -109.53 0.73 19.35 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 125.873 1.669 . . . . 1.0 111.576 173.533 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 13.3 t-20 -152.05 95.84 2.12 Favored 'General case' 0 C--N 1.344 0.335 0 O-C-N 120.567 -1.333 . . . . 1.0 110.182 -159.287 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 74.94 11.16 83.92 Favored Glycine 0 CA--C 1.531 1.058 0 CA-C-O 118.583 -1.12 . . . . 1.0 112.414 -170.479 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.445 ' CD1' HD11 ' A' ' 18' ' ' ILE . 59.3 t-105 -50.25 154.96 1.08 Allowed 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 125.513 1.525 . . . . 1.0 113.105 175.981 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -159.22 100.63 1.54 Allowed 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 106.045 -1.835 . . . . 1.0 106.045 -178.146 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 162.51 -6.84 0.08 OUTLIER Glycine 0 CA--C 1.532 1.133 0 CA-C-O 118.762 -1.021 . . . . 1.0 115.278 173.369 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' MET . . . . . 0.42 ' CB ' ' HE1' ' A' ' 14' ' ' TRP . 30.6 ttp -129.76 9.69 5.46 Favored 'General case' 0 CA--C 1.539 0.519 0 CA-C-N 119.128 1.464 . . . . 1.0 111.975 175.244 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.445 HD11 ' CD1' ' A' ' 14' ' ' TRP . 1.6 mp . . . . . 0 CA--C 1.538 0.506 0 N-CA-C 107.314 -1.365 . . . . 1.0 107.314 -178.02 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.329 0 N-CA-C 110.027 -1.229 . . . . 1.0 110.027 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.5 tp -57.98 -47.65 82.36 Favored 'General case' 0 N--CA 1.466 0.365 0 C-N-CA 124.25 1.02 . . . . 1.0 112.325 -172.212 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.6 t80 -63.59 -44.75 93.13 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 124.306 1.042 . . . . 1.0 109.759 -177.862 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -51.63 -50.64 41.9 Favored Glycine 0 CA--C 1.533 1.191 0 CA-C-N 114.241 -1.345 . . . . 1.0 112.044 170.016 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -63.1 -40.07 96.56 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 118.369 1.084 . . . . 1.0 112.147 179.667 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.0 mt -63.58 -62.93 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.773 0 C-N-CA 127.673 2.389 . . . . 1.0 106.433 178.736 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -53.85 -32.46 53.05 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 123.599 0.76 . . . . 1.0 112.278 175.999 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.57 -53.98 40.78 Favored Glycine 0 CA--C 1.53 0.992 0 CA-C-N 119.81 1.186 . . . . 1.0 111.158 171.614 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -56.04 -28.01 55.63 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 123.657 0.783 . . . . 1.0 112.443 174.406 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -69.0 -10.27 13.16 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.889 0 C-N-CA 124.798 1.239 . . . . 1.0 110.446 -174.163 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -123.81 8.53 8.78 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 126.972 2.109 . . . . 1.0 110.946 176.452 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -156.46 92.99 1.36 Allowed 'General case' 0 C--N 1.343 0.294 0 O-C-N 120.513 -1.367 . . . . 1.0 109.285 -169.436 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 85.16 6.49 84.48 Favored Glycine 0 CA--C 1.53 0.988 0 CA-C-O 118.749 -1.028 . . . . 1.0 112.663 -172.183 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.54 ' CD1' HD11 ' A' ' 18' ' ' ILE . 55.3 t-105 -55.79 155.14 6.22 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 124.739 1.216 . . . . 1.0 112.525 176.791 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -162.16 104.06 1.13 Allowed 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 105.421 -2.066 . . . . 1.0 105.421 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 162.07 -8.59 0.1 OUTLIER Glycine 0 CA--C 1.528 0.895 0 CA-C-O 118.939 -0.923 . . . . 1.0 115.048 174.581 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 31.7 ttm -132.09 8.34 4.38 Favored 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 118.913 1.356 . . . . 1.0 112.257 174.726 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.54 HD11 ' CD1' ' A' ' 14' ' ' TRP . 0.7 OUTLIER . . . . . 0 CA--C 1.535 0.375 0 C-N-CA 124.695 1.198 . . . . 1.0 108.955 -179.476 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.245 0 N-CA-C 110.211 -1.155 . . . . 1.0 110.211 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.9 tp -56.12 -48.85 75.41 Favored 'General case' 0 N--CA 1.467 0.388 0 C-N-CA 124.613 1.165 . . . . 1.0 112.604 -170.604 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.5 t80 -63.63 -46.05 87.45 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 124.341 1.056 . . . . 1.0 110.068 -176.97 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.55 -50.05 49.98 Favored Glycine 0 CA--C 1.53 1.015 0 CA-C-N 114.194 -1.367 . . . . 1.0 111.667 170.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.0 -40.94 97.36 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 118.174 0.987 . . . . 1.0 111.944 178.849 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.2 mt -63.58 -63.18 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.782 0 C-N-CA 127.509 2.324 . . . . 1.0 107.251 179.267 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -58.13 -29.17 65.33 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 123.508 0.723 . . . . 1.0 112.484 178.715 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.62 -54.29 29.78 Favored Glycine 0 CA--C 1.529 0.951 0 CA-C-N 119.464 1.029 . . . . 1.0 110.832 170.038 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -52.24 -28.62 19.35 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 124.413 1.085 . . . . 1.0 112.42 174.608 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -65.99 -11.63 12.92 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.867 0 C-N-CA 125.825 1.65 . . . . 1.0 111.016 -175.213 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -126.81 8.25 6.84 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 126.663 1.985 . . . . 1.0 110.877 174.32 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -148.1 83.53 1.51 Allowed 'General case' 0 C--O 1.234 0.274 0 O-C-N 120.817 -1.177 . . . . 1.0 108.719 -166.69 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 88.33 7.38 72.91 Favored Glycine 0 CA--C 1.531 1.054 0 CA-C-O 118.992 -0.893 . . . . 1.0 112.587 -173.958 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.496 ' CD1' HD11 ' A' ' 18' ' ' ILE . 55.8 t-105 -52.87 155.23 2.46 Favored 'General case' 0 N--CA 1.452 -0.336 0 C-N-CA 125.655 1.582 . . . . 1.0 113.185 175.698 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -160.35 102.65 1.4 Allowed 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 126.275 1.83 . . . . 1.0 106.124 178.744 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 167.92 -17.44 0.08 OUTLIER Glycine 0 CA--C 1.529 0.94 0 CA-C-O 118.842 -0.977 . . . . 1.0 114.959 170.247 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' MET . . . . . 0.433 ' HB2' ' HE1' ' A' ' 14' ' ' TRP . 0.0 OUTLIER -126.68 19.14 7.31 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-N 118.828 1.314 . . . . 1.0 112.662 175.607 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.496 HD11 ' CD1' ' A' ' 14' ' ' TRP . 1.4 mp . . . . . 0 CA--C 1.537 0.465 0 N-CA-C 106.853 -1.536 . . . . 1.0 106.853 172.736 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.238 0 N-CA-C 109.808 -1.317 . . . . 1.0 109.808 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 14.9 tp -55.45 -51.4 67.06 Favored 'General case' 0 N--CA 1.466 0.351 0 C-N-CA 124.836 1.254 . . . . 1.0 113.068 -169.064 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.5 t80 -63.8 -46.25 86.0 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 124.155 0.982 . . . . 1.0 110.136 -176.348 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.73 -49.18 54.69 Favored Glycine 0 CA--C 1.532 1.12 0 CA-C-N 114.02 -1.446 . . . . 1.0 111.723 171.046 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.81 -40.26 96.83 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 118.059 0.93 . . . . 1.0 111.751 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.55 -63.02 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.835 0 C-N-CA 127.318 2.247 . . . . 1.0 106.969 178.502 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -55.93 -34.39 65.57 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 122.991 0.516 . . . . 1.0 112.141 178.296 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -61.91 -50.96 60.48 Favored Glycine 0 CA--C 1.531 1.089 0 O-C-N 120.817 -1.177 . . . . 1.0 111.328 172.732 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -56.81 -25.03 54.85 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 124.505 1.122 . . . . 1.0 112.58 173.73 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -68.43 -16.32 20.82 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.948 0 C-N-CA 124.571 1.148 . . . . 1.0 110.415 -172.779 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -110.69 1.85 18.17 Favored 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 125.752 1.621 . . . . 1.0 111.439 172.553 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -150.32 81.97 1.36 Allowed 'General case' 0 C--O 1.235 0.337 0 O-C-N 120.969 -1.082 . . . . 1.0 108.95 -160.454 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 95.41 -0.18 63.4 Favored Glycine 0 CA--C 1.53 0.988 0 CA-C-O 118.947 -0.918 . . . . 1.0 112.789 -176.18 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.532 ' CD1' HD11 ' A' ' 18' ' ' ILE . 57.5 t-105 -54.61 154.47 4.86 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 125.06 1.344 . . . . 1.0 112.661 173.257 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -158.09 116.53 3.08 Favored 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 125.729 1.612 . . . . 1.0 107.065 159.08 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 173.19 4.11 0.03 OUTLIER Glycine 0 CA--C 1.527 0.816 0 C-N-CA 128.582 2.991 . . . . 1.0 111.829 165.162 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 22.0 ttp -143.67 10.05 1.59 Allowed 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 125.173 1.389 . . . . 1.0 112.995 178.145 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.532 HD11 ' CD1' ' A' ' 14' ' ' TRP . 2.4 mp . . . . . 0 CA--C 1.54 0.588 0 CA-C-O 122.723 1.249 . . . . 1.0 107.635 172.311 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.266 0 N-CA-C 110.112 -1.195 . . . . 1.0 110.112 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.3 tp -55.66 -49.13 73.73 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 124.656 1.182 . . . . 1.0 112.755 -170.506 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -63.63 -46.92 83.5 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 124.251 1.02 . . . . 1.0 110.134 -176.648 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.05 -50.06 46.81 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-N 114.083 -1.417 . . . . 1.0 111.61 171.16 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.26 -41.17 98.21 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 117.986 0.893 . . . . 1.0 111.928 178.916 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.2 mt -63.48 -63.24 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 C-N-CA 127.458 2.303 . . . . 1.0 107.196 179.606 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.87 -33.04 68.27 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 122.887 0.475 . . . . 1.0 111.98 179.014 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -61.0 -52.4 52.49 Favored Glycine 0 CA--C 1.53 1.004 0 CA-C-N 119.883 1.219 . . . . 1.0 111.09 171.671 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -54.4 -27.82 39.33 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 124.096 0.958 . . . . 1.0 112.396 173.888 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -68.38 -12.12 15.33 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.956 0 C-N-CA 125.199 1.399 . . . . 1.0 110.161 -174.595 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -117.11 1.77 12.57 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 125.92 1.688 . . . . 1.0 111.516 173.431 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -149.53 84.3 1.42 Allowed 'General case' 0 C--O 1.234 0.261 0 O-C-N 121.111 -0.993 . . . . 1.0 108.573 -160.167 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 87.68 6.73 76.31 Favored Glycine 0 CA--C 1.531 1.041 0 CA-C-O 118.725 -1.042 . . . . 1.0 112.613 -174.034 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.498 ' CD1' HD11 ' A' ' 18' ' ' ILE . 54.6 t-105 -53.68 152.49 5.2 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 124.878 1.271 . . . . 1.0 112.208 173.386 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -158.48 116.56 2.96 Favored 'General case' 0 N--CA 1.441 -0.924 0 C-N-CA 125.81 1.644 . . . . 1.0 107.042 159.147 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.407 ' H ' ' H ' ' A' ' 17' ' ' MET . . . 172.4 5.28 0.03 OUTLIER Glycine 0 CA--C 1.528 0.882 0 C-N-CA 129.248 3.308 . . . . 1.0 111.747 168.907 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' MET . . . . . 0.414 ' CB ' ' HE1' ' A' ' 14' ' ' TRP . 23.2 ttm -147.91 10.77 0.93 Allowed 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 125.054 1.341 . . . . 1.0 113.329 178.868 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.498 HD11 ' CD1' ' A' ' 14' ' ' TRP . 3.1 mp . . . . . 0 CA--C 1.544 0.745 0 N-CA-C 106.581 -1.637 . . . . 1.0 106.581 172.225 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.313 0 N-CA-C 110.478 -1.049 . . . . 1.0 110.478 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.4 tp -55.83 -48.19 75.91 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 124.528 1.131 . . . . 1.0 112.578 -170.543 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -63.65 -45.51 89.85 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 124.567 1.147 . . . . 1.0 110.123 -176.424 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.01 -50.89 49.33 Favored Glycine 0 CA--C 1.531 1.087 0 CA-C-N 113.973 -1.467 . . . . 1.0 111.595 170.302 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.8 -38.6 91.3 Favored 'General case' 0 CA--C 1.535 0.396 0 CA-C-N 118.126 0.963 . . . . 1.0 112.072 179.22 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.7 mt -63.58 -62.96 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 C-N-CA 127.516 2.326 . . . . 1.0 106.717 178.376 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.66 -34.21 69.13 Favored 'General case' 0 CA--C 1.541 0.635 0 CA-C-O 119.134 -0.46 . . . . 1.0 111.793 179.124 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -60.0 -50.21 70.16 Favored Glycine 0 CA--C 1.532 1.14 0 CA-C-N 120.049 1.295 . . . . 1.0 111.235 172.36 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -54.75 -31.06 58.04 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 124.242 1.017 . . . . 1.0 112.143 173.845 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -68.21 -11.83 14.87 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.822 0 C-N-CA 126.463 1.905 . . . . 1.0 111.112 -172.189 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -121.1 6.65 10.28 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.788 1.635 . . . . 1.0 111.348 176.714 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 27.1 t-20 -138.84 -45.87 0.48 Allowed 'General case' 0 N--CA 1.466 0.336 0 O-C-N 121.312 -0.867 . . . . 1.0 113.29 -161.665 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.24 14.49 8.29 Favored Glycine 0 CA--C 1.528 0.863 0 C-N-CA 124.687 1.137 . . . . 1.0 111.477 175.806 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.589 ' CD1' HD11 ' A' ' 18' ' ' ILE . 57.7 t-105 -60.13 163.05 5.17 Favored 'General case' 0 N--CA 1.447 -0.582 0 C-N-CA 126.281 1.832 . . . . 1.0 113.845 -168.017 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -150.06 95.48 2.29 Favored 'General case' 0 N--CA 1.445 -0.715 0 C-N-CA 125.271 1.429 . . . . 1.0 108.127 177.131 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 166.72 -5.0 0.05 OUTLIER Glycine 0 CA--C 1.534 1.27 0 N-CA-C 117.085 1.594 . . . . 1.0 117.085 171.562 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' MET . . . . . 0.477 ' H ' HD12 ' A' ' 18' ' ' ILE . 4.0 ppp? -130.68 9.68 5.05 Favored 'General case' 0 N--CA 1.475 0.786 0 CA-C-N 119.541 1.67 . . . . 1.0 113.628 167.831 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.589 HD11 ' CD1' ' A' ' 14' ' ' TRP . 0.5 OUTLIER . . . . . 0 CA--C 1.541 0.621 0 N-CA-C 107.543 -1.28 . . . . 1.0 107.543 -176.615 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.225 0 N-CA-C 110.131 -1.188 . . . . 1.0 110.131 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.1 tp -55.04 -49.13 72.34 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 124.625 1.17 . . . . 1.0 112.582 -170.778 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -63.77 -46.75 83.83 Favored 'General case' 0 C--N 1.331 -0.199 0 C-N-CA 124.325 1.05 . . . . 1.0 110.327 -176.316 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.52 -49.3 57.84 Favored Glycine 0 CA--C 1.531 1.071 0 CA-C-N 114.168 -1.378 . . . . 1.0 111.48 171.703 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.58 -39.78 94.79 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-N 117.989 0.895 . . . . 1.0 111.932 178.894 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.6 mt -63.75 -63.05 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.801 0 C-N-CA 127.524 2.33 . . . . 1.0 106.866 178.578 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.44 -31.63 66.09 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 122.972 0.509 . . . . 1.0 112.256 179.009 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.72 -51.55 52.95 Favored Glycine 0 CA--C 1.53 1.0 0 CA-C-N 119.954 1.252 . . . . 1.0 111.018 171.09 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -54.12 -26.68 28.7 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 124.072 0.949 . . . . 1.0 112.36 173.671 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -67.76 -10.04 11.72 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.878 0 C-N-CA 125.175 1.39 . . . . 1.0 110.59 -175.372 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -127.16 6.76 6.48 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 126.524 1.93 . . . . 1.0 111.376 173.788 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 13.1 t-20 -148.51 93.36 2.13 Favored 'General case' 0 C--N 1.342 0.239 0 O-C-N 120.81 -1.181 . . . . 1.0 109.691 -164.384 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 76.93 10.84 85.99 Favored Glycine 0 CA--C 1.533 1.187 0 CA-C-O 118.979 -0.901 . . . . 1.0 112.199 -167.623 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.5 ' CD1' HD11 ' A' ' 18' ' ' ILE . 53.2 t-105 -53.82 161.09 1.22 Allowed 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 126.06 1.744 . . . . 1.0 113.228 176.877 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -152.49 98.08 2.33 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 125.579 1.552 . . . . 1.0 107.754 177.391 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.411 ' H ' HD12 ' A' ' 18' ' ' ILE . . . 161.3 -4.44 0.09 OUTLIER Glycine 0 CA--C 1.531 1.074 0 N-CA-C 116.29 1.276 . . . . 1.0 116.29 170.026 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 4.3 ppp? -116.65 -0.9 12.25 Favored 'General case' 0 N--CA 1.47 0.551 0 CA-C-N 119.17 1.485 . . . . 1.0 112.695 169.451 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.5 HD11 ' CD1' ' A' ' 14' ' ' TRP . 1.4 mp . . . . . 0 CA--C 1.543 0.69 0 CA-C-O 123.281 1.515 . . . . 1.0 107.54 -168.076 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.173 0 N-CA-C 110.186 -1.165 . . . . 1.0 110.186 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.7 tp -55.84 -50.25 71.08 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 124.89 1.276 . . . . 1.0 112.963 -170.225 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.2 t80 -63.53 -47.93 79.62 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 124.077 0.951 . . . . 1.0 110.241 -176.806 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -50.89 -50.46 38.05 Favored Glycine 0 CA--C 1.53 0.969 0 CA-C-N 114.087 -1.415 . . . . 1.0 111.485 171.338 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.01 -43.23 99.19 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 117.896 0.848 . . . . 1.0 111.722 178.842 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.4 mt -63.51 -63.31 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.673 0 C-N-CA 127.246 2.218 . . . . 1.0 107.55 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -60.73 -27.85 68.23 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 123.579 0.752 . . . . 1.0 112.524 -179.226 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.55 -55.16 21.95 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 110.655 -0.978 . . . . 1.0 110.655 169.697 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -51.22 -31.41 20.46 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 124.657 1.183 . . . . 1.0 112.297 176.124 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -60.07 -17.53 14.03 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.737 0 C-N-CA 126.631 1.973 . . . . 1.0 111.615 -174.263 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -129.58 9.84 5.56 Favored 'General case' 0 CA--C 1.545 0.767 0 C-N-CA 125.942 1.697 . . . . 1.0 110.391 177.36 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -147.6 78.91 1.47 Allowed 'General case' 0 C--O 1.234 0.279 0 C-N-CA 124.869 1.268 . . . . 1.0 108.905 -170.055 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 98.96 -3.16 58.48 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-O 119.198 -0.779 . . . . 1.0 112.875 -177.65 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.608 ' CD1' HD12 ' A' ' 18' ' ' ILE . 24.6 t-105 -55.17 155.76 4.59 Favored 'General case' 0 N--CA 1.456 -0.174 0 C-N-CA 124.795 1.238 . . . . 1.0 112.321 168.362 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -157.01 116.23 3.38 Favored 'General case' 0 N--CA 1.428 -1.572 0 C-N-CA 124.875 1.27 . . . . 1.0 108.156 158.798 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -160.61 -102.68 0.18 Allowed Glycine 0 CA--C 1.524 0.598 0 C-N-CA 125.557 1.551 . . . . 1.0 109.487 169.639 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 4.8 mpp? -71.03 6.75 1.43 Allowed 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 124.718 1.207 . . . . 1.0 113.242 -177.659 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.608 HD12 ' CD1' ' A' ' 14' ' ' TRP . 48.6 mt . . . . . 0 CA--C 1.533 0.3 0 N-CA-C 105.769 -1.937 . . . . 1.0 105.769 176.22 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.306 0 N-CA-C 110.225 -1.15 . . . . 1.0 110.225 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.1 tp -56.86 -49.18 76.24 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 124.57 1.148 . . . . 1.0 112.596 -171.268 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -63.65 -45.52 89.83 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 124.45 1.1 . . . . 1.0 110.128 -176.706 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.98 -50.16 56.07 Favored Glycine 0 CA--C 1.532 1.115 0 CA-C-N 114.031 -1.44 . . . . 1.0 111.497 171.097 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.08 -38.31 88.36 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 118.044 0.922 . . . . 1.0 112.095 179.145 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.9 mt -63.58 -63.22 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.694 0 C-N-CA 127.855 2.462 . . . . 1.0 107.299 176.993 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.8 -26.53 58.12 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 113.062 0.764 . . . . 1.0 113.062 177.773 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -67.32 -56.02 13.48 Favored Glycine 0 CA--C 1.531 1.073 0 CA-C-N 119.312 0.96 . . . . 1.0 111.066 168.35 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -47.98 -34.41 9.24 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 125.687 1.595 . . . . 1.0 112.193 175.058 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -57.29 -19.98 11.97 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.771 0 C-N-CA 127.336 2.254 . . . . 1.0 111.629 -175.984 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -132.15 15.09 4.66 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 126.783 2.033 . . . . 1.0 111.275 -178.355 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 21.4 t-20 -137.31 -33.45 0.74 Allowed 'General case' 0 N--CA 1.467 0.405 0 O-C-N 121.352 -0.842 . . . . 1.0 113.236 -170.889 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -139.42 9.21 3.2 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-O 119.017 -0.88 . . . . 1.0 112.53 174.647 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.675 ' CD1' HD12 ' A' ' 18' ' ' ILE . 35.3 t-105 -62.51 145.35 54.49 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 118.152 0.976 . . . . 1.0 113.271 -173.01 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 48.0 mt-10 -155.11 114.47 3.66 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 105.32 -2.104 . . . . 1.0 105.32 158.968 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -167.06 -24.79 0.02 OUTLIER Glycine 0 CA--C 1.53 0.982 0 N-CA-C 115.603 1.001 . . . . 1.0 115.603 168.738 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -133.74 -0.41 3.16 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 118.669 1.235 . . . . 1.0 112.962 172.235 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.675 HD12 ' CD1' ' A' ' 14' ' ' TRP . 59.8 mt . . . . . 0 CA--C 1.532 0.26 0 N-CA-C 105.147 -2.168 . . . . 1.0 105.147 -176.221 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.371 0 N-CA-C 109.89 -1.284 . . . . 1.0 109.89 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.3 tp -56.28 -48.58 76.34 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 124.419 1.088 . . . . 1.0 112.594 -170.552 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.1 t80 -63.7 -47.23 82.02 Favored 'General case' 0 N--CA 1.455 -0.206 0 C-N-CA 124.401 1.08 . . . . 1.0 110.105 -176.96 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -51.73 -50.61 42.61 Favored Glycine 0 CA--C 1.531 1.068 0 CA-C-N 114.178 -1.374 . . . . 1.0 111.538 171.156 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.18 -40.51 96.29 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 117.966 0.883 . . . . 1.0 112.031 179.197 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.9 mt -63.59 -63.18 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.704 0 C-N-CA 127.662 2.385 . . . . 1.0 107.061 178.947 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -58.84 -28.42 66.05 Favored 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 123.432 0.693 . . . . 1.0 112.513 179.261 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.1 -54.84 25.13 Favored Glycine 0 CA--C 1.528 0.894 0 CA-C-N 119.331 0.969 . . . . 1.0 110.762 169.782 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -51.92 -29.83 21.83 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 124.582 1.153 . . . . 1.0 112.478 175.443 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -61.98 -17.41 17.56 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.876 0 C-N-CA 126.055 1.742 . . . . 1.0 110.916 -175.432 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -123.17 6.45 9.16 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 127.04 2.136 . . . . 1.0 110.634 176.663 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -148.22 80.59 1.47 Allowed 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.596 1.159 . . . . 1.0 108.882 -167.265 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 96.29 -5.54 65.42 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 124.029 0.823 . . . . 1.0 113.049 -179.203 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.525 ' CD1' HD12 ' A' ' 18' ' ' ILE . 3.7 t-105 -60.03 155.24 17.34 Favored 'General case' 0 N--CA 1.456 -0.158 0 CA-C-N 118.027 0.913 . . . . 1.0 112.083 166.701 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -158.74 115.98 2.81 Favored 'General case' 0 N--CA 1.428 -1.534 0 C-N-CA 125.515 1.526 . . . . 1.0 107.784 158.708 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -168.79 -26.07 0.02 OUTLIER Glycine 0 CA--C 1.53 1.013 0 N-CA-C 115.57 0.988 . . . . 1.0 115.57 165.372 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 93.0 mtp -132.76 4.13 3.85 Favored 'General case' 0 N--CA 1.473 0.71 0 CA-C-N 118.947 1.374 . . . . 1.0 112.661 176.903 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.525 HD12 ' CD1' ' A' ' 14' ' ' TRP . 66.4 mt . . . . . 0 CA--C 1.534 0.342 0 N-CA-C 105.303 -2.11 . . . . 1.0 105.303 178.482 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.309 0 N-CA-C 110.294 -1.122 . . . . 1.0 110.294 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.4 tp -56.33 -47.39 78.89 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 124.506 1.123 . . . . 1.0 112.454 -171.779 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 7.8 t80 -63.55 -45.45 90.48 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 124.54 1.136 . . . . 1.0 110.06 -176.958 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.69 -51.9 41.55 Favored Glycine 0 CA--C 1.531 1.059 0 CA-C-N 114.096 -1.411 . . . . 1.0 111.474 170.197 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.48 -38.43 87.24 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 118.061 0.931 . . . . 1.0 112.175 179.611 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.8 mt -63.65 -62.99 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.706 0 C-N-CA 127.721 2.408 . . . . 1.0 106.963 177.38 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.65 -27.4 58.47 Favored 'General case' 0 CA--C 1.541 0.597 0 N-CA-C 113.077 0.769 . . . . 1.0 113.077 177.983 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -67.75 -55.15 15.28 Favored Glycine 0 CA--C 1.53 0.971 0 CA-C-N 119.748 1.158 . . . . 1.0 110.797 169.078 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -49.14 -30.05 6.19 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 125.096 1.359 . . . . 1.0 112.568 174.799 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -59.6 -20.9 19.74 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.848 0 C-N-CA 126.409 1.884 . . . . 1.0 111.074 -177.925 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -121.64 4.57 10.09 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 126.454 1.902 . . . . 1.0 111.048 175.111 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -141.34 76.87 1.57 Allowed 'General case' 0 C--N 1.339 0.13 0 O-C-N 120.363 -1.461 . . . . 1.0 107.971 -166.453 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 93.54 4.27 64.09 Favored Glycine 0 CA--C 1.528 0.898 0 CA-C-O 118.434 -1.203 . . . . 1.0 113.364 -179.029 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.471 ' CD1' HD12 ' A' ' 18' ' ' ILE . 11.9 t-105 -53.82 148.64 9.86 Favored 'General case' 0 C--N 1.34 0.162 0 CA-C-N 118.925 1.362 . . . . 1.0 112.466 170.121 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -166.34 116.32 0.96 Allowed 'General case' 0 N--CA 1.441 -0.917 0 C-N-CA 125.077 1.351 . . . . 1.0 108.476 158.285 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -168.39 8.24 0.05 OUTLIER Glycine 0 CA--C 1.53 0.971 0 C-N-CA 126.26 1.886 . . . . 1.0 115.2 163.466 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 9.1 ttp -167.92 7.78 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.411 1.484 . . . . 1.0 113.189 -174.208 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.471 HD12 ' CD1' ' A' ' 14' ' ' TRP . 41.1 mt . . . . . 0 CA--C 1.543 0.689 0 N-CA-C 104.485 -2.413 . . . . 1.0 104.485 -179.068 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.25 0 N-CA-C 110.382 -1.087 . . . . 1.0 110.382 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 15.0 tp -55.48 -48.77 74.03 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 124.822 1.249 . . . . 1.0 112.673 -172.574 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -63.44 -45.41 91.03 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 124.469 1.108 . . . . 1.0 110.01 -177.394 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.67 -49.86 51.52 Favored Glycine 0 CA--C 1.531 1.061 0 CA-C-N 114.126 -1.397 . . . . 1.0 111.796 170.211 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -63.6 -39.29 94.01 Favored 'General case' 0 CA--C 1.537 0.46 0 CA-C-N 118.298 1.049 . . . . 1.0 112.038 179.451 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.4 mt -63.39 -63.17 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.826 0 C-N-CA 127.586 2.354 . . . . 1.0 106.915 177.797 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -55.34 -32.63 62.68 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.033 0.533 . . . . 1.0 112.252 177.234 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -61.99 -52.24 51.54 Favored Glycine 0 CA--C 1.531 1.053 0 CA-C-N 119.879 1.218 . . . . 1.0 111.039 171.805 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -54.53 -26.84 34.25 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 124.196 0.998 . . . . 1.0 112.42 173.391 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -70.15 -9.41 12.4 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.043 0 C-N-CA 125.103 1.361 . . . . 1.0 109.653 -175.67 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -118.19 1.36 11.9 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 125.71 1.604 . . . . 1.0 111.468 171.738 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -151.96 81.19 1.27 Allowed 'General case' 0 C--O 1.234 0.261 0 O-C-N 121.072 -1.018 . . . . 1.0 108.707 -161.519 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 99.01 0.82 57.23 Favored Glycine 0 CA--C 1.531 1.075 0 CA-C-O 119.065 -0.853 . . . . 1.0 112.572 -173.366 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.762 ' CD1' HD13 ' A' ' 18' ' ' ILE . 62.4 t-105 -53.06 155.09 2.66 Favored 'General case' 0 N--CA 1.452 -0.356 0 C-N-CA 125.65 1.58 . . . . 1.0 112.728 174.576 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -141.79 -115.68 0.12 Allowed 'General case' 0 N--CA 1.442 -0.85 0 N-CA-C 105.047 -2.205 . . . . 1.0 105.047 -176.509 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 58.64 -75.58 0.01 OUTLIER Glycine 0 CA--C 1.531 1.086 0 C-N-CA 126.183 1.849 . . . . 1.0 113.437 -177.509 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.1 ttt -102.34 -10.6 19.34 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 125.35 1.46 . . . . 1.0 112.503 173.005 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.762 HD13 ' CD1' ' A' ' 14' ' ' TRP . 3.3 mp . . . . . 0 CA--C 1.543 0.689 0 C-N-CA 128.178 2.591 . . . . 1.0 106.126 176.749 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.271 0 N-CA-C 110.135 -1.186 . . . . 1.0 110.135 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.6 tp -56.65 -49.04 76.19 Favored 'General case' 0 N--CA 1.468 0.425 0 C-N-CA 124.51 1.124 . . . . 1.0 112.635 -170.478 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -63.71 -45.27 90.72 Favored 'General case' 0 C--O 1.225 -0.203 0 C-N-CA 124.358 1.063 . . . . 1.0 110.031 -176.972 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.83 -50.23 51.01 Favored Glycine 0 CA--C 1.532 1.145 0 CA-C-N 113.976 -1.465 . . . . 1.0 111.724 170.5 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.86 -39.05 93.2 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 118.258 1.029 . . . . 1.0 112.048 179.315 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.0 mt -63.73 -62.94 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 C-N-CA 127.384 2.274 . . . . 1.0 106.827 177.968 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.82 -31.74 65.03 Favored 'General case' 0 CA--C 1.542 0.644 0 N-CA-C 112.387 0.514 . . . . 1.0 112.387 178.326 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.66 -49.86 61.96 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-N 119.846 1.203 . . . . 1.0 111.329 172.018 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -54.24 -26.88 31.12 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 123.929 0.892 . . . . 1.0 112.241 172.478 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -68.84 -10.71 13.7 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.061 0 C-N-CA 124.878 1.271 . . . . 1.0 109.88 -174.523 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -118.71 2.51 11.68 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.027 1.731 . . . . 1.0 111.47 172.02 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -149.12 82.23 1.43 Allowed 'General case' 0 C--O 1.235 0.303 0 O-C-N 120.995 -1.066 . . . . 1.0 109.029 -164.167 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 97.23 -1.97 60.97 Favored Glycine 0 CA--C 1.532 1.094 0 CA-C-O 118.98 -0.9 . . . . 1.0 112.719 -175.783 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.853 ' CD1' HD13 ' A' ' 18' ' ' ILE . 56.1 t-105 -50.75 150.16 3.0 Favored 'General case' 0 C--O 1.233 0.202 0 C-N-CA 125.738 1.615 . . . . 1.0 113.055 173.326 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -123.94 -105.73 0.35 Allowed 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 126.827 2.051 . . . . 1.0 107.873 177.621 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 63.37 -68.91 0.03 OUTLIER Glycine 0 CA--C 1.534 1.24 0 CA-C-N 121.868 2.122 . . . . 1.0 114.683 174.885 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 67.5 mtt -123.56 -3.98 8.28 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 126.56 1.944 . . . . 1.0 112.937 172.627 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.853 HD13 ' CD1' ' A' ' 14' ' ' TRP . 3.2 mp . . . . . 0 CA--C 1.541 0.621 0 C-N-CA 128.327 2.651 . . . . 1.0 105.442 174.594 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.289 0 N-CA-C 110.132 -1.187 . . . . 1.0 110.132 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.9 tp -55.39 -48.28 74.57 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 124.424 1.09 . . . . 1.0 112.737 -169.374 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -63.47 -47.1 83.19 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 124.453 1.101 . . . . 1.0 110.659 -174.78 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.56 -51.55 47.47 Favored Glycine 0 CA--C 1.531 1.042 0 CA-C-N 113.918 -1.492 . . . . 1.0 111.026 170.701 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.91 -37.08 83.28 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 117.806 0.803 . . . . 1.0 112.489 179.506 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.53 -63.13 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 C-N-CA 127.771 2.429 . . . . 1.0 106.931 177.031 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -58.12 -27.79 64.06 Favored 'General case' 0 CA--C 1.539 0.547 0 N-CA-C 112.708 0.632 . . . . 1.0 112.708 179.417 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -67.48 -53.54 24.28 Favored Glycine 0 CA--C 1.531 1.055 0 CA-C-N 119.391 0.996 . . . . 1.0 111.302 169.502 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -51.44 -28.38 12.89 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 124.896 1.278 . . . . 1.0 112.397 174.338 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -65.98 -9.59 8.8 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.936 0 C-N-CA 126.161 1.784 . . . . 1.0 110.876 -175.858 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -130.13 8.9 5.2 Favored 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 126.723 2.009 . . . . 1.0 110.811 173.771 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -148.41 81.77 1.47 Allowed 'General case' 0 C--O 1.234 0.287 0 O-C-N 120.826 -1.171 . . . . 1.0 108.466 -166.47 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 91.89 7.26 64.58 Favored Glycine 0 CA--C 1.531 1.047 0 CA-C-O 119.023 -0.876 . . . . 1.0 112.393 -171.318 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.653 ' CD1' HD13 ' A' ' 18' ' ' ILE . 60.4 t-105 -59.22 156.78 11.73 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 124.756 1.222 . . . . 1.0 112.098 175.684 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -140.02 -107.11 0.16 Allowed 'General case' 0 N--CA 1.449 -0.475 0 CA-C-N 115.433 -0.803 . . . . 1.0 108.883 167.977 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 65.79 -59.74 0.13 Allowed Glycine 0 CA--C 1.534 1.234 0 C-N-CA 126.839 2.162 . . . . 1.0 114.41 177.235 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 12.8 tmm? -128.81 -11.21 4.89 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 127.108 2.163 . . . . 1.0 112.666 175.537 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.653 HD13 ' CD1' ' A' ' 14' ' ' TRP . 2.5 mp . . . . . 0 CA--C 1.536 0.438 0 C-N-CA 128.687 2.795 . . . . 1.0 107.553 174.607 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.237 0 N-CA-C 110.169 -1.172 . . . . 1.0 110.169 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.2 tp -56.4 -47.96 77.92 Favored 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 124.442 1.097 . . . . 1.0 112.638 -170.538 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -63.58 -46.12 87.29 Favored 'General case' 0 C--N 1.33 -0.239 0 C-N-CA 124.406 1.082 . . . . 1.0 110.227 -177.016 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.33 -51.33 42.88 Favored Glycine 0 CA--C 1.53 1.025 0 CA-C-N 114.034 -1.439 . . . . 1.0 111.536 170.443 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.94 -39.09 90.88 Favored 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 117.953 0.877 . . . . 1.0 112.164 179.419 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.8 mt -63.57 -63.09 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.763 0 C-N-CA 127.568 2.347 . . . . 1.0 107.019 178.013 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.96 -29.44 63.21 Favored 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 112.537 0.569 . . . . 1.0 112.537 178.556 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.74 -53.43 34.73 Favored Glycine 0 CA--C 1.531 1.092 0 CA-C-N 119.447 1.021 . . . . 1.0 111.236 170.1 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -52.92 -30.77 36.39 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 124.955 1.302 . . . . 1.0 112.353 174.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -64.67 -14.04 15.46 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.846 0 C-N-CA 126.754 2.021 . . . . 1.0 111.456 -173.87 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -122.47 9.74 9.72 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 126.4 1.88 . . . . 1.0 110.749 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -140.37 -41.53 0.42 Allowed 'General case' 0 N--CA 1.465 0.323 0 O-C-N 121.096 -1.002 . . . . 1.0 113.522 -163.208 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -129.08 11.97 6.13 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 124.275 0.94 . . . . 1.0 112.046 175.173 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.559 ' CD1' HD11 ' A' ' 18' ' ' ILE . 54.0 t-105 -62.55 153.39 32.04 Favored 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 125.564 1.545 . . . . 1.0 113.405 -169.77 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -161.95 116.67 1.93 Allowed 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 127.391 2.276 . . . . 1.0 106.578 159.083 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 172.63 -3.36 0.03 OUTLIER Glycine 0 CA--C 1.529 0.936 0 C-N-CA 129.066 3.222 . . . . 1.0 111.11 171.457 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 11.8 ttt -144.44 12.08 1.51 Allowed 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 124.3 1.04 . . . . 1.0 113.058 176.877 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.559 HD11 ' CD1' ' A' ' 14' ' ' TRP . 0.9 OUTLIER -103.37 33.42 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.647 0 CA-C-O 123.34 1.543 . . . . 1.0 108.34 167.26 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 23.6 t0 -74.3 91.04 2.15 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 126.649 1.98 . . . . 1.0 109.414 -172.23 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.968 0 C-N-CA 125.565 1.555 . . . . 1.0 112.894 -176.619 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.324 0 N-CA-C 110.127 -1.189 . . . . 1.0 110.127 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.0 tp -56.0 -48.35 76.06 Favored 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 124.414 1.085 . . . . 1.0 112.576 -170.118 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -63.62 -46.73 84.38 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 124.456 1.103 . . . . 1.0 110.192 -176.79 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.68 -49.17 54.43 Favored Glycine 0 CA--C 1.53 1.004 0 CA-C-N 114.022 -1.445 . . . . 1.0 111.6 171.043 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -63.76 -39.81 95.18 Favored 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 118.198 0.999 . . . . 1.0 111.925 178.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.2 mt -63.63 -63.05 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.775 0 C-N-CA 127.434 2.294 . . . . 1.0 107.173 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.27 -34.13 68.34 Favored 'General case' 0 CA--C 1.542 0.641 0 CA-C-O 119.33 -0.367 . . . . 1.0 111.648 177.696 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -59.25 -50.67 65.33 Favored Glycine 0 CA--C 1.531 1.055 0 O-C-N 120.65 -1.281 . . . . 1.0 111.271 172.168 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -54.43 -33.04 58.68 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 124.186 0.994 . . . . 1.0 111.86 173.88 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -66.71 -14.65 18.21 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.916 0 C-N-CA 126.115 1.766 . . . . 1.0 110.065 -173.023 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -111.44 -1.17 16.01 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.331 1.452 . . . . 1.0 112.154 177.619 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 49.1 m-80 -138.05 -43.11 0.52 Allowed 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 119.623 1.101 . . . . 1.0 113.202 -159.186 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -121.29 8.92 10.26 Favored Glycine 0 CA--C 1.526 0.738 0 C-N-CA 124.133 0.873 . . . . 1.0 111.724 176.578 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.535 ' CD1' HD11 ' A' ' 18' ' ' ILE . 55.1 t-105 -62.59 154.53 28.71 Favored 'General case' 0 N--CA 1.444 -0.726 0 C-N-CA 125.472 1.509 . . . . 1.0 113.028 -170.736 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -160.73 116.42 2.25 Favored 'General case' 0 N--CA 1.44 -0.95 0 C-N-CA 125.797 1.639 . . . . 1.0 106.977 159.048 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 175.38 -7.99 0.03 OUTLIER Glycine 0 CA--C 1.53 0.979 0 C-N-CA 128.98 3.181 . . . . 1.0 110.642 168.095 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' MET . . . . . 0.463 ' HB3' ' HE1' ' A' ' 14' ' ' TRP . 8.0 tpt -133.1 8.41 4.04 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 125.174 1.39 . . . . 1.0 113.451 177.59 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.535 HD11 ' CD1' ' A' ' 14' ' ' TRP . 1.6 mp -103.27 34.02 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.665 0 CA-C-O 123.123 1.44 . . . . 1.0 108.288 170.223 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 17.7 t0 -76.61 95.75 4.01 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 125.977 1.711 . . . . 1.0 108.097 178.778 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.004 0 C-N-CA 125.148 1.356 . . . . 1.0 112.933 178.501 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.199 0 N-CA-C 109.956 -1.258 . . . . 1.0 109.956 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.4 tp -56.12 -48.83 75.46 Favored 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 124.519 1.128 . . . . 1.0 112.582 -171.153 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.2 t80 -63.62 -45.58 89.65 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 124.585 1.154 . . . . 1.0 109.988 -176.069 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.39 -50.27 53.38 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-N 114.026 -1.443 . . . . 1.0 111.648 170.525 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.83 -38.73 91.94 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 118.101 0.95 . . . . 1.0 112.134 178.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.2 mt -63.46 -63.18 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.774 0 C-N-CA 127.606 2.362 . . . . 1.0 106.877 178.268 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.68 -34.75 67.7 Favored 'General case' 0 CA--C 1.543 0.677 0 CA-C-O 119.263 -0.398 . . . . 1.0 111.809 178.375 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -60.6 -49.92 73.26 Favored Glycine 0 CA--C 1.531 1.047 0 O-C-N 120.667 -1.271 . . . . 1.0 111.348 172.691 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -55.39 -31.29 61.7 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 124.2 1.0 . . . . 1.0 112.064 173.191 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -67.59 -14.24 17.95 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.91 0 C-N-CA 125.761 1.624 . . . . 1.0 109.737 -173.799 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -110.08 -0.79 17.85 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 125.503 1.521 . . . . 1.0 111.94 177.592 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 50.3 m-80 -139.55 -41.68 0.45 Allowed 'General case' 0 N--CA 1.472 0.651 0 CA-C-N 119.74 1.155 . . . . 1.0 113.398 -159.259 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -124.45 9.05 8.29 Favored Glycine 0 CA--C 1.527 0.815 0 C-N-CA 124.222 0.915 . . . . 1.0 111.892 177.089 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.509 ' CD1' HD11 ' A' ' 18' ' ' ILE . 50.4 t-105 -60.21 154.68 19.19 Favored 'General case' 0 N--CA 1.446 -0.641 0 C-N-CA 125.789 1.636 . . . . 1.0 113.469 -171.393 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -160.83 116.56 2.23 Favored 'General case' 0 N--CA 1.44 -0.946 0 C-N-CA 125.703 1.601 . . . . 1.0 107.308 158.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 170.51 3.61 0.03 OUTLIER Glycine 0 CA--C 1.528 0.845 0 C-N-CA 128.554 2.978 . . . . 1.0 111.656 165.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 15.1 ttp -143.86 14.35 1.72 Allowed 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.017 1.327 . . . . 1.0 112.654 175.469 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.509 HD11 ' CD1' ' A' ' 14' ' ' TRP . 2.1 mp -103.31 37.3 0.27 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-O 122.914 1.34 . . . . 1.0 108.095 167.542 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 53.6 t0 -137.84 110.63 7.64 Favored 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 127.022 2.129 . . . . 1.0 107.432 170.911 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.035 0 C-N-CA 124.807 1.194 . . . . 1.0 111.546 165.463 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.313 0 N-CA-C 110.219 -1.152 . . . . 1.0 110.219 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.6 tp -56.39 -48.63 76.5 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 124.605 1.162 . . . . 1.0 112.57 -171.391 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.4 t80 -63.57 -45.86 88.53 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 124.348 1.059 . . . . 1.0 109.97 -177.129 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -51.67 -51.05 40.41 Favored Glycine 0 CA--C 1.531 1.038 0 CA-C-N 114.017 -1.447 . . . . 1.0 111.689 170.169 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.58 -39.45 93.74 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 118.26 1.03 . . . . 1.0 112.124 179.563 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.56 -63.05 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.763 0 C-N-CA 127.442 2.297 . . . . 1.0 106.969 178.23 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.04 -32.14 63.78 Favored 'General case' 0 CA--C 1.541 0.631 0 O-C-N 122.021 -0.424 . . . . 1.0 112.132 177.489 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -61.51 -52.84 48.54 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-N 119.951 1.251 . . . . 1.0 111.088 171.093 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -51.72 -33.67 35.47 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 124.192 0.997 . . . . 1.0 112.069 174.299 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -64.08 -13.96 14.55 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.907 0 C-N-CA 126.801 2.04 . . . . 1.0 111.333 -172.823 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -126.63 6.76 6.83 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 125.733 1.613 . . . . 1.0 111.711 178.517 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -139.23 -32.45 0.66 Allowed 'General case' 0 N--CA 1.471 0.61 0 O-C-N 121.231 -0.918 . . . . 1.0 112.805 -163.71 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -137.32 13.65 3.76 Favored Glycine 0 CA--C 1.526 0.735 0 C-N-CA 124.338 0.97 . . . . 1.0 111.627 174.865 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.478 ' CD1' HD11 ' A' ' 18' ' ' ILE . 56.8 t-105 -56.47 157.16 5.32 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 126.278 1.831 . . . . 1.0 113.648 -168.556 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -157.39 115.04 3.09 Favored 'General case' 0 N--CA 1.436 -1.171 0 N-CA-C 101.663 -3.458 . . . . 1.0 101.663 176.948 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 149.86 -4.01 0.62 Allowed Glycine 0 CA--C 1.531 1.045 0 C-N-CA 125.059 1.314 . . . . 1.0 114.866 167.637 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' MET . . . . . 0.42 ' CB ' ' HE1' ' A' ' 14' ' ' TRP . 15.7 ttt -130.75 9.72 5.02 Favored 'General case' 0 CA--C 1.54 0.576 0 CA-C-N 118.847 1.324 . . . . 1.0 111.961 172.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.478 HD11 ' CD1' ' A' ' 14' ' ' TRP . 1.2 mp -103.34 42.0 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.522 0 N-CA-C 107.51 -1.293 . . . . 1.0 107.51 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -124.7 99.68 6.28 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 126.503 1.921 . . . . 1.0 107.085 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.175 0 CA-C-O 119.273 -0.737 . . . . 1.0 114.787 -176.431 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.251 0 N-CA-C 109.917 -1.273 . . . . 1.0 109.917 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 8.4 tp -54.83 -50.49 68.46 Favored 'General case' 0 N--CA 1.467 0.388 0 C-N-CA 124.586 1.154 . . . . 1.0 112.76 -169.581 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.2 t80 -63.71 -46.79 83.84 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 124.17 0.988 . . . . 1.0 110.383 -175.129 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.16 -51.03 49.25 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-N 114.032 -1.44 . . . . 1.0 111.428 171.408 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -60.97 -40.63 94.13 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 123.682 0.793 . . . . 1.0 111.835 178.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.3 mt -63.43 -63.21 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.794 0 C-N-CA 127.511 2.324 . . . . 1.0 107.082 178.873 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.99 -33.22 66.91 Favored 'General case' 0 CA--C 1.542 0.65 0 CA-C-O 118.999 -0.524 . . . . 1.0 112.148 179.634 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.37 -50.92 58.71 Favored Glycine 0 CA--C 1.532 1.097 0 CA-C-N 120.062 1.301 . . . . 1.0 111.339 171.431 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -53.42 -30.63 41.35 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 124.457 1.103 . . . . 1.0 112.22 173.744 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -66.93 -13.72 16.97 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.921 0 C-N-CA 126.27 1.828 . . . . 1.0 110.546 -173.645 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -112.18 1.72 16.35 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 125.054 1.342 . . . . 1.0 111.905 176.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 12.5 t30 -139.09 -48.64 0.49 Allowed 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 119.353 0.978 . . . . 1.0 112.862 -159.547 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -118.71 9.86 12.61 Favored Glycine 0 CA--C 1.527 0.833 0 C-N-CA 124.303 0.954 . . . . 1.0 111.965 178.117 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.403 ' CD1' HD11 ' A' ' 18' ' ' ILE . 65.0 t-105 -56.93 164.93 1.38 Allowed 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 126.395 1.878 . . . . 1.0 114.55 -168.372 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -150.13 91.16 1.74 Allowed 'General case' 0 N--CA 1.442 -0.869 0 C-N-CA 125.054 1.342 . . . . 1.0 111.265 -175.716 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 165.94 -16.13 0.09 OUTLIER Glycine 0 CA--C 1.529 0.942 0 CA-C-N 115.405 -0.816 . . . . 1.0 114.734 165.053 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 1.3 mpt? -107.69 6.78 28.04 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 124.38 1.072 . . . . 1.0 111.766 175.825 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.479 HD12 ' N ' ' A' ' 18' ' ' ILE . 1.6 mp -103.37 44.29 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.525 0 N-CA-C 106.844 -1.539 . . . . 1.0 106.844 -174.5 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 33.0 t0 -128.27 85.17 2.31 Favored 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 125.925 1.69 . . . . 1.0 107.982 -179.171 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 0.998 0 C-N-CA 125.209 1.385 . . . . 1.0 110.398 -175.394 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.21 0 N-CA-C 110.155 -1.178 . . . . 1.0 110.155 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 8.7 tp -54.91 -49.05 72.22 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 124.522 1.129 . . . . 1.0 112.695 -169.147 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 12.2 t80 -63.76 -47.17 82.07 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 124.319 1.048 . . . . 1.0 110.538 -175.377 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.21 -51.11 48.96 Favored Glycine 0 CA--C 1.53 1.021 0 CA-C-N 114.072 -1.422 . . . . 1.0 111.287 171.187 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.19 -39.53 90.52 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 117.74 0.77 . . . . 1.0 111.952 179.28 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.47 -63.1 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.78 0 C-N-CA 127.654 2.381 . . . . 1.0 107.143 178.174 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.48 -29.93 64.67 Favored 'General case' 0 CA--C 1.539 0.543 0 N-CA-C 112.714 0.635 . . . . 1.0 112.714 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.58 -52.68 32.89 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-N 119.702 1.137 . . . . 1.0 111.206 170.094 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -52.43 -28.61 20.65 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 124.64 1.176 . . . . 1.0 112.3 174.415 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -64.83 -13.1 14.16 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.871 0 C-N-CA 125.98 1.712 . . . . 1.0 110.887 -175.568 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -126.82 6.94 6.71 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 126.357 1.863 . . . . 1.0 111.371 175.032 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 -147.69 90.61 1.87 Allowed 'General case' 0 C--N 1.341 0.196 0 O-C-N 120.956 -1.09 . . . . 1.0 109.291 -165.034 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 77.35 12.7 84.32 Favored Glycine 0 CA--C 1.532 1.124 0 CA-C-O 118.632 -1.094 . . . . 1.0 112.378 -169.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.449 ' CD1' HD11 ' A' ' 18' ' ' ILE . 55.8 t-105 -51.99 156.15 1.62 Allowed 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.492 1.517 . . . . 1.0 112.967 176.62 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -159.1 101.92 1.6 Allowed 'General case' 0 N--CA 1.445 -0.711 0 C-N-CA 126.241 1.816 . . . . 1.0 106.327 -179.224 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 159.5 -5.79 0.12 Allowed Glycine 0 CA--C 1.53 1.03 0 CA-C-O 118.861 -0.966 . . . . 1.0 115.254 171.373 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' MET . . . . . 0.44 ' CB ' ' HE1' ' A' ' 14' ' ' TRP . 13.3 ttt -128.52 11.19 6.26 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 118.92 1.36 . . . . 1.0 111.947 174.095 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.449 HD11 ' CD1' ' A' ' 14' ' ' TRP . 1.7 mp -103.31 42.13 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 C-N-CA 124.977 1.311 . . . . 1.0 107.473 179.411 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 31.6 t0 -142.37 100.28 3.67 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 126.255 1.822 . . . . 1.0 106.894 -179.549 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.723 0 C-N-CA 123.86 0.743 . . . . 1.0 112.38 175.128 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.254 0 N-CA-C 110.165 -1.174 . . . . 1.0 110.165 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.5 tp -56.19 -48.63 76.01 Favored 'General case' 0 N--CA 1.468 0.449 0 C-N-CA 124.494 1.118 . . . . 1.0 112.659 -171.635 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -63.64 -45.42 90.32 Favored 'General case' 0 N--CA 1.455 -0.206 0 C-N-CA 124.18 0.992 . . . . 1.0 109.724 -178.11 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -50.74 -50.42 37.33 Favored Glycine 0 CA--C 1.532 1.13 0 CA-C-N 114.138 -1.392 . . . . 1.0 112.124 170.169 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -63.0 -41.53 99.61 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 118.143 0.972 . . . . 1.0 111.854 179.253 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.56 -63.01 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.843 0 C-N-CA 127.339 2.255 . . . . 1.0 106.695 179.663 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -54.25 -37.59 64.84 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.636 0.774 . . . . 1.0 111.814 177.332 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.34 -51.73 55.89 Favored Glycine 0 CA--C 1.531 1.049 0 CA-C-N 119.825 1.193 . . . . 1.0 111.42 173.346 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -58.46 -26.43 63.35 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 124.244 1.018 . . . . 1.0 112.712 174.031 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -68.91 -18.24 22.81 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.78 0 CA-C-N 119.776 1.171 . . . . 1.0 110.604 -172.123 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -109.53 0.73 19.35 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 125.873 1.669 . . . . 1.0 111.576 173.533 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 13.3 t-20 -152.05 95.84 2.12 Favored 'General case' 0 C--N 1.344 0.335 0 O-C-N 120.567 -1.333 . . . . 1.0 110.182 -159.287 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 74.94 11.16 83.92 Favored Glycine 0 CA--C 1.531 1.058 0 CA-C-O 118.583 -1.12 . . . . 1.0 112.414 -170.479 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.445 ' CD1' HD11 ' A' ' 18' ' ' ILE . 59.3 t-105 -50.25 154.96 1.08 Allowed 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 125.513 1.525 . . . . 1.0 113.105 175.981 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -159.22 100.63 1.54 Allowed 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 106.045 -1.835 . . . . 1.0 106.045 -178.146 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 162.51 -6.84 0.08 OUTLIER Glycine 0 CA--C 1.532 1.133 0 CA-C-O 118.762 -1.021 . . . . 1.0 115.278 173.369 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' MET . . . . . 0.42 ' CB ' ' HE1' ' A' ' 14' ' ' TRP . 30.6 ttp -129.76 9.69 5.46 Favored 'General case' 0 CA--C 1.539 0.519 0 CA-C-N 119.128 1.464 . . . . 1.0 111.975 175.244 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.445 HD11 ' CD1' ' A' ' 14' ' ' TRP . 1.6 mp -103.29 42.6 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.506 0 N-CA-C 107.314 -1.365 . . . . 1.0 107.314 -178.02 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 25.4 t0 -130.63 95.82 3.95 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 126.102 1.761 . . . . 1.0 107.934 -174.179 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.405 0 N-CA-C 109.259 -1.536 . . . . 1.0 109.259 177.663 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.329 0 N-CA-C 110.027 -1.229 . . . . 1.0 110.027 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.5 tp -57.98 -47.65 82.36 Favored 'General case' 0 N--CA 1.466 0.365 0 C-N-CA 124.25 1.02 . . . . 1.0 112.325 -172.212 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.6 t80 -63.59 -44.75 93.13 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 124.306 1.042 . . . . 1.0 109.759 -177.862 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -51.63 -50.64 41.9 Favored Glycine 0 CA--C 1.533 1.191 0 CA-C-N 114.241 -1.345 . . . . 1.0 112.044 170.016 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -63.1 -40.07 96.56 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 118.369 1.084 . . . . 1.0 112.147 179.667 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.0 mt -63.58 -62.93 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.773 0 C-N-CA 127.673 2.389 . . . . 1.0 106.433 178.736 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -53.85 -32.46 53.05 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 123.599 0.76 . . . . 1.0 112.278 175.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.57 -53.98 40.78 Favored Glycine 0 CA--C 1.53 0.992 0 CA-C-N 119.81 1.186 . . . . 1.0 111.158 171.614 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -56.04 -28.01 55.63 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 123.657 0.783 . . . . 1.0 112.443 174.406 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -69.0 -10.27 13.16 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.889 0 C-N-CA 124.798 1.239 . . . . 1.0 110.446 -174.163 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -123.81 8.53 8.78 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 126.972 2.109 . . . . 1.0 110.946 176.452 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -156.46 92.99 1.36 Allowed 'General case' 0 C--N 1.343 0.294 0 O-C-N 120.513 -1.367 . . . . 1.0 109.285 -169.436 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 85.16 6.49 84.48 Favored Glycine 0 CA--C 1.53 0.988 0 CA-C-O 118.749 -1.028 . . . . 1.0 112.663 -172.183 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.54 ' CD1' HD11 ' A' ' 18' ' ' ILE . 55.3 t-105 -55.79 155.14 6.22 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 124.739 1.216 . . . . 1.0 112.525 176.791 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -162.16 104.06 1.13 Allowed 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 105.421 -2.066 . . . . 1.0 105.421 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 162.07 -8.59 0.1 OUTLIER Glycine 0 CA--C 1.528 0.895 0 CA-C-O 118.939 -0.923 . . . . 1.0 115.048 174.581 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 31.7 ttm -132.09 8.34 4.38 Favored 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 118.913 1.356 . . . . 1.0 112.257 174.726 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.54 HD11 ' CD1' ' A' ' 14' ' ' TRP . 0.7 OUTLIER -103.37 36.52 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.375 0 C-N-CA 124.695 1.198 . . . . 1.0 108.955 -179.476 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 32.4 t0 -146.09 97.74 2.99 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 125.398 1.479 . . . . 1.0 108.792 -175.023 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.789 0 CA-C-N 116.072 -0.513 . . . . 1.0 112.753 164.865 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.245 0 N-CA-C 110.211 -1.155 . . . . 1.0 110.211 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.9 tp -56.12 -48.85 75.41 Favored 'General case' 0 N--CA 1.467 0.388 0 C-N-CA 124.613 1.165 . . . . 1.0 112.604 -170.604 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.5 t80 -63.63 -46.05 87.45 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 124.341 1.056 . . . . 1.0 110.068 -176.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.55 -50.05 49.98 Favored Glycine 0 CA--C 1.53 1.015 0 CA-C-N 114.194 -1.367 . . . . 1.0 111.667 170.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.0 -40.94 97.36 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 118.174 0.987 . . . . 1.0 111.944 178.849 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.2 mt -63.58 -63.18 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.782 0 C-N-CA 127.509 2.324 . . . . 1.0 107.251 179.267 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -58.13 -29.17 65.33 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 123.508 0.723 . . . . 1.0 112.484 178.715 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.62 -54.29 29.78 Favored Glycine 0 CA--C 1.529 0.951 0 CA-C-N 119.464 1.029 . . . . 1.0 110.832 170.038 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -52.24 -28.62 19.35 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 124.413 1.085 . . . . 1.0 112.42 174.608 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -65.99 -11.63 12.92 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.867 0 C-N-CA 125.825 1.65 . . . . 1.0 111.016 -175.213 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -126.81 8.25 6.84 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 126.663 1.985 . . . . 1.0 110.877 174.32 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -148.1 83.53 1.51 Allowed 'General case' 0 C--O 1.234 0.274 0 O-C-N 120.817 -1.177 . . . . 1.0 108.719 -166.69 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 88.33 7.38 72.91 Favored Glycine 0 CA--C 1.531 1.054 0 CA-C-O 118.992 -0.893 . . . . 1.0 112.587 -173.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.496 ' CD1' HD11 ' A' ' 18' ' ' ILE . 55.8 t-105 -52.87 155.23 2.46 Favored 'General case' 0 N--CA 1.452 -0.336 0 C-N-CA 125.655 1.582 . . . . 1.0 113.185 175.698 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -160.35 102.65 1.4 Allowed 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 126.275 1.83 . . . . 1.0 106.124 178.744 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 167.92 -17.44 0.08 OUTLIER Glycine 0 CA--C 1.529 0.94 0 CA-C-O 118.842 -0.977 . . . . 1.0 114.959 170.247 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' MET . . . . . 0.433 ' HB2' ' HE1' ' A' ' 14' ' ' TRP . 0.0 OUTLIER -126.68 19.14 7.31 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-N 118.828 1.314 . . . . 1.0 112.662 175.607 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.496 HD11 ' CD1' ' A' ' 14' ' ' TRP . 1.4 mp -103.26 43.63 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.465 0 N-CA-C 106.853 -1.536 . . . . 1.0 106.853 172.736 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -134.47 100.53 4.68 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 125.999 1.72 . . . . 1.0 107.749 -177.457 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.758 0 C-N-CA 124.925 1.25 . . . . 1.0 112.678 169.769 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.238 0 N-CA-C 109.808 -1.317 . . . . 1.0 109.808 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 14.9 tp -55.45 -51.4 67.06 Favored 'General case' 0 N--CA 1.466 0.351 0 C-N-CA 124.836 1.254 . . . . 1.0 113.068 -169.064 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.5 t80 -63.8 -46.25 86.0 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 124.155 0.982 . . . . 1.0 110.136 -176.348 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.73 -49.18 54.69 Favored Glycine 0 CA--C 1.532 1.12 0 CA-C-N 114.02 -1.446 . . . . 1.0 111.723 171.046 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.81 -40.26 96.83 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 118.059 0.93 . . . . 1.0 111.751 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.55 -63.02 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.835 0 C-N-CA 127.318 2.247 . . . . 1.0 106.969 178.502 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -55.93 -34.39 65.57 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 122.991 0.516 . . . . 1.0 112.141 178.296 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -61.91 -50.96 60.48 Favored Glycine 0 CA--C 1.531 1.089 0 O-C-N 120.817 -1.177 . . . . 1.0 111.328 172.732 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -56.81 -25.03 54.85 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 124.505 1.122 . . . . 1.0 112.58 173.73 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -68.43 -16.32 20.82 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.948 0 C-N-CA 124.571 1.148 . . . . 1.0 110.415 -172.779 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -110.69 1.85 18.17 Favored 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 125.752 1.621 . . . . 1.0 111.439 172.553 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -150.32 81.97 1.36 Allowed 'General case' 0 C--O 1.235 0.337 0 O-C-N 120.969 -1.082 . . . . 1.0 108.95 -160.454 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 95.41 -0.18 63.4 Favored Glycine 0 CA--C 1.53 0.988 0 CA-C-O 118.947 -0.918 . . . . 1.0 112.789 -176.18 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.532 ' CD1' HD11 ' A' ' 18' ' ' ILE . 57.5 t-105 -54.61 154.47 4.86 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 125.06 1.344 . . . . 1.0 112.661 173.257 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -158.09 116.53 3.08 Favored 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 125.729 1.612 . . . . 1.0 107.065 159.08 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 173.19 4.11 0.03 OUTLIER Glycine 0 CA--C 1.527 0.816 0 C-N-CA 128.582 2.991 . . . . 1.0 111.829 165.162 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 22.0 ttp -143.67 10.05 1.59 Allowed 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 125.173 1.389 . . . . 1.0 112.995 178.145 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.532 HD11 ' CD1' ' A' ' 14' ' ' TRP . 2.4 mp -103.14 40.73 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 CA-C-O 122.723 1.249 . . . . 1.0 107.635 172.311 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 30.2 t0 -132.5 101.44 5.33 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 126.955 2.102 . . . . 1.0 106.802 176.528 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.335 0.477 0 N-CA-C 109.927 -1.269 . . . . 1.0 109.927 -175.463 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.266 0 N-CA-C 110.112 -1.195 . . . . 1.0 110.112 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.3 tp -55.66 -49.13 73.73 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 124.656 1.182 . . . . 1.0 112.755 -170.506 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -63.63 -46.92 83.5 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 124.251 1.02 . . . . 1.0 110.134 -176.648 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.05 -50.06 46.81 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-N 114.083 -1.417 . . . . 1.0 111.61 171.16 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.26 -41.17 98.21 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 117.986 0.893 . . . . 1.0 111.928 178.916 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.2 mt -63.48 -63.24 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 C-N-CA 127.458 2.303 . . . . 1.0 107.196 179.606 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.87 -33.04 68.27 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 122.887 0.475 . . . . 1.0 111.98 179.014 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -61.0 -52.4 52.49 Favored Glycine 0 CA--C 1.53 1.004 0 CA-C-N 119.883 1.219 . . . . 1.0 111.09 171.671 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -54.4 -27.82 39.33 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 124.096 0.958 . . . . 1.0 112.396 173.888 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -68.38 -12.12 15.33 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.956 0 C-N-CA 125.199 1.399 . . . . 1.0 110.161 -174.595 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -117.11 1.77 12.57 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 125.92 1.688 . . . . 1.0 111.516 173.431 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -149.53 84.3 1.42 Allowed 'General case' 0 C--O 1.234 0.261 0 O-C-N 121.111 -0.993 . . . . 1.0 108.573 -160.167 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 87.68 6.73 76.31 Favored Glycine 0 CA--C 1.531 1.041 0 CA-C-O 118.725 -1.042 . . . . 1.0 112.613 -174.034 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.498 ' CD1' HD11 ' A' ' 18' ' ' ILE . 54.6 t-105 -53.68 152.49 5.2 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 124.878 1.271 . . . . 1.0 112.208 173.386 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -158.48 116.56 2.96 Favored 'General case' 0 N--CA 1.441 -0.924 0 C-N-CA 125.81 1.644 . . . . 1.0 107.042 159.147 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.407 ' H ' ' H ' ' A' ' 17' ' ' MET . . . 172.4 5.28 0.03 OUTLIER Glycine 0 CA--C 1.528 0.882 0 C-N-CA 129.248 3.308 . . . . 1.0 111.747 168.907 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' MET . . . . . 0.414 ' CB ' ' HE1' ' A' ' 14' ' ' TRP . 23.2 ttm -147.91 10.77 0.93 Allowed 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 125.054 1.341 . . . . 1.0 113.329 178.868 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.498 HD11 ' CD1' ' A' ' 14' ' ' TRP . 3.1 mp -103.14 44.07 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.745 0 N-CA-C 106.581 -1.637 . . . . 1.0 106.581 172.225 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 17.6 t0 -123.4 96.61 5.05 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 127.458 2.303 . . . . 1.0 106.238 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.749 0 N-CA-C 109.527 -1.429 . . . . 1.0 109.527 -168.123 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.313 0 N-CA-C 110.478 -1.049 . . . . 1.0 110.478 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.4 tp -55.83 -48.19 75.91 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 124.528 1.131 . . . . 1.0 112.578 -170.543 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -63.65 -45.51 89.85 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 124.567 1.147 . . . . 1.0 110.123 -176.424 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.01 -50.89 49.33 Favored Glycine 0 CA--C 1.531 1.087 0 CA-C-N 113.973 -1.467 . . . . 1.0 111.595 170.302 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.8 -38.6 91.3 Favored 'General case' 0 CA--C 1.535 0.396 0 CA-C-N 118.126 0.963 . . . . 1.0 112.072 179.22 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.7 mt -63.58 -62.96 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 C-N-CA 127.516 2.326 . . . . 1.0 106.717 178.376 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.66 -34.21 69.13 Favored 'General case' 0 CA--C 1.541 0.635 0 CA-C-O 119.134 -0.46 . . . . 1.0 111.793 179.124 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -60.0 -50.21 70.16 Favored Glycine 0 CA--C 1.532 1.14 0 CA-C-N 120.049 1.295 . . . . 1.0 111.235 172.36 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -54.75 -31.06 58.04 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 124.242 1.017 . . . . 1.0 112.143 173.845 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -68.21 -11.83 14.87 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.822 0 C-N-CA 126.463 1.905 . . . . 1.0 111.112 -172.189 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -121.1 6.65 10.28 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.788 1.635 . . . . 1.0 111.348 176.714 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 27.1 t-20 -138.84 -45.87 0.48 Allowed 'General case' 0 N--CA 1.466 0.336 0 O-C-N 121.312 -0.867 . . . . 1.0 113.29 -161.665 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.24 14.49 8.29 Favored Glycine 0 CA--C 1.528 0.863 0 C-N-CA 124.687 1.137 . . . . 1.0 111.477 175.806 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.589 ' CD1' HD11 ' A' ' 18' ' ' ILE . 57.7 t-105 -60.13 163.05 5.17 Favored 'General case' 0 N--CA 1.447 -0.582 0 C-N-CA 126.281 1.832 . . . . 1.0 113.845 -168.017 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -150.06 95.48 2.29 Favored 'General case' 0 N--CA 1.445 -0.715 0 C-N-CA 125.271 1.429 . . . . 1.0 108.127 177.131 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 166.72 -5.0 0.05 OUTLIER Glycine 0 CA--C 1.534 1.27 0 N-CA-C 117.085 1.594 . . . . 1.0 117.085 171.562 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' MET . . . . . 0.477 ' H ' HD12 ' A' ' 18' ' ' ILE . 4.0 ppp? -130.68 9.68 5.05 Favored 'General case' 0 N--CA 1.475 0.786 0 CA-C-N 119.541 1.67 . . . . 1.0 113.628 167.831 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.589 HD11 ' CD1' ' A' ' 14' ' ' TRP . 0.5 OUTLIER -103.3 42.29 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 N-CA-C 107.543 -1.28 . . . . 1.0 107.543 -176.615 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 11.3 p-10 -113.38 -0.97 14.33 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 126.172 1.789 . . . . 1.0 112.899 -160.885 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.085 0 N-CA-C 110.426 -1.07 . . . . 1.0 110.426 166.19 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.225 0 N-CA-C 110.131 -1.188 . . . . 1.0 110.131 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.1 tp -55.04 -49.13 72.34 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 124.625 1.17 . . . . 1.0 112.582 -170.778 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -63.77 -46.75 83.83 Favored 'General case' 0 C--N 1.331 -0.199 0 C-N-CA 124.325 1.05 . . . . 1.0 110.327 -176.316 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.52 -49.3 57.84 Favored Glycine 0 CA--C 1.531 1.071 0 CA-C-N 114.168 -1.378 . . . . 1.0 111.48 171.703 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.58 -39.78 94.79 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-N 117.989 0.895 . . . . 1.0 111.932 178.894 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.6 mt -63.75 -63.05 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.801 0 C-N-CA 127.524 2.33 . . . . 1.0 106.866 178.578 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.44 -31.63 66.09 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 122.972 0.509 . . . . 1.0 112.256 179.009 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.72 -51.55 52.95 Favored Glycine 0 CA--C 1.53 1.0 0 CA-C-N 119.954 1.252 . . . . 1.0 111.018 171.09 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -54.12 -26.68 28.7 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 124.072 0.949 . . . . 1.0 112.36 173.671 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -67.76 -10.04 11.72 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.878 0 C-N-CA 125.175 1.39 . . . . 1.0 110.59 -175.372 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -127.16 6.76 6.48 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 126.524 1.93 . . . . 1.0 111.376 173.788 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 13.1 t-20 -148.51 93.36 2.13 Favored 'General case' 0 C--N 1.342 0.239 0 O-C-N 120.81 -1.181 . . . . 1.0 109.691 -164.384 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 76.93 10.84 85.99 Favored Glycine 0 CA--C 1.533 1.187 0 CA-C-O 118.979 -0.901 . . . . 1.0 112.199 -167.623 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.5 ' CD1' HD11 ' A' ' 18' ' ' ILE . 53.2 t-105 -53.82 161.09 1.22 Allowed 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 126.06 1.744 . . . . 1.0 113.228 176.877 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -152.49 98.08 2.33 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 125.579 1.552 . . . . 1.0 107.754 177.391 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.411 ' H ' HD12 ' A' ' 18' ' ' ILE . . . 161.3 -4.44 0.09 OUTLIER Glycine 0 CA--C 1.531 1.074 0 N-CA-C 116.29 1.276 . . . . 1.0 116.29 170.026 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 4.3 ppp? -116.65 -0.9 12.25 Favored 'General case' 0 N--CA 1.47 0.551 0 CA-C-N 119.17 1.485 . . . . 1.0 112.695 169.451 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.5 HD11 ' CD1' ' A' ' 14' ' ' TRP . 1.4 mp -103.03 34.88 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.69 0 CA-C-O 123.281 1.515 . . . . 1.0 107.54 -168.076 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 24.1 t0 -91.38 93.1 8.87 Favored 'General case' 0 N--CA 1.454 -0.257 0 C-N-CA 125.8 1.64 . . . . 1.0 109.146 -171.376 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.962 0 C-N-CA 125.094 1.331 . . . . 1.0 112.952 174.435 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.173 0 N-CA-C 110.186 -1.165 . . . . 1.0 110.186 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.7 tp -55.84 -50.25 71.08 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 124.89 1.276 . . . . 1.0 112.963 -170.225 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.2 t80 -63.53 -47.93 79.62 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 124.077 0.951 . . . . 1.0 110.241 -176.806 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -50.89 -50.46 38.05 Favored Glycine 0 CA--C 1.53 0.969 0 CA-C-N 114.087 -1.415 . . . . 1.0 111.485 171.338 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.01 -43.23 99.19 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 117.896 0.848 . . . . 1.0 111.722 178.842 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.4 mt -63.51 -63.31 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.673 0 C-N-CA 127.246 2.218 . . . . 1.0 107.55 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -60.73 -27.85 68.23 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 123.579 0.752 . . . . 1.0 112.524 -179.226 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.55 -55.16 21.95 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 110.655 -0.978 . . . . 1.0 110.655 169.697 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -51.22 -31.41 20.46 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 124.657 1.183 . . . . 1.0 112.297 176.124 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -60.07 -17.53 14.03 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.737 0 C-N-CA 126.631 1.973 . . . . 1.0 111.615 -174.263 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -129.58 9.84 5.56 Favored 'General case' 0 CA--C 1.545 0.767 0 C-N-CA 125.942 1.697 . . . . 1.0 110.391 177.36 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -147.6 78.91 1.47 Allowed 'General case' 0 C--O 1.234 0.279 0 C-N-CA 124.869 1.268 . . . . 1.0 108.905 -170.055 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 98.96 -3.16 58.48 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-O 119.198 -0.779 . . . . 1.0 112.875 -177.65 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.608 ' CD1' HD12 ' A' ' 18' ' ' ILE . 24.6 t-105 -55.17 155.76 4.59 Favored 'General case' 0 N--CA 1.456 -0.174 0 C-N-CA 124.795 1.238 . . . . 1.0 112.321 168.362 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -157.01 116.23 3.38 Favored 'General case' 0 N--CA 1.428 -1.572 0 C-N-CA 124.875 1.27 . . . . 1.0 108.156 158.798 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -160.61 -102.68 0.18 Allowed Glycine 0 CA--C 1.524 0.598 0 C-N-CA 125.557 1.551 . . . . 1.0 109.487 169.639 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 4.8 mpp? -71.03 6.75 1.43 Allowed 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 124.718 1.207 . . . . 1.0 113.242 -177.659 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.608 HD12 ' CD1' ' A' ' 14' ' ' TRP . 48.6 mt -104.03 56.9 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.3 0 N-CA-C 105.769 -1.937 . . . . 1.0 105.769 176.22 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -133.1 102.14 5.48 Favored 'General case' 0 N--CA 1.453 -0.276 0 C-N-CA 125.596 1.558 . . . . 1.0 107.646 179.225 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.595 0 C-N-CA 125.096 1.331 . . . . 1.0 110.725 175.75 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.306 0 N-CA-C 110.225 -1.15 . . . . 1.0 110.225 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.1 tp -56.86 -49.18 76.24 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 124.57 1.148 . . . . 1.0 112.596 -171.268 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -63.65 -45.52 89.83 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 124.45 1.1 . . . . 1.0 110.128 -176.706 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.98 -50.16 56.07 Favored Glycine 0 CA--C 1.532 1.115 0 CA-C-N 114.031 -1.44 . . . . 1.0 111.497 171.097 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.08 -38.31 88.36 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 118.044 0.922 . . . . 1.0 112.095 179.145 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.9 mt -63.58 -63.22 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.694 0 C-N-CA 127.855 2.462 . . . . 1.0 107.299 176.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.8 -26.53 58.12 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 113.062 0.764 . . . . 1.0 113.062 177.773 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -67.32 -56.02 13.48 Favored Glycine 0 CA--C 1.531 1.073 0 CA-C-N 119.312 0.96 . . . . 1.0 111.066 168.35 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -47.98 -34.41 9.24 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 125.687 1.595 . . . . 1.0 112.193 175.058 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -57.29 -19.98 11.97 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.771 0 C-N-CA 127.336 2.254 . . . . 1.0 111.629 -175.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -132.15 15.09 4.66 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 126.783 2.033 . . . . 1.0 111.275 -178.355 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 21.4 t-20 -137.31 -33.45 0.74 Allowed 'General case' 0 N--CA 1.467 0.405 0 O-C-N 121.352 -0.842 . . . . 1.0 113.236 -170.889 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -139.42 9.21 3.2 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-O 119.017 -0.88 . . . . 1.0 112.53 174.647 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.675 ' CD1' HD12 ' A' ' 18' ' ' ILE . 35.3 t-105 -62.51 145.35 54.49 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 118.152 0.976 . . . . 1.0 113.271 -173.01 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 48.0 mt-10 -155.11 114.47 3.66 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 105.32 -2.104 . . . . 1.0 105.32 158.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -167.06 -24.79 0.02 OUTLIER Glycine 0 CA--C 1.53 0.982 0 N-CA-C 115.603 1.001 . . . . 1.0 115.603 168.738 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -133.74 -0.41 3.16 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 118.669 1.235 . . . . 1.0 112.962 172.235 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.675 HD12 ' CD1' ' A' ' 14' ' ' TRP . 59.8 mt -104.1 53.19 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.26 0 N-CA-C 105.147 -2.168 . . . . 1.0 105.147 -176.221 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -138.78 97.17 3.27 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 126.539 1.936 . . . . 1.0 106.683 -174.519 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.122 0 C-N-CA 123.898 0.761 . . . . 1.0 114.399 178.617 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.371 0 N-CA-C 109.89 -1.284 . . . . 1.0 109.89 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.3 tp -56.28 -48.58 76.34 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 124.419 1.088 . . . . 1.0 112.594 -170.552 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.1 t80 -63.7 -47.23 82.02 Favored 'General case' 0 N--CA 1.455 -0.206 0 C-N-CA 124.401 1.08 . . . . 1.0 110.105 -176.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -51.73 -50.61 42.61 Favored Glycine 0 CA--C 1.531 1.068 0 CA-C-N 114.178 -1.374 . . . . 1.0 111.538 171.156 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.18 -40.51 96.29 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 117.966 0.883 . . . . 1.0 112.031 179.197 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.9 mt -63.59 -63.18 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.704 0 C-N-CA 127.662 2.385 . . . . 1.0 107.061 178.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -58.84 -28.42 66.05 Favored 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 123.432 0.693 . . . . 1.0 112.513 179.261 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.1 -54.84 25.13 Favored Glycine 0 CA--C 1.528 0.894 0 CA-C-N 119.331 0.969 . . . . 1.0 110.762 169.782 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -51.92 -29.83 21.83 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 124.582 1.153 . . . . 1.0 112.478 175.443 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -61.98 -17.41 17.56 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.876 0 C-N-CA 126.055 1.742 . . . . 1.0 110.916 -175.432 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -123.17 6.45 9.16 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 127.04 2.136 . . . . 1.0 110.634 176.663 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -148.22 80.59 1.47 Allowed 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.596 1.159 . . . . 1.0 108.882 -167.265 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 96.29 -5.54 65.42 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 124.029 0.823 . . . . 1.0 113.049 -179.203 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.525 ' CD1' HD12 ' A' ' 18' ' ' ILE . 3.7 t-105 -60.03 155.24 17.34 Favored 'General case' 0 N--CA 1.456 -0.158 0 CA-C-N 118.027 0.913 . . . . 1.0 112.083 166.701 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -158.74 115.98 2.81 Favored 'General case' 0 N--CA 1.428 -1.534 0 C-N-CA 125.515 1.526 . . . . 1.0 107.784 158.708 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -168.79 -26.07 0.02 OUTLIER Glycine 0 CA--C 1.53 1.013 0 N-CA-C 115.57 0.988 . . . . 1.0 115.57 165.372 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 93.0 mtp -132.76 4.13 3.85 Favored 'General case' 0 N--CA 1.473 0.71 0 CA-C-N 118.947 1.374 . . . . 1.0 112.661 176.903 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.525 HD12 ' CD1' ' A' ' 14' ' ' TRP . 66.4 mt -104.18 54.05 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 N-CA-C 105.303 -2.11 . . . . 1.0 105.303 178.482 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 21.7 t0 -144.7 97.07 2.97 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 126.097 1.759 . . . . 1.0 107.617 -176.164 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.84 0 N-CA-C 110.598 -1.001 . . . . 1.0 110.598 177.351 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.309 0 N-CA-C 110.294 -1.122 . . . . 1.0 110.294 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.4 tp -56.33 -47.39 78.89 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 124.506 1.123 . . . . 1.0 112.454 -171.779 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 7.8 t80 -63.55 -45.45 90.48 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 124.54 1.136 . . . . 1.0 110.06 -176.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.69 -51.9 41.55 Favored Glycine 0 CA--C 1.531 1.059 0 CA-C-N 114.096 -1.411 . . . . 1.0 111.474 170.197 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.48 -38.43 87.24 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 118.061 0.931 . . . . 1.0 112.175 179.611 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.8 mt -63.65 -62.99 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.706 0 C-N-CA 127.721 2.408 . . . . 1.0 106.963 177.38 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.65 -27.4 58.47 Favored 'General case' 0 CA--C 1.541 0.597 0 N-CA-C 113.077 0.769 . . . . 1.0 113.077 177.983 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -67.75 -55.15 15.28 Favored Glycine 0 CA--C 1.53 0.971 0 CA-C-N 119.748 1.158 . . . . 1.0 110.797 169.078 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -49.14 -30.05 6.19 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 125.096 1.359 . . . . 1.0 112.568 174.799 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -59.6 -20.9 19.74 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.848 0 C-N-CA 126.409 1.884 . . . . 1.0 111.074 -177.925 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -121.64 4.57 10.09 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 126.454 1.902 . . . . 1.0 111.048 175.111 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -141.34 76.87 1.57 Allowed 'General case' 0 C--N 1.339 0.13 0 O-C-N 120.363 -1.461 . . . . 1.0 107.971 -166.453 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 93.54 4.27 64.09 Favored Glycine 0 CA--C 1.528 0.898 0 CA-C-O 118.434 -1.203 . . . . 1.0 113.364 -179.029 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.471 ' CD1' HD12 ' A' ' 18' ' ' ILE . 11.9 t-105 -53.82 148.64 9.86 Favored 'General case' 0 C--N 1.34 0.162 0 CA-C-N 118.925 1.362 . . . . 1.0 112.466 170.121 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -166.34 116.32 0.96 Allowed 'General case' 0 N--CA 1.441 -0.917 0 C-N-CA 125.077 1.351 . . . . 1.0 108.476 158.285 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -168.39 8.24 0.05 OUTLIER Glycine 0 CA--C 1.53 0.971 0 C-N-CA 126.26 1.886 . . . . 1.0 115.2 163.466 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 9.1 ttp -167.92 7.78 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.411 1.484 . . . . 1.0 113.189 -174.208 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.471 HD12 ' CD1' ' A' ' 14' ' ' TRP . 41.1 mt -123.12 43.01 0.68 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 N-CA-C 104.485 -2.413 . . . . 1.0 104.485 -179.068 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 10.4 p-10 -98.84 -5.35 31.21 Favored 'General case' 0 N--CA 1.462 0.17 0 C-N-CA 128.011 2.525 . . . . 1.0 113.948 -158.814 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.706 0 C-N-CA 125.176 1.37 . . . . 1.0 109.843 178.566 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.25 0 N-CA-C 110.382 -1.087 . . . . 1.0 110.382 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 15.0 tp -55.48 -48.77 74.03 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 124.822 1.249 . . . . 1.0 112.673 -172.574 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -63.44 -45.41 91.03 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 124.469 1.108 . . . . 1.0 110.01 -177.394 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.67 -49.86 51.52 Favored Glycine 0 CA--C 1.531 1.061 0 CA-C-N 114.126 -1.397 . . . . 1.0 111.796 170.211 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -63.6 -39.29 94.01 Favored 'General case' 0 CA--C 1.537 0.46 0 CA-C-N 118.298 1.049 . . . . 1.0 112.038 179.451 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.4 mt -63.39 -63.17 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.826 0 C-N-CA 127.586 2.354 . . . . 1.0 106.915 177.797 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -55.34 -32.63 62.68 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.033 0.533 . . . . 1.0 112.252 177.234 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -61.99 -52.24 51.54 Favored Glycine 0 CA--C 1.531 1.053 0 CA-C-N 119.879 1.218 . . . . 1.0 111.039 171.805 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -54.53 -26.84 34.25 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 124.196 0.998 . . . . 1.0 112.42 173.391 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -70.15 -9.41 12.4 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.043 0 C-N-CA 125.103 1.361 . . . . 1.0 109.653 -175.67 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -118.19 1.36 11.9 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 125.71 1.604 . . . . 1.0 111.468 171.738 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -151.96 81.19 1.27 Allowed 'General case' 0 C--O 1.234 0.261 0 O-C-N 121.072 -1.018 . . . . 1.0 108.707 -161.519 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 99.01 0.82 57.23 Favored Glycine 0 CA--C 1.531 1.075 0 CA-C-O 119.065 -0.853 . . . . 1.0 112.572 -173.366 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.762 ' CD1' HD13 ' A' ' 18' ' ' ILE . 62.4 t-105 -53.06 155.09 2.66 Favored 'General case' 0 N--CA 1.452 -0.356 0 C-N-CA 125.65 1.58 . . . . 1.0 112.728 174.576 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -141.79 -115.68 0.12 Allowed 'General case' 0 N--CA 1.442 -0.85 0 N-CA-C 105.047 -2.205 . . . . 1.0 105.047 -176.509 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 58.64 -75.58 0.01 OUTLIER Glycine 0 CA--C 1.531 1.086 0 C-N-CA 126.183 1.849 . . . . 1.0 113.437 -177.509 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.1 ttt -102.34 -10.6 19.34 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 125.35 1.46 . . . . 1.0 112.503 173.005 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.762 HD13 ' CD1' ' A' ' 14' ' ' TRP . 3.3 mp -103.3 41.68 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 C-N-CA 128.178 2.591 . . . . 1.0 106.126 176.749 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 42.6 t0 -76.19 96.41 3.9 Favored 'General case' 0 C--O 1.234 0.249 0 C-N-CA 125.129 1.372 . . . . 1.0 109.026 176.643 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.245 0 CA-C-O 118.174 -1.348 . . . . 1.0 114.535 177.158 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.271 0 N-CA-C 110.135 -1.186 . . . . 1.0 110.135 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.6 tp -56.65 -49.04 76.19 Favored 'General case' 0 N--CA 1.468 0.425 0 C-N-CA 124.51 1.124 . . . . 1.0 112.635 -170.478 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -63.71 -45.27 90.72 Favored 'General case' 0 C--O 1.225 -0.203 0 C-N-CA 124.358 1.063 . . . . 1.0 110.031 -176.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.83 -50.23 51.01 Favored Glycine 0 CA--C 1.532 1.145 0 CA-C-N 113.976 -1.465 . . . . 1.0 111.724 170.5 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.86 -39.05 93.2 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 118.258 1.029 . . . . 1.0 112.048 179.315 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.0 mt -63.73 -62.94 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 C-N-CA 127.384 2.274 . . . . 1.0 106.827 177.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.82 -31.74 65.03 Favored 'General case' 0 CA--C 1.542 0.644 0 N-CA-C 112.387 0.514 . . . . 1.0 112.387 178.326 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.66 -49.86 61.96 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-N 119.846 1.203 . . . . 1.0 111.329 172.018 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -54.24 -26.88 31.12 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 123.929 0.892 . . . . 1.0 112.241 172.478 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -68.84 -10.71 13.7 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.061 0 C-N-CA 124.878 1.271 . . . . 1.0 109.88 -174.523 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -118.71 2.51 11.68 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.027 1.731 . . . . 1.0 111.47 172.02 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -149.12 82.23 1.43 Allowed 'General case' 0 C--O 1.235 0.303 0 O-C-N 120.995 -1.066 . . . . 1.0 109.029 -164.167 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 97.23 -1.97 60.97 Favored Glycine 0 CA--C 1.532 1.094 0 CA-C-O 118.98 -0.9 . . . . 1.0 112.719 -175.783 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.853 ' CD1' HD13 ' A' ' 18' ' ' ILE . 56.1 t-105 -50.75 150.16 3.0 Favored 'General case' 0 C--O 1.233 0.202 0 C-N-CA 125.738 1.615 . . . . 1.0 113.055 173.326 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -123.94 -105.73 0.35 Allowed 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 126.827 2.051 . . . . 1.0 107.873 177.621 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 63.37 -68.91 0.03 OUTLIER Glycine 0 CA--C 1.534 1.24 0 CA-C-N 121.868 2.122 . . . . 1.0 114.683 174.885 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 67.5 mtt -123.56 -3.98 8.28 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 126.56 1.944 . . . . 1.0 112.937 172.627 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.853 HD13 ' CD1' ' A' ' 14' ' ' TRP . 3.2 mp -103.59 47.12 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 C-N-CA 128.327 2.651 . . . . 1.0 105.442 174.594 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 22.1 t0 -139.13 102.01 4.41 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 126.718 2.007 . . . . 1.0 106.532 173.906 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.748 0 N-CA-C 109.729 -1.348 . . . . 1.0 109.729 -171.765 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.289 0 N-CA-C 110.132 -1.187 . . . . 1.0 110.132 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.9 tp -55.39 -48.28 74.57 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 124.424 1.09 . . . . 1.0 112.737 -169.374 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -63.47 -47.1 83.19 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 124.453 1.101 . . . . 1.0 110.659 -174.78 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.56 -51.55 47.47 Favored Glycine 0 CA--C 1.531 1.042 0 CA-C-N 113.918 -1.492 . . . . 1.0 111.026 170.701 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.91 -37.08 83.28 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 117.806 0.803 . . . . 1.0 112.489 179.506 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.53 -63.13 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 C-N-CA 127.771 2.429 . . . . 1.0 106.931 177.031 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -58.12 -27.79 64.06 Favored 'General case' 0 CA--C 1.539 0.547 0 N-CA-C 112.708 0.632 . . . . 1.0 112.708 179.417 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -67.48 -53.54 24.28 Favored Glycine 0 CA--C 1.531 1.055 0 CA-C-N 119.391 0.996 . . . . 1.0 111.302 169.502 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -51.44 -28.38 12.89 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 124.896 1.278 . . . . 1.0 112.397 174.338 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -65.98 -9.59 8.8 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.936 0 C-N-CA 126.161 1.784 . . . . 1.0 110.876 -175.858 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -130.13 8.9 5.2 Favored 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 126.723 2.009 . . . . 1.0 110.811 173.771 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -148.41 81.77 1.47 Allowed 'General case' 0 C--O 1.234 0.287 0 O-C-N 120.826 -1.171 . . . . 1.0 108.466 -166.47 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 91.89 7.26 64.58 Favored Glycine 0 CA--C 1.531 1.047 0 CA-C-O 119.023 -0.876 . . . . 1.0 112.393 -171.318 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.653 ' CD1' HD13 ' A' ' 18' ' ' ILE . 60.4 t-105 -59.22 156.78 11.73 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 124.756 1.222 . . . . 1.0 112.098 175.684 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -140.02 -107.11 0.16 Allowed 'General case' 0 N--CA 1.449 -0.475 0 CA-C-N 115.433 -0.803 . . . . 1.0 108.883 167.977 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 65.79 -59.74 0.13 Allowed Glycine 0 CA--C 1.534 1.234 0 C-N-CA 126.839 2.162 . . . . 1.0 114.41 177.235 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 12.8 tmm? -128.81 -11.21 4.89 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 127.108 2.163 . . . . 1.0 112.666 175.537 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.653 HD13 ' CD1' ' A' ' 14' ' ' TRP . 2.5 mp -114.41 44.26 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.438 0 C-N-CA 128.687 2.795 . . . . 1.0 107.553 174.607 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -68.62 66.56 0.13 Allowed 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 128.792 2.837 . . . . 1.0 112.499 -176.353 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.073 0 C-N-CA 125.971 1.748 . . . . 1.0 114.758 -179.152 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.237 0 N-CA-C 110.169 -1.172 . . . . 1.0 110.169 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.2 tp -56.4 -47.96 77.92 Favored 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 124.442 1.097 . . . . 1.0 112.638 -170.538 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -63.58 -46.12 87.29 Favored 'General case' 0 C--N 1.33 -0.239 0 C-N-CA 124.406 1.082 . . . . 1.0 110.227 -177.016 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.33 -51.33 42.88 Favored Glycine 0 CA--C 1.53 1.025 0 CA-C-N 114.034 -1.439 . . . . 1.0 111.536 170.443 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.94 -39.09 90.88 Favored 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 117.953 0.877 . . . . 1.0 112.164 179.419 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.8 mt -63.57 -63.09 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.763 0 C-N-CA 127.568 2.347 . . . . 1.0 107.019 178.013 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.96 -29.44 63.21 Favored 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 112.537 0.569 . . . . 1.0 112.537 178.556 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.74 -53.43 34.73 Favored Glycine 0 CA--C 1.531 1.092 0 CA-C-N 119.447 1.021 . . . . 1.0 111.236 170.1 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -52.92 -30.77 36.39 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 124.955 1.302 . . . . 1.0 112.353 174.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -64.67 -14.04 15.46 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.846 0 C-N-CA 126.754 2.021 . . . . 1.0 111.456 -173.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -122.47 9.74 9.72 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 126.4 1.88 . . . . 1.0 110.749 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -140.37 -41.53 0.42 Allowed 'General case' 0 N--CA 1.465 0.323 0 O-C-N 121.096 -1.002 . . . . 1.0 113.522 -163.208 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -129.08 11.97 6.13 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 124.275 0.94 . . . . 1.0 112.046 175.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.559 ' CD1' HD11 ' A' ' 18' ' ' ILE . 54.0 t-105 -62.55 153.39 32.04 Favored 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 125.564 1.545 . . . . 1.0 113.405 -169.77 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -161.95 116.67 1.93 Allowed 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 127.391 2.276 . . . . 1.0 106.578 159.083 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 172.63 -3.36 0.03 OUTLIER Glycine 0 CA--C 1.529 0.936 0 C-N-CA 129.066 3.222 . . . . 1.0 111.11 171.457 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 11.8 ttt -144.44 12.08 1.51 Allowed 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 124.3 1.04 . . . . 1.0 113.058 176.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.559 HD11 ' CD1' ' A' ' 14' ' ' TRP . 0.9 OUTLIER . . . . . 0 CA--C 1.542 0.647 0 CA-C-O 123.34 1.543 . . . . 1.0 108.34 167.26 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.324 0 N-CA-C 110.127 -1.189 . . . . 1.0 110.127 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.0 tp -56.0 -48.35 76.06 Favored 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 124.414 1.085 . . . . 1.0 112.576 -170.118 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -63.62 -46.73 84.38 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 124.456 1.103 . . . . 1.0 110.192 -176.79 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.68 -49.17 54.43 Favored Glycine 0 CA--C 1.53 1.004 0 CA-C-N 114.022 -1.445 . . . . 1.0 111.6 171.043 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -63.76 -39.81 95.18 Favored 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 118.198 0.999 . . . . 1.0 111.925 178.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.2 mt -63.63 -63.05 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.775 0 C-N-CA 127.434 2.294 . . . . 1.0 107.173 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.27 -34.13 68.34 Favored 'General case' 0 CA--C 1.542 0.641 0 CA-C-O 119.33 -0.367 . . . . 1.0 111.648 177.696 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -59.25 -50.67 65.33 Favored Glycine 0 CA--C 1.531 1.055 0 O-C-N 120.65 -1.281 . . . . 1.0 111.271 172.168 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -54.43 -33.04 58.68 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 124.186 0.994 . . . . 1.0 111.86 173.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -66.71 -14.65 18.21 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.916 0 C-N-CA 126.115 1.766 . . . . 1.0 110.065 -173.023 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -111.44 -1.17 16.01 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.331 1.452 . . . . 1.0 112.154 177.619 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 49.1 m-80 -138.05 -43.11 0.52 Allowed 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 119.623 1.101 . . . . 1.0 113.202 -159.186 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -121.29 8.92 10.26 Favored Glycine 0 CA--C 1.526 0.738 0 C-N-CA 124.133 0.873 . . . . 1.0 111.724 176.578 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.535 ' CD1' HD11 ' A' ' 18' ' ' ILE . 55.1 t-105 -62.59 154.53 28.71 Favored 'General case' 0 N--CA 1.444 -0.726 0 C-N-CA 125.472 1.509 . . . . 1.0 113.028 -170.736 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -160.73 116.42 2.25 Favored 'General case' 0 N--CA 1.44 -0.95 0 C-N-CA 125.797 1.639 . . . . 1.0 106.977 159.048 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 175.38 -7.99 0.03 OUTLIER Glycine 0 CA--C 1.53 0.979 0 C-N-CA 128.98 3.181 . . . . 1.0 110.642 168.095 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . 0.463 ' HB3' ' HE1' ' A' ' 14' ' ' TRP . 8.0 tpt -133.1 8.41 4.04 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 125.174 1.39 . . . . 1.0 113.451 177.59 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.535 HD11 ' CD1' ' A' ' 14' ' ' TRP . 1.6 mp . . . . . 0 CA--C 1.542 0.665 0 CA-C-O 123.123 1.44 . . . . 1.0 108.288 170.223 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.199 0 N-CA-C 109.956 -1.258 . . . . 1.0 109.956 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.4 tp -56.12 -48.83 75.46 Favored 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 124.519 1.128 . . . . 1.0 112.582 -171.153 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.2 t80 -63.62 -45.58 89.65 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 124.585 1.154 . . . . 1.0 109.988 -176.069 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.39 -50.27 53.38 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-N 114.026 -1.443 . . . . 1.0 111.648 170.525 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.83 -38.73 91.94 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 118.101 0.95 . . . . 1.0 112.134 178.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.2 mt -63.46 -63.18 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.774 0 C-N-CA 127.606 2.362 . . . . 1.0 106.877 178.268 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.68 -34.75 67.7 Favored 'General case' 0 CA--C 1.543 0.677 0 CA-C-O 119.263 -0.398 . . . . 1.0 111.809 178.375 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -60.6 -49.92 73.26 Favored Glycine 0 CA--C 1.531 1.047 0 O-C-N 120.667 -1.271 . . . . 1.0 111.348 172.691 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -55.39 -31.29 61.7 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 124.2 1.0 . . . . 1.0 112.064 173.191 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -67.59 -14.24 17.95 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.91 0 C-N-CA 125.761 1.624 . . . . 1.0 109.737 -173.799 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -110.08 -0.79 17.85 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 125.503 1.521 . . . . 1.0 111.94 177.592 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 50.3 m-80 -139.55 -41.68 0.45 Allowed 'General case' 0 N--CA 1.472 0.651 0 CA-C-N 119.74 1.155 . . . . 1.0 113.398 -159.259 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -124.45 9.05 8.29 Favored Glycine 0 CA--C 1.527 0.815 0 C-N-CA 124.222 0.915 . . . . 1.0 111.892 177.089 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.509 ' CD1' HD11 ' A' ' 18' ' ' ILE . 50.4 t-105 -60.21 154.68 19.19 Favored 'General case' 0 N--CA 1.446 -0.641 0 C-N-CA 125.789 1.636 . . . . 1.0 113.469 -171.393 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -160.83 116.56 2.23 Favored 'General case' 0 N--CA 1.44 -0.946 0 C-N-CA 125.703 1.601 . . . . 1.0 107.308 158.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 170.51 3.61 0.03 OUTLIER Glycine 0 CA--C 1.528 0.845 0 C-N-CA 128.554 2.978 . . . . 1.0 111.656 165.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 15.1 ttp -143.86 14.35 1.72 Allowed 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.017 1.327 . . . . 1.0 112.654 175.469 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.509 HD11 ' CD1' ' A' ' 14' ' ' TRP . 2.1 mp . . . . . 0 CA--C 1.537 0.462 0 CA-C-O 122.914 1.34 . . . . 1.0 108.095 167.542 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.313 0 N-CA-C 110.219 -1.152 . . . . 1.0 110.219 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.6 tp -56.39 -48.63 76.5 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 124.605 1.162 . . . . 1.0 112.57 -171.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.4 t80 -63.57 -45.86 88.53 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 124.348 1.059 . . . . 1.0 109.97 -177.129 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -51.67 -51.05 40.41 Favored Glycine 0 CA--C 1.531 1.038 0 CA-C-N 114.017 -1.447 . . . . 1.0 111.689 170.169 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.58 -39.45 93.74 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 118.26 1.03 . . . . 1.0 112.124 179.563 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.56 -63.05 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.763 0 C-N-CA 127.442 2.297 . . . . 1.0 106.969 178.23 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.04 -32.14 63.78 Favored 'General case' 0 CA--C 1.541 0.631 0 O-C-N 122.021 -0.424 . . . . 1.0 112.132 177.489 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -61.51 -52.84 48.54 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-N 119.951 1.251 . . . . 1.0 111.088 171.093 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -51.72 -33.67 35.47 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 124.192 0.997 . . . . 1.0 112.069 174.299 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -64.08 -13.96 14.55 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.907 0 C-N-CA 126.801 2.04 . . . . 1.0 111.333 -172.823 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -126.63 6.76 6.83 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 125.733 1.613 . . . . 1.0 111.711 178.517 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -139.23 -32.45 0.66 Allowed 'General case' 0 N--CA 1.471 0.61 0 O-C-N 121.231 -0.918 . . . . 1.0 112.805 -163.71 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -137.32 13.65 3.76 Favored Glycine 0 CA--C 1.526 0.735 0 C-N-CA 124.338 0.97 . . . . 1.0 111.627 174.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.478 ' CD1' HD11 ' A' ' 18' ' ' ILE . 56.8 t-105 -56.47 157.16 5.32 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 126.278 1.831 . . . . 1.0 113.648 -168.556 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -157.39 115.04 3.09 Favored 'General case' 0 N--CA 1.436 -1.171 0 N-CA-C 101.663 -3.458 . . . . 1.0 101.663 176.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 149.86 -4.01 0.62 Allowed Glycine 0 CA--C 1.531 1.045 0 C-N-CA 125.059 1.314 . . . . 1.0 114.866 167.637 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . 0.42 ' CB ' ' HE1' ' A' ' 14' ' ' TRP . 15.7 ttt -130.75 9.72 5.02 Favored 'General case' 0 CA--C 1.54 0.576 0 CA-C-N 118.847 1.324 . . . . 1.0 111.961 172.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.478 HD11 ' CD1' ' A' ' 14' ' ' TRP . 1.2 mp . . . . . 0 CA--C 1.539 0.522 0 N-CA-C 107.51 -1.293 . . . . 1.0 107.51 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.251 0 N-CA-C 109.917 -1.273 . . . . 1.0 109.917 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 8.4 tp -54.83 -50.49 68.46 Favored 'General case' 0 N--CA 1.467 0.388 0 C-N-CA 124.586 1.154 . . . . 1.0 112.76 -169.581 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.2 t80 -63.71 -46.79 83.84 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 124.17 0.988 . . . . 1.0 110.383 -175.129 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.16 -51.03 49.25 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-N 114.032 -1.44 . . . . 1.0 111.428 171.408 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -60.97 -40.63 94.13 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 123.682 0.793 . . . . 1.0 111.835 178.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.3 mt -63.43 -63.21 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.794 0 C-N-CA 127.511 2.324 . . . . 1.0 107.082 178.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.99 -33.22 66.91 Favored 'General case' 0 CA--C 1.542 0.65 0 CA-C-O 118.999 -0.524 . . . . 1.0 112.148 179.634 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.37 -50.92 58.71 Favored Glycine 0 CA--C 1.532 1.097 0 CA-C-N 120.062 1.301 . . . . 1.0 111.339 171.431 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -53.42 -30.63 41.35 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 124.457 1.103 . . . . 1.0 112.22 173.744 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -66.93 -13.72 16.97 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.921 0 C-N-CA 126.27 1.828 . . . . 1.0 110.546 -173.645 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -112.18 1.72 16.35 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 125.054 1.342 . . . . 1.0 111.905 176.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 12.5 t30 -139.09 -48.64 0.49 Allowed 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 119.353 0.978 . . . . 1.0 112.862 -159.547 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -118.71 9.86 12.61 Favored Glycine 0 CA--C 1.527 0.833 0 C-N-CA 124.303 0.954 . . . . 1.0 111.965 178.117 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.403 ' CD1' HD11 ' A' ' 18' ' ' ILE . 65.0 t-105 -56.93 164.93 1.38 Allowed 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 126.395 1.878 . . . . 1.0 114.55 -168.372 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -150.13 91.16 1.74 Allowed 'General case' 0 N--CA 1.442 -0.869 0 C-N-CA 125.054 1.342 . . . . 1.0 111.265 -175.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 165.94 -16.13 0.09 OUTLIER Glycine 0 CA--C 1.529 0.942 0 CA-C-N 115.405 -0.816 . . . . 1.0 114.734 165.053 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 1.3 mpt? -107.69 6.78 28.04 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 124.38 1.072 . . . . 1.0 111.766 175.825 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.479 ' N ' HD12 ' A' ' 18' ' ' ILE . 1.6 mp . . . . . 0 CA--C 1.539 0.525 0 N-CA-C 106.844 -1.539 . . . . 1.0 106.844 -174.5 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.21 0 N-CA-C 110.155 -1.178 . . . . 1.0 110.155 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 8.7 tp -54.91 -49.05 72.22 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 124.522 1.129 . . . . 1.0 112.695 -169.147 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 12.2 t80 -63.76 -47.17 82.07 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 124.319 1.048 . . . . 1.0 110.538 -175.377 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.21 -51.11 48.96 Favored Glycine 0 CA--C 1.53 1.021 0 CA-C-N 114.072 -1.422 . . . . 1.0 111.287 171.187 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.19 -39.53 90.52 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 117.74 0.77 . . . . 1.0 111.952 179.28 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.47 -63.1 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.78 0 C-N-CA 127.654 2.381 . . . . 1.0 107.143 178.174 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.48 -29.93 64.67 Favored 'General case' 0 CA--C 1.539 0.543 0 N-CA-C 112.714 0.635 . . . . 1.0 112.714 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.58 -52.68 32.89 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-N 119.702 1.137 . . . . 1.0 111.206 170.094 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -52.43 -28.61 20.65 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 124.64 1.176 . . . . 1.0 112.3 174.415 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -64.83 -13.1 14.16 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.871 0 C-N-CA 125.98 1.712 . . . . 1.0 110.887 -175.568 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -126.82 6.94 6.71 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 126.357 1.863 . . . . 1.0 111.371 175.032 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 -147.69 90.61 1.87 Allowed 'General case' 0 C--N 1.341 0.196 0 O-C-N 120.956 -1.09 . . . . 1.0 109.291 -165.034 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 77.35 12.7 84.32 Favored Glycine 0 CA--C 1.532 1.124 0 CA-C-O 118.632 -1.094 . . . . 1.0 112.378 -169.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.449 ' CD1' HD11 ' A' ' 18' ' ' ILE . 55.8 t-105 -51.99 156.15 1.62 Allowed 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.492 1.517 . . . . 1.0 112.967 176.62 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -159.1 101.92 1.6 Allowed 'General case' 0 N--CA 1.445 -0.711 0 C-N-CA 126.241 1.816 . . . . 1.0 106.327 -179.224 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 159.5 -5.79 0.12 Allowed Glycine 0 CA--C 1.53 1.03 0 CA-C-O 118.861 -0.966 . . . . 1.0 115.254 171.373 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . 0.44 ' CB ' ' HE1' ' A' ' 14' ' ' TRP . 13.3 ttt -128.52 11.19 6.26 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 118.92 1.36 . . . . 1.0 111.947 174.095 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.449 HD11 ' CD1' ' A' ' 14' ' ' TRP . 1.7 mp . . . . . 0 CA--C 1.538 0.503 0 C-N-CA 124.977 1.311 . . . . 1.0 107.473 179.411 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.254 0 N-CA-C 110.165 -1.174 . . . . 1.0 110.165 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.5 tp -56.19 -48.63 76.01 Favored 'General case' 0 N--CA 1.468 0.449 0 C-N-CA 124.494 1.118 . . . . 1.0 112.659 -171.635 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -63.64 -45.42 90.32 Favored 'General case' 0 N--CA 1.455 -0.206 0 C-N-CA 124.18 0.992 . . . . 1.0 109.724 -178.11 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -50.74 -50.42 37.33 Favored Glycine 0 CA--C 1.532 1.13 0 CA-C-N 114.138 -1.392 . . . . 1.0 112.124 170.169 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -63.0 -41.53 99.61 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 118.143 0.972 . . . . 1.0 111.854 179.253 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.56 -63.01 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.843 0 C-N-CA 127.339 2.255 . . . . 1.0 106.695 179.663 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -54.25 -37.59 64.84 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.636 0.774 . . . . 1.0 111.814 177.332 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.34 -51.73 55.89 Favored Glycine 0 CA--C 1.531 1.049 0 CA-C-N 119.825 1.193 . . . . 1.0 111.42 173.346 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -58.46 -26.43 63.35 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 124.244 1.018 . . . . 1.0 112.712 174.031 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -68.91 -18.24 22.81 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.78 0 CA-C-N 119.776 1.171 . . . . 1.0 110.604 -172.123 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -109.53 0.73 19.35 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 125.873 1.669 . . . . 1.0 111.576 173.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 13.3 t-20 -152.05 95.84 2.12 Favored 'General case' 0 C--N 1.344 0.335 0 O-C-N 120.567 -1.333 . . . . 1.0 110.182 -159.287 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 74.94 11.16 83.92 Favored Glycine 0 CA--C 1.531 1.058 0 CA-C-O 118.583 -1.12 . . . . 1.0 112.414 -170.479 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.445 ' CD1' HD11 ' A' ' 18' ' ' ILE . 59.3 t-105 -50.25 154.96 1.08 Allowed 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 125.513 1.525 . . . . 1.0 113.105 175.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -159.22 100.63 1.54 Allowed 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 106.045 -1.835 . . . . 1.0 106.045 -178.146 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 162.51 -6.84 0.08 OUTLIER Glycine 0 CA--C 1.532 1.133 0 CA-C-O 118.762 -1.021 . . . . 1.0 115.278 173.369 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . 0.42 ' CB ' ' HE1' ' A' ' 14' ' ' TRP . 30.6 ttp -129.76 9.69 5.46 Favored 'General case' 0 CA--C 1.539 0.519 0 CA-C-N 119.128 1.464 . . . . 1.0 111.975 175.244 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.445 HD11 ' CD1' ' A' ' 14' ' ' TRP . 1.6 mp . . . . . 0 CA--C 1.538 0.506 0 N-CA-C 107.314 -1.365 . . . . 1.0 107.314 -178.02 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.329 0 N-CA-C 110.027 -1.229 . . . . 1.0 110.027 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.5 tp -57.98 -47.65 82.36 Favored 'General case' 0 N--CA 1.466 0.365 0 C-N-CA 124.25 1.02 . . . . 1.0 112.325 -172.212 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.6 t80 -63.59 -44.75 93.13 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 124.306 1.042 . . . . 1.0 109.759 -177.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -51.63 -50.64 41.9 Favored Glycine 0 CA--C 1.533 1.191 0 CA-C-N 114.241 -1.345 . . . . 1.0 112.044 170.016 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -63.1 -40.07 96.56 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 118.369 1.084 . . . . 1.0 112.147 179.667 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.0 mt -63.58 -62.93 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.773 0 C-N-CA 127.673 2.389 . . . . 1.0 106.433 178.736 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -53.85 -32.46 53.05 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 123.599 0.76 . . . . 1.0 112.278 175.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.57 -53.98 40.78 Favored Glycine 0 CA--C 1.53 0.992 0 CA-C-N 119.81 1.186 . . . . 1.0 111.158 171.614 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -56.04 -28.01 55.63 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 123.657 0.783 . . . . 1.0 112.443 174.406 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -69.0 -10.27 13.16 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.889 0 C-N-CA 124.798 1.239 . . . . 1.0 110.446 -174.163 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -123.81 8.53 8.78 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 126.972 2.109 . . . . 1.0 110.946 176.452 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -156.46 92.99 1.36 Allowed 'General case' 0 C--N 1.343 0.294 0 O-C-N 120.513 -1.367 . . . . 1.0 109.285 -169.436 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 85.16 6.49 84.48 Favored Glycine 0 CA--C 1.53 0.988 0 CA-C-O 118.749 -1.028 . . . . 1.0 112.663 -172.183 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.54 ' CD1' HD11 ' A' ' 18' ' ' ILE . 55.3 t-105 -55.79 155.14 6.22 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 124.739 1.216 . . . . 1.0 112.525 176.791 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -162.16 104.06 1.13 Allowed 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 105.421 -2.066 . . . . 1.0 105.421 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 162.07 -8.59 0.1 OUTLIER Glycine 0 CA--C 1.528 0.895 0 CA-C-O 118.939 -0.923 . . . . 1.0 115.048 174.581 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 31.7 ttm -132.09 8.34 4.38 Favored 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 118.913 1.356 . . . . 1.0 112.257 174.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.54 HD11 ' CD1' ' A' ' 14' ' ' TRP . 0.7 OUTLIER . . . . . 0 CA--C 1.535 0.375 0 C-N-CA 124.695 1.198 . . . . 1.0 108.955 -179.476 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.245 0 N-CA-C 110.211 -1.155 . . . . 1.0 110.211 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.9 tp -56.12 -48.85 75.41 Favored 'General case' 0 N--CA 1.467 0.388 0 C-N-CA 124.613 1.165 . . . . 1.0 112.604 -170.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.5 t80 -63.63 -46.05 87.45 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 124.341 1.056 . . . . 1.0 110.068 -176.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.55 -50.05 49.98 Favored Glycine 0 CA--C 1.53 1.015 0 CA-C-N 114.194 -1.367 . . . . 1.0 111.667 170.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.0 -40.94 97.36 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 118.174 0.987 . . . . 1.0 111.944 178.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.2 mt -63.58 -63.18 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.782 0 C-N-CA 127.509 2.324 . . . . 1.0 107.251 179.267 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -58.13 -29.17 65.33 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 123.508 0.723 . . . . 1.0 112.484 178.715 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.62 -54.29 29.78 Favored Glycine 0 CA--C 1.529 0.951 0 CA-C-N 119.464 1.029 . . . . 1.0 110.832 170.038 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -52.24 -28.62 19.35 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 124.413 1.085 . . . . 1.0 112.42 174.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -65.99 -11.63 12.92 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.867 0 C-N-CA 125.825 1.65 . . . . 1.0 111.016 -175.213 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -126.81 8.25 6.84 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 126.663 1.985 . . . . 1.0 110.877 174.32 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -148.1 83.53 1.51 Allowed 'General case' 0 C--O 1.234 0.274 0 O-C-N 120.817 -1.177 . . . . 1.0 108.719 -166.69 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 88.33 7.38 72.91 Favored Glycine 0 CA--C 1.531 1.054 0 CA-C-O 118.992 -0.893 . . . . 1.0 112.587 -173.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.496 ' CD1' HD11 ' A' ' 18' ' ' ILE . 55.8 t-105 -52.87 155.23 2.46 Favored 'General case' 0 N--CA 1.452 -0.336 0 C-N-CA 125.655 1.582 . . . . 1.0 113.185 175.698 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -160.35 102.65 1.4 Allowed 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 126.275 1.83 . . . . 1.0 106.124 178.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 167.92 -17.44 0.08 OUTLIER Glycine 0 CA--C 1.529 0.94 0 CA-C-O 118.842 -0.977 . . . . 1.0 114.959 170.247 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . 0.433 ' HB2' ' HE1' ' A' ' 14' ' ' TRP . 0.0 OUTLIER -126.68 19.14 7.31 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-N 118.828 1.314 . . . . 1.0 112.662 175.607 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.496 HD11 ' CD1' ' A' ' 14' ' ' TRP . 1.4 mp . . . . . 0 CA--C 1.537 0.465 0 N-CA-C 106.853 -1.536 . . . . 1.0 106.853 172.736 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.238 0 N-CA-C 109.808 -1.317 . . . . 1.0 109.808 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 14.9 tp -55.45 -51.4 67.06 Favored 'General case' 0 N--CA 1.466 0.351 0 C-N-CA 124.836 1.254 . . . . 1.0 113.068 -169.064 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.5 t80 -63.8 -46.25 86.0 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 124.155 0.982 . . . . 1.0 110.136 -176.348 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.73 -49.18 54.69 Favored Glycine 0 CA--C 1.532 1.12 0 CA-C-N 114.02 -1.446 . . . . 1.0 111.723 171.046 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.81 -40.26 96.83 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 118.059 0.93 . . . . 1.0 111.751 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.55 -63.02 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.835 0 C-N-CA 127.318 2.247 . . . . 1.0 106.969 178.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -55.93 -34.39 65.57 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 122.991 0.516 . . . . 1.0 112.141 178.296 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -61.91 -50.96 60.48 Favored Glycine 0 CA--C 1.531 1.089 0 O-C-N 120.817 -1.177 . . . . 1.0 111.328 172.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -56.81 -25.03 54.85 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 124.505 1.122 . . . . 1.0 112.58 173.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -68.43 -16.32 20.82 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.948 0 C-N-CA 124.571 1.148 . . . . 1.0 110.415 -172.779 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -110.69 1.85 18.17 Favored 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 125.752 1.621 . . . . 1.0 111.439 172.553 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -150.32 81.97 1.36 Allowed 'General case' 0 C--O 1.235 0.337 0 O-C-N 120.969 -1.082 . . . . 1.0 108.95 -160.454 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 95.41 -0.18 63.4 Favored Glycine 0 CA--C 1.53 0.988 0 CA-C-O 118.947 -0.918 . . . . 1.0 112.789 -176.18 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.532 ' CD1' HD11 ' A' ' 18' ' ' ILE . 57.5 t-105 -54.61 154.47 4.86 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 125.06 1.344 . . . . 1.0 112.661 173.257 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -158.09 116.53 3.08 Favored 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 125.729 1.612 . . . . 1.0 107.065 159.08 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 173.19 4.11 0.03 OUTLIER Glycine 0 CA--C 1.527 0.816 0 C-N-CA 128.582 2.991 . . . . 1.0 111.829 165.162 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 22.0 ttp -143.67 10.05 1.59 Allowed 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 125.173 1.389 . . . . 1.0 112.995 178.145 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.532 HD11 ' CD1' ' A' ' 14' ' ' TRP . 2.4 mp . . . . . 0 CA--C 1.54 0.588 0 CA-C-O 122.723 1.249 . . . . 1.0 107.635 172.311 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.266 0 N-CA-C 110.112 -1.195 . . . . 1.0 110.112 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.3 tp -55.66 -49.13 73.73 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 124.656 1.182 . . . . 1.0 112.755 -170.506 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -63.63 -46.92 83.5 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 124.251 1.02 . . . . 1.0 110.134 -176.648 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.05 -50.06 46.81 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-N 114.083 -1.417 . . . . 1.0 111.61 171.16 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.26 -41.17 98.21 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 117.986 0.893 . . . . 1.0 111.928 178.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.2 mt -63.48 -63.24 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 C-N-CA 127.458 2.303 . . . . 1.0 107.196 179.606 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.87 -33.04 68.27 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 122.887 0.475 . . . . 1.0 111.98 179.014 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -61.0 -52.4 52.49 Favored Glycine 0 CA--C 1.53 1.004 0 CA-C-N 119.883 1.219 . . . . 1.0 111.09 171.671 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -54.4 -27.82 39.33 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 124.096 0.958 . . . . 1.0 112.396 173.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -68.38 -12.12 15.33 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.956 0 C-N-CA 125.199 1.399 . . . . 1.0 110.161 -174.595 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -117.11 1.77 12.57 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 125.92 1.688 . . . . 1.0 111.516 173.431 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -149.53 84.3 1.42 Allowed 'General case' 0 C--O 1.234 0.261 0 O-C-N 121.111 -0.993 . . . . 1.0 108.573 -160.167 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 87.68 6.73 76.31 Favored Glycine 0 CA--C 1.531 1.041 0 CA-C-O 118.725 -1.042 . . . . 1.0 112.613 -174.034 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.498 ' CD1' HD11 ' A' ' 18' ' ' ILE . 54.6 t-105 -53.68 152.49 5.2 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 124.878 1.271 . . . . 1.0 112.208 173.386 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -158.48 116.56 2.96 Favored 'General case' 0 N--CA 1.441 -0.924 0 C-N-CA 125.81 1.644 . . . . 1.0 107.042 159.147 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.407 ' H ' ' H ' ' A' ' 17' ' ' MET . . . 172.4 5.28 0.03 OUTLIER Glycine 0 CA--C 1.528 0.882 0 C-N-CA 129.248 3.308 . . . . 1.0 111.747 168.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . 0.414 ' CB ' ' HE1' ' A' ' 14' ' ' TRP . 23.2 ttm -147.91 10.77 0.93 Allowed 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 125.054 1.341 . . . . 1.0 113.329 178.868 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.498 HD11 ' CD1' ' A' ' 14' ' ' TRP . 3.1 mp . . . . . 0 CA--C 1.544 0.745 0 N-CA-C 106.581 -1.637 . . . . 1.0 106.581 172.225 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.313 0 N-CA-C 110.478 -1.049 . . . . 1.0 110.478 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.4 tp -55.83 -48.19 75.91 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 124.528 1.131 . . . . 1.0 112.578 -170.543 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -63.65 -45.51 89.85 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 124.567 1.147 . . . . 1.0 110.123 -176.424 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.01 -50.89 49.33 Favored Glycine 0 CA--C 1.531 1.087 0 CA-C-N 113.973 -1.467 . . . . 1.0 111.595 170.302 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.8 -38.6 91.3 Favored 'General case' 0 CA--C 1.535 0.396 0 CA-C-N 118.126 0.963 . . . . 1.0 112.072 179.22 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.7 mt -63.58 -62.96 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 C-N-CA 127.516 2.326 . . . . 1.0 106.717 178.376 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.66 -34.21 69.13 Favored 'General case' 0 CA--C 1.541 0.635 0 CA-C-O 119.134 -0.46 . . . . 1.0 111.793 179.124 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -60.0 -50.21 70.16 Favored Glycine 0 CA--C 1.532 1.14 0 CA-C-N 120.049 1.295 . . . . 1.0 111.235 172.36 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -54.75 -31.06 58.04 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 124.242 1.017 . . . . 1.0 112.143 173.845 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -68.21 -11.83 14.87 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.822 0 C-N-CA 126.463 1.905 . . . . 1.0 111.112 -172.189 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -121.1 6.65 10.28 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.788 1.635 . . . . 1.0 111.348 176.714 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 27.1 t-20 -138.84 -45.87 0.48 Allowed 'General case' 0 N--CA 1.466 0.336 0 O-C-N 121.312 -0.867 . . . . 1.0 113.29 -161.665 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.24 14.49 8.29 Favored Glycine 0 CA--C 1.528 0.863 0 C-N-CA 124.687 1.137 . . . . 1.0 111.477 175.806 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.589 ' CD1' HD11 ' A' ' 18' ' ' ILE . 57.7 t-105 -60.13 163.05 5.17 Favored 'General case' 0 N--CA 1.447 -0.582 0 C-N-CA 126.281 1.832 . . . . 1.0 113.845 -168.017 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -150.06 95.48 2.29 Favored 'General case' 0 N--CA 1.445 -0.715 0 C-N-CA 125.271 1.429 . . . . 1.0 108.127 177.131 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 166.72 -5.0 0.05 OUTLIER Glycine 0 CA--C 1.534 1.27 0 N-CA-C 117.085 1.594 . . . . 1.0 117.085 171.562 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . 0.477 ' H ' HD12 ' A' ' 18' ' ' ILE . 4.0 ppp? -130.68 9.68 5.05 Favored 'General case' 0 N--CA 1.475 0.786 0 CA-C-N 119.541 1.67 . . . . 1.0 113.628 167.831 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.589 HD11 ' CD1' ' A' ' 14' ' ' TRP . 0.5 OUTLIER . . . . . 0 CA--C 1.541 0.621 0 N-CA-C 107.543 -1.28 . . . . 1.0 107.543 -176.615 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.225 0 N-CA-C 110.131 -1.188 . . . . 1.0 110.131 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.1 tp -55.04 -49.13 72.34 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 124.625 1.17 . . . . 1.0 112.582 -170.778 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -63.77 -46.75 83.83 Favored 'General case' 0 C--N 1.331 -0.199 0 C-N-CA 124.325 1.05 . . . . 1.0 110.327 -176.316 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.52 -49.3 57.84 Favored Glycine 0 CA--C 1.531 1.071 0 CA-C-N 114.168 -1.378 . . . . 1.0 111.48 171.703 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.58 -39.78 94.79 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-N 117.989 0.895 . . . . 1.0 111.932 178.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.6 mt -63.75 -63.05 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.801 0 C-N-CA 127.524 2.33 . . . . 1.0 106.866 178.578 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.44 -31.63 66.09 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 122.972 0.509 . . . . 1.0 112.256 179.009 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.72 -51.55 52.95 Favored Glycine 0 CA--C 1.53 1.0 0 CA-C-N 119.954 1.252 . . . . 1.0 111.018 171.09 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -54.12 -26.68 28.7 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 124.072 0.949 . . . . 1.0 112.36 173.671 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -67.76 -10.04 11.72 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.878 0 C-N-CA 125.175 1.39 . . . . 1.0 110.59 -175.372 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -127.16 6.76 6.48 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 126.524 1.93 . . . . 1.0 111.376 173.788 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 13.1 t-20 -148.51 93.36 2.13 Favored 'General case' 0 C--N 1.342 0.239 0 O-C-N 120.81 -1.181 . . . . 1.0 109.691 -164.384 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 76.93 10.84 85.99 Favored Glycine 0 CA--C 1.533 1.187 0 CA-C-O 118.979 -0.901 . . . . 1.0 112.199 -167.623 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.5 ' CD1' HD11 ' A' ' 18' ' ' ILE . 53.2 t-105 -53.82 161.09 1.22 Allowed 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 126.06 1.744 . . . . 1.0 113.228 176.877 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -152.49 98.08 2.33 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 125.579 1.552 . . . . 1.0 107.754 177.391 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.411 ' H ' HD12 ' A' ' 18' ' ' ILE . . . 161.3 -4.44 0.09 OUTLIER Glycine 0 CA--C 1.531 1.074 0 N-CA-C 116.29 1.276 . . . . 1.0 116.29 170.026 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 4.3 ppp? -116.65 -0.9 12.25 Favored 'General case' 0 N--CA 1.47 0.551 0 CA-C-N 119.17 1.485 . . . . 1.0 112.695 169.451 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.5 HD11 ' CD1' ' A' ' 14' ' ' TRP . 1.4 mp . . . . . 0 CA--C 1.543 0.69 0 CA-C-O 123.281 1.515 . . . . 1.0 107.54 -168.076 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.173 0 N-CA-C 110.186 -1.165 . . . . 1.0 110.186 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.7 tp -55.84 -50.25 71.08 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 124.89 1.276 . . . . 1.0 112.963 -170.225 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.2 t80 -63.53 -47.93 79.62 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 124.077 0.951 . . . . 1.0 110.241 -176.806 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -50.89 -50.46 38.05 Favored Glycine 0 CA--C 1.53 0.969 0 CA-C-N 114.087 -1.415 . . . . 1.0 111.485 171.338 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.01 -43.23 99.19 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 117.896 0.848 . . . . 1.0 111.722 178.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.4 mt -63.51 -63.31 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.673 0 C-N-CA 127.246 2.218 . . . . 1.0 107.55 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -60.73 -27.85 68.23 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 123.579 0.752 . . . . 1.0 112.524 -179.226 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.55 -55.16 21.95 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 110.655 -0.978 . . . . 1.0 110.655 169.697 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -51.22 -31.41 20.46 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 124.657 1.183 . . . . 1.0 112.297 176.124 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -60.07 -17.53 14.03 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.737 0 C-N-CA 126.631 1.973 . . . . 1.0 111.615 -174.263 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -129.58 9.84 5.56 Favored 'General case' 0 CA--C 1.545 0.767 0 C-N-CA 125.942 1.697 . . . . 1.0 110.391 177.36 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -147.6 78.91 1.47 Allowed 'General case' 0 C--O 1.234 0.279 0 C-N-CA 124.869 1.268 . . . . 1.0 108.905 -170.055 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 98.96 -3.16 58.48 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-O 119.198 -0.779 . . . . 1.0 112.875 -177.65 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.608 ' CD1' HD12 ' A' ' 18' ' ' ILE . 24.6 t-105 -55.17 155.76 4.59 Favored 'General case' 0 N--CA 1.456 -0.174 0 C-N-CA 124.795 1.238 . . . . 1.0 112.321 168.362 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -157.01 116.23 3.38 Favored 'General case' 0 N--CA 1.428 -1.572 0 C-N-CA 124.875 1.27 . . . . 1.0 108.156 158.798 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -160.61 -102.68 0.18 Allowed Glycine 0 CA--C 1.524 0.598 0 C-N-CA 125.557 1.551 . . . . 1.0 109.487 169.639 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 4.8 mpp? -71.03 6.75 1.43 Allowed 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 124.718 1.207 . . . . 1.0 113.242 -177.659 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.608 HD12 ' CD1' ' A' ' 14' ' ' TRP . 48.6 mt . . . . . 0 CA--C 1.533 0.3 0 N-CA-C 105.769 -1.937 . . . . 1.0 105.769 176.22 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.306 0 N-CA-C 110.225 -1.15 . . . . 1.0 110.225 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.1 tp -56.86 -49.18 76.24 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 124.57 1.148 . . . . 1.0 112.596 -171.268 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -63.65 -45.52 89.83 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 124.45 1.1 . . . . 1.0 110.128 -176.706 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.98 -50.16 56.07 Favored Glycine 0 CA--C 1.532 1.115 0 CA-C-N 114.031 -1.44 . . . . 1.0 111.497 171.097 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.08 -38.31 88.36 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 118.044 0.922 . . . . 1.0 112.095 179.145 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.9 mt -63.58 -63.22 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.694 0 C-N-CA 127.855 2.462 . . . . 1.0 107.299 176.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.8 -26.53 58.12 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 113.062 0.764 . . . . 1.0 113.062 177.773 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -67.32 -56.02 13.48 Favored Glycine 0 CA--C 1.531 1.073 0 CA-C-N 119.312 0.96 . . . . 1.0 111.066 168.35 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -47.98 -34.41 9.24 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 125.687 1.595 . . . . 1.0 112.193 175.058 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -57.29 -19.98 11.97 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.771 0 C-N-CA 127.336 2.254 . . . . 1.0 111.629 -175.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -132.15 15.09 4.66 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 126.783 2.033 . . . . 1.0 111.275 -178.355 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 21.4 t-20 -137.31 -33.45 0.74 Allowed 'General case' 0 N--CA 1.467 0.405 0 O-C-N 121.352 -0.842 . . . . 1.0 113.236 -170.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -139.42 9.21 3.2 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-O 119.017 -0.88 . . . . 1.0 112.53 174.647 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.675 ' CD1' HD12 ' A' ' 18' ' ' ILE . 35.3 t-105 -62.51 145.35 54.49 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 118.152 0.976 . . . . 1.0 113.271 -173.01 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 48.0 mt-10 -155.11 114.47 3.66 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 105.32 -2.104 . . . . 1.0 105.32 158.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -167.06 -24.79 0.02 OUTLIER Glycine 0 CA--C 1.53 0.982 0 N-CA-C 115.603 1.001 . . . . 1.0 115.603 168.738 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -133.74 -0.41 3.16 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 118.669 1.235 . . . . 1.0 112.962 172.235 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.675 HD12 ' CD1' ' A' ' 14' ' ' TRP . 59.8 mt . . . . . 0 CA--C 1.532 0.26 0 N-CA-C 105.147 -2.168 . . . . 1.0 105.147 -176.221 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.371 0 N-CA-C 109.89 -1.284 . . . . 1.0 109.89 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.3 tp -56.28 -48.58 76.34 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 124.419 1.088 . . . . 1.0 112.594 -170.552 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.1 t80 -63.7 -47.23 82.02 Favored 'General case' 0 N--CA 1.455 -0.206 0 C-N-CA 124.401 1.08 . . . . 1.0 110.105 -176.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -51.73 -50.61 42.61 Favored Glycine 0 CA--C 1.531 1.068 0 CA-C-N 114.178 -1.374 . . . . 1.0 111.538 171.156 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.18 -40.51 96.29 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 117.966 0.883 . . . . 1.0 112.031 179.197 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.9 mt -63.59 -63.18 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.704 0 C-N-CA 127.662 2.385 . . . . 1.0 107.061 178.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -58.84 -28.42 66.05 Favored 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 123.432 0.693 . . . . 1.0 112.513 179.261 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.1 -54.84 25.13 Favored Glycine 0 CA--C 1.528 0.894 0 CA-C-N 119.331 0.969 . . . . 1.0 110.762 169.782 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -51.92 -29.83 21.83 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 124.582 1.153 . . . . 1.0 112.478 175.443 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -61.98 -17.41 17.56 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.876 0 C-N-CA 126.055 1.742 . . . . 1.0 110.916 -175.432 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -123.17 6.45 9.16 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 127.04 2.136 . . . . 1.0 110.634 176.663 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -148.22 80.59 1.47 Allowed 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.596 1.159 . . . . 1.0 108.882 -167.265 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 96.29 -5.54 65.42 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 124.029 0.823 . . . . 1.0 113.049 -179.203 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.525 ' CD1' HD12 ' A' ' 18' ' ' ILE . 3.7 t-105 -60.03 155.24 17.34 Favored 'General case' 0 N--CA 1.456 -0.158 0 CA-C-N 118.027 0.913 . . . . 1.0 112.083 166.701 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -158.74 115.98 2.81 Favored 'General case' 0 N--CA 1.428 -1.534 0 C-N-CA 125.515 1.526 . . . . 1.0 107.784 158.708 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -168.79 -26.07 0.02 OUTLIER Glycine 0 CA--C 1.53 1.013 0 N-CA-C 115.57 0.988 . . . . 1.0 115.57 165.372 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 93.0 mtp -132.76 4.13 3.85 Favored 'General case' 0 N--CA 1.473 0.71 0 CA-C-N 118.947 1.374 . . . . 1.0 112.661 176.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.525 HD12 ' CD1' ' A' ' 14' ' ' TRP . 66.4 mt . . . . . 0 CA--C 1.534 0.342 0 N-CA-C 105.303 -2.11 . . . . 1.0 105.303 178.482 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.309 0 N-CA-C 110.294 -1.122 . . . . 1.0 110.294 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.4 tp -56.33 -47.39 78.89 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 124.506 1.123 . . . . 1.0 112.454 -171.779 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 7.8 t80 -63.55 -45.45 90.48 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 124.54 1.136 . . . . 1.0 110.06 -176.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.69 -51.9 41.55 Favored Glycine 0 CA--C 1.531 1.059 0 CA-C-N 114.096 -1.411 . . . . 1.0 111.474 170.197 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.48 -38.43 87.24 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 118.061 0.931 . . . . 1.0 112.175 179.611 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.8 mt -63.65 -62.99 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.706 0 C-N-CA 127.721 2.408 . . . . 1.0 106.963 177.38 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.65 -27.4 58.47 Favored 'General case' 0 CA--C 1.541 0.597 0 N-CA-C 113.077 0.769 . . . . 1.0 113.077 177.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -67.75 -55.15 15.28 Favored Glycine 0 CA--C 1.53 0.971 0 CA-C-N 119.748 1.158 . . . . 1.0 110.797 169.078 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -49.14 -30.05 6.19 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 125.096 1.359 . . . . 1.0 112.568 174.799 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -59.6 -20.9 19.74 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.848 0 C-N-CA 126.409 1.884 . . . . 1.0 111.074 -177.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -121.64 4.57 10.09 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 126.454 1.902 . . . . 1.0 111.048 175.111 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -141.34 76.87 1.57 Allowed 'General case' 0 C--N 1.339 0.13 0 O-C-N 120.363 -1.461 . . . . 1.0 107.971 -166.453 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 93.54 4.27 64.09 Favored Glycine 0 CA--C 1.528 0.898 0 CA-C-O 118.434 -1.203 . . . . 1.0 113.364 -179.029 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.471 ' CD1' HD12 ' A' ' 18' ' ' ILE . 11.9 t-105 -53.82 148.64 9.86 Favored 'General case' 0 C--N 1.34 0.162 0 CA-C-N 118.925 1.362 . . . . 1.0 112.466 170.121 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -166.34 116.32 0.96 Allowed 'General case' 0 N--CA 1.441 -0.917 0 C-N-CA 125.077 1.351 . . . . 1.0 108.476 158.285 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -168.39 8.24 0.05 OUTLIER Glycine 0 CA--C 1.53 0.971 0 C-N-CA 126.26 1.886 . . . . 1.0 115.2 163.466 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 9.1 ttp -167.92 7.78 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.411 1.484 . . . . 1.0 113.189 -174.208 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.471 HD12 ' CD1' ' A' ' 14' ' ' TRP . 41.1 mt . . . . . 0 CA--C 1.543 0.689 0 N-CA-C 104.485 -2.413 . . . . 1.0 104.485 -179.068 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.25 0 N-CA-C 110.382 -1.087 . . . . 1.0 110.382 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 15.0 tp -55.48 -48.77 74.03 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 124.822 1.249 . . . . 1.0 112.673 -172.574 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -63.44 -45.41 91.03 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 124.469 1.108 . . . . 1.0 110.01 -177.394 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.67 -49.86 51.52 Favored Glycine 0 CA--C 1.531 1.061 0 CA-C-N 114.126 -1.397 . . . . 1.0 111.796 170.211 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -63.6 -39.29 94.01 Favored 'General case' 0 CA--C 1.537 0.46 0 CA-C-N 118.298 1.049 . . . . 1.0 112.038 179.451 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.4 mt -63.39 -63.17 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.826 0 C-N-CA 127.586 2.354 . . . . 1.0 106.915 177.797 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -55.34 -32.63 62.68 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.033 0.533 . . . . 1.0 112.252 177.234 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -61.99 -52.24 51.54 Favored Glycine 0 CA--C 1.531 1.053 0 CA-C-N 119.879 1.218 . . . . 1.0 111.039 171.805 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -54.53 -26.84 34.25 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 124.196 0.998 . . . . 1.0 112.42 173.391 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -70.15 -9.41 12.4 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.043 0 C-N-CA 125.103 1.361 . . . . 1.0 109.653 -175.67 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -118.19 1.36 11.9 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 125.71 1.604 . . . . 1.0 111.468 171.738 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -151.96 81.19 1.27 Allowed 'General case' 0 C--O 1.234 0.261 0 O-C-N 121.072 -1.018 . . . . 1.0 108.707 -161.519 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 99.01 0.82 57.23 Favored Glycine 0 CA--C 1.531 1.075 0 CA-C-O 119.065 -0.853 . . . . 1.0 112.572 -173.366 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.762 ' CD1' HD13 ' A' ' 18' ' ' ILE . 62.4 t-105 -53.06 155.09 2.66 Favored 'General case' 0 N--CA 1.452 -0.356 0 C-N-CA 125.65 1.58 . . . . 1.0 112.728 174.576 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -141.79 -115.68 0.12 Allowed 'General case' 0 N--CA 1.442 -0.85 0 N-CA-C 105.047 -2.205 . . . . 1.0 105.047 -176.509 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 58.64 -75.58 0.01 OUTLIER Glycine 0 CA--C 1.531 1.086 0 C-N-CA 126.183 1.849 . . . . 1.0 113.437 -177.509 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.1 ttt -102.34 -10.6 19.34 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 125.35 1.46 . . . . 1.0 112.503 173.005 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.762 HD13 ' CD1' ' A' ' 14' ' ' TRP . 3.3 mp . . . . . 0 CA--C 1.543 0.689 0 C-N-CA 128.178 2.591 . . . . 1.0 106.126 176.749 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.271 0 N-CA-C 110.135 -1.186 . . . . 1.0 110.135 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.6 tp -56.65 -49.04 76.19 Favored 'General case' 0 N--CA 1.468 0.425 0 C-N-CA 124.51 1.124 . . . . 1.0 112.635 -170.478 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -63.71 -45.27 90.72 Favored 'General case' 0 C--O 1.225 -0.203 0 C-N-CA 124.358 1.063 . . . . 1.0 110.031 -176.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.83 -50.23 51.01 Favored Glycine 0 CA--C 1.532 1.145 0 CA-C-N 113.976 -1.465 . . . . 1.0 111.724 170.5 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.86 -39.05 93.2 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 118.258 1.029 . . . . 1.0 112.048 179.315 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.0 mt -63.73 -62.94 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 C-N-CA 127.384 2.274 . . . . 1.0 106.827 177.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.82 -31.74 65.03 Favored 'General case' 0 CA--C 1.542 0.644 0 N-CA-C 112.387 0.514 . . . . 1.0 112.387 178.326 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.66 -49.86 61.96 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-N 119.846 1.203 . . . . 1.0 111.329 172.018 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -54.24 -26.88 31.12 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 123.929 0.892 . . . . 1.0 112.241 172.478 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -68.84 -10.71 13.7 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.061 0 C-N-CA 124.878 1.271 . . . . 1.0 109.88 -174.523 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -118.71 2.51 11.68 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.027 1.731 . . . . 1.0 111.47 172.02 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -149.12 82.23 1.43 Allowed 'General case' 0 C--O 1.235 0.303 0 O-C-N 120.995 -1.066 . . . . 1.0 109.029 -164.167 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 97.23 -1.97 60.97 Favored Glycine 0 CA--C 1.532 1.094 0 CA-C-O 118.98 -0.9 . . . . 1.0 112.719 -175.783 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.853 ' CD1' HD13 ' A' ' 18' ' ' ILE . 56.1 t-105 -50.75 150.16 3.0 Favored 'General case' 0 C--O 1.233 0.202 0 C-N-CA 125.738 1.615 . . . . 1.0 113.055 173.326 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -123.94 -105.73 0.35 Allowed 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 126.827 2.051 . . . . 1.0 107.873 177.621 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 63.37 -68.91 0.03 OUTLIER Glycine 0 CA--C 1.534 1.24 0 CA-C-N 121.868 2.122 . . . . 1.0 114.683 174.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 67.5 mtt -123.56 -3.98 8.28 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 126.56 1.944 . . . . 1.0 112.937 172.627 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.853 HD13 ' CD1' ' A' ' 14' ' ' TRP . 3.2 mp . . . . . 0 CA--C 1.541 0.621 0 C-N-CA 128.327 2.651 . . . . 1.0 105.442 174.594 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.289 0 N-CA-C 110.132 -1.187 . . . . 1.0 110.132 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.9 tp -55.39 -48.28 74.57 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 124.424 1.09 . . . . 1.0 112.737 -169.374 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -63.47 -47.1 83.19 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 124.453 1.101 . . . . 1.0 110.659 -174.78 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.56 -51.55 47.47 Favored Glycine 0 CA--C 1.531 1.042 0 CA-C-N 113.918 -1.492 . . . . 1.0 111.026 170.701 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.91 -37.08 83.28 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 117.806 0.803 . . . . 1.0 112.489 179.506 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.53 -63.13 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 C-N-CA 127.771 2.429 . . . . 1.0 106.931 177.031 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -58.12 -27.79 64.06 Favored 'General case' 0 CA--C 1.539 0.547 0 N-CA-C 112.708 0.632 . . . . 1.0 112.708 179.417 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -67.48 -53.54 24.28 Favored Glycine 0 CA--C 1.531 1.055 0 CA-C-N 119.391 0.996 . . . . 1.0 111.302 169.502 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -51.44 -28.38 12.89 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 124.896 1.278 . . . . 1.0 112.397 174.338 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -65.98 -9.59 8.8 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.936 0 C-N-CA 126.161 1.784 . . . . 1.0 110.876 -175.858 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -130.13 8.9 5.2 Favored 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 126.723 2.009 . . . . 1.0 110.811 173.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -148.41 81.77 1.47 Allowed 'General case' 0 C--O 1.234 0.287 0 O-C-N 120.826 -1.171 . . . . 1.0 108.466 -166.47 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 91.89 7.26 64.58 Favored Glycine 0 CA--C 1.531 1.047 0 CA-C-O 119.023 -0.876 . . . . 1.0 112.393 -171.318 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.653 ' CD1' HD13 ' A' ' 18' ' ' ILE . 60.4 t-105 -59.22 156.78 11.73 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 124.756 1.222 . . . . 1.0 112.098 175.684 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -140.02 -107.11 0.16 Allowed 'General case' 0 N--CA 1.449 -0.475 0 CA-C-N 115.433 -0.803 . . . . 1.0 108.883 167.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 65.79 -59.74 0.13 Allowed Glycine 0 CA--C 1.534 1.234 0 C-N-CA 126.839 2.162 . . . . 1.0 114.41 177.235 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 12.8 tmm? -128.81 -11.21 4.89 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 127.108 2.163 . . . . 1.0 112.666 175.537 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.653 HD13 ' CD1' ' A' ' 14' ' ' TRP . 2.5 mp . . . . . 0 CA--C 1.536 0.438 0 C-N-CA 128.687 2.795 . . . . 1.0 107.553 174.607 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.237 0 N-CA-C 110.169 -1.172 . . . . 1.0 110.169 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.2 tp -56.4 -47.96 77.92 Favored 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 124.442 1.097 . . . . 1.0 112.638 -170.538 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -63.58 -46.12 87.29 Favored 'General case' 0 C--N 1.33 -0.239 0 C-N-CA 124.406 1.082 . . . . 1.0 110.227 -177.016 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.33 -51.33 42.88 Favored Glycine 0 CA--C 1.53 1.025 0 CA-C-N 114.034 -1.439 . . . . 1.0 111.536 170.443 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.94 -39.09 90.88 Favored 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 117.953 0.877 . . . . 1.0 112.164 179.419 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.8 mt -63.57 -63.09 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.763 0 C-N-CA 127.568 2.347 . . . . 1.0 107.019 178.013 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.96 -29.44 63.21 Favored 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 112.537 0.569 . . . . 1.0 112.537 178.556 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.74 -53.43 34.73 Favored Glycine 0 CA--C 1.531 1.092 0 CA-C-N 119.447 1.021 . . . . 1.0 111.236 170.1 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -52.92 -30.77 36.39 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 124.955 1.302 . . . . 1.0 112.353 174.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -64.67 -14.04 15.46 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.846 0 C-N-CA 126.754 2.021 . . . . 1.0 111.456 -173.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -122.47 9.74 9.72 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 126.4 1.88 . . . . 1.0 110.749 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -140.37 -41.53 0.42 Allowed 'General case' 0 N--CA 1.465 0.323 0 O-C-N 121.096 -1.002 . . . . 1.0 113.522 -163.208 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -129.08 11.97 6.13 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 124.275 0.94 . . . . 1.0 112.046 175.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.559 ' CD1' HD11 ' A' ' 18' ' ' ILE . 54.0 t-105 -62.55 153.39 32.04 Favored 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 125.564 1.545 . . . . 1.0 113.405 -169.77 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.7 tp10 -161.95 116.67 1.93 Allowed 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 127.391 2.276 . . . . 1.0 106.578 159.083 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 172.63 -3.36 0.03 OUTLIER Glycine 0 CA--C 1.529 0.936 0 C-N-CA 129.066 3.222 . . . . 1.0 111.11 171.457 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 11.8 ttt -144.44 12.08 1.51 Allowed 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 124.3 1.04 . . . . 1.0 113.058 176.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.559 HD11 ' CD1' ' A' ' 14' ' ' TRP . 0.9 OUTLIER -103.37 33.42 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.647 0 CA-C-O 123.34 1.543 . . . . 1.0 108.34 167.26 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 23.6 t0 -74.3 91.04 2.15 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 126.649 1.98 . . . . 1.0 109.414 -172.23 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.968 0 C-N-CA 125.565 1.555 . . . . 1.0 112.894 -176.619 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.324 0 N-CA-C 110.127 -1.189 . . . . 1.0 110.127 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.0 tp -56.0 -48.35 76.06 Favored 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 124.414 1.085 . . . . 1.0 112.576 -170.118 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -63.62 -46.73 84.38 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 124.456 1.103 . . . . 1.0 110.192 -176.79 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.68 -49.17 54.43 Favored Glycine 0 CA--C 1.53 1.004 0 CA-C-N 114.022 -1.445 . . . . 1.0 111.6 171.043 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -63.76 -39.81 95.18 Favored 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 118.198 0.999 . . . . 1.0 111.925 178.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.2 mt -63.63 -63.05 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.775 0 C-N-CA 127.434 2.294 . . . . 1.0 107.173 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.27 -34.13 68.34 Favored 'General case' 0 CA--C 1.542 0.641 0 CA-C-O 119.33 -0.367 . . . . 1.0 111.648 177.696 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -59.25 -50.67 65.33 Favored Glycine 0 CA--C 1.531 1.055 0 O-C-N 120.65 -1.281 . . . . 1.0 111.271 172.168 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -54.43 -33.04 58.68 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 124.186 0.994 . . . . 1.0 111.86 173.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -66.71 -14.65 18.21 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.916 0 C-N-CA 126.115 1.766 . . . . 1.0 110.065 -173.023 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -111.44 -1.17 16.01 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 125.331 1.452 . . . . 1.0 112.154 177.619 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 49.1 m-80 -138.05 -43.11 0.52 Allowed 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 119.623 1.101 . . . . 1.0 113.202 -159.186 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -121.29 8.92 10.26 Favored Glycine 0 CA--C 1.526 0.738 0 C-N-CA 124.133 0.873 . . . . 1.0 111.724 176.578 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.535 ' CD1' HD11 ' A' ' 18' ' ' ILE . 55.1 t-105 -62.59 154.53 28.71 Favored 'General case' 0 N--CA 1.444 -0.726 0 C-N-CA 125.472 1.509 . . . . 1.0 113.028 -170.736 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -160.73 116.42 2.25 Favored 'General case' 0 N--CA 1.44 -0.95 0 C-N-CA 125.797 1.639 . . . . 1.0 106.977 159.048 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 175.38 -7.99 0.03 OUTLIER Glycine 0 CA--C 1.53 0.979 0 C-N-CA 128.98 3.181 . . . . 1.0 110.642 168.095 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . 0.463 ' HB3' ' HE1' ' A' ' 14' ' ' TRP . 8.0 tpt -133.1 8.41 4.04 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 125.174 1.39 . . . . 1.0 113.451 177.59 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.535 HD11 ' CD1' ' A' ' 14' ' ' TRP . 1.6 mp -103.27 34.02 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.665 0 CA-C-O 123.123 1.44 . . . . 1.0 108.288 170.223 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 17.7 t0 -76.61 95.75 4.01 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 125.977 1.711 . . . . 1.0 108.097 178.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.004 0 C-N-CA 125.148 1.356 . . . . 1.0 112.933 178.501 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.199 0 N-CA-C 109.956 -1.258 . . . . 1.0 109.956 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.4 tp -56.12 -48.83 75.46 Favored 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 124.519 1.128 . . . . 1.0 112.582 -171.153 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.2 t80 -63.62 -45.58 89.65 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 124.585 1.154 . . . . 1.0 109.988 -176.069 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.39 -50.27 53.38 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-N 114.026 -1.443 . . . . 1.0 111.648 170.525 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.83 -38.73 91.94 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 118.101 0.95 . . . . 1.0 112.134 178.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.2 mt -63.46 -63.18 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.774 0 C-N-CA 127.606 2.362 . . . . 1.0 106.877 178.268 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.68 -34.75 67.7 Favored 'General case' 0 CA--C 1.543 0.677 0 CA-C-O 119.263 -0.398 . . . . 1.0 111.809 178.375 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -60.6 -49.92 73.26 Favored Glycine 0 CA--C 1.531 1.047 0 O-C-N 120.667 -1.271 . . . . 1.0 111.348 172.691 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -55.39 -31.29 61.7 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 124.2 1.0 . . . . 1.0 112.064 173.191 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -67.59 -14.24 17.95 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.91 0 C-N-CA 125.761 1.624 . . . . 1.0 109.737 -173.799 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -110.08 -0.79 17.85 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 125.503 1.521 . . . . 1.0 111.94 177.592 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 50.3 m-80 -139.55 -41.68 0.45 Allowed 'General case' 0 N--CA 1.472 0.651 0 CA-C-N 119.74 1.155 . . . . 1.0 113.398 -159.259 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -124.45 9.05 8.29 Favored Glycine 0 CA--C 1.527 0.815 0 C-N-CA 124.222 0.915 . . . . 1.0 111.892 177.089 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.509 ' CD1' HD11 ' A' ' 18' ' ' ILE . 50.4 t-105 -60.21 154.68 19.19 Favored 'General case' 0 N--CA 1.446 -0.641 0 C-N-CA 125.789 1.636 . . . . 1.0 113.469 -171.393 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -160.83 116.56 2.23 Favored 'General case' 0 N--CA 1.44 -0.946 0 C-N-CA 125.703 1.601 . . . . 1.0 107.308 158.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 170.51 3.61 0.03 OUTLIER Glycine 0 CA--C 1.528 0.845 0 C-N-CA 128.554 2.978 . . . . 1.0 111.656 165.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 15.1 ttp -143.86 14.35 1.72 Allowed 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.017 1.327 . . . . 1.0 112.654 175.469 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.509 HD11 ' CD1' ' A' ' 14' ' ' TRP . 2.1 mp -103.31 37.3 0.27 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-O 122.914 1.34 . . . . 1.0 108.095 167.542 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 53.6 t0 -137.84 110.63 7.64 Favored 'General case' 0 N--CA 1.447 -0.577 0 C-N-CA 127.022 2.129 . . . . 1.0 107.432 170.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.035 0 C-N-CA 124.807 1.194 . . . . 1.0 111.546 165.463 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.313 0 N-CA-C 110.219 -1.152 . . . . 1.0 110.219 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.6 tp -56.39 -48.63 76.5 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 124.605 1.162 . . . . 1.0 112.57 -171.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.4 t80 -63.57 -45.86 88.53 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 124.348 1.059 . . . . 1.0 109.97 -177.129 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -51.67 -51.05 40.41 Favored Glycine 0 CA--C 1.531 1.038 0 CA-C-N 114.017 -1.447 . . . . 1.0 111.689 170.169 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.58 -39.45 93.74 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 118.26 1.03 . . . . 1.0 112.124 179.563 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.56 -63.05 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.763 0 C-N-CA 127.442 2.297 . . . . 1.0 106.969 178.23 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.04 -32.14 63.78 Favored 'General case' 0 CA--C 1.541 0.631 0 O-C-N 122.021 -0.424 . . . . 1.0 112.132 177.489 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -61.51 -52.84 48.54 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-N 119.951 1.251 . . . . 1.0 111.088 171.093 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -51.72 -33.67 35.47 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 124.192 0.997 . . . . 1.0 112.069 174.299 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -64.08 -13.96 14.55 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.907 0 C-N-CA 126.801 2.04 . . . . 1.0 111.333 -172.823 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -126.63 6.76 6.83 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 125.733 1.613 . . . . 1.0 111.711 178.517 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -139.23 -32.45 0.66 Allowed 'General case' 0 N--CA 1.471 0.61 0 O-C-N 121.231 -0.918 . . . . 1.0 112.805 -163.71 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -137.32 13.65 3.76 Favored Glycine 0 CA--C 1.526 0.735 0 C-N-CA 124.338 0.97 . . . . 1.0 111.627 174.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.478 ' CD1' HD11 ' A' ' 18' ' ' ILE . 56.8 t-105 -56.47 157.16 5.32 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 126.278 1.831 . . . . 1.0 113.648 -168.556 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -157.39 115.04 3.09 Favored 'General case' 0 N--CA 1.436 -1.171 0 N-CA-C 101.663 -3.458 . . . . 1.0 101.663 176.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 149.86 -4.01 0.62 Allowed Glycine 0 CA--C 1.531 1.045 0 C-N-CA 125.059 1.314 . . . . 1.0 114.866 167.637 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . 0.42 ' CB ' ' HE1' ' A' ' 14' ' ' TRP . 15.7 ttt -130.75 9.72 5.02 Favored 'General case' 0 CA--C 1.54 0.576 0 CA-C-N 118.847 1.324 . . . . 1.0 111.961 172.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.478 HD11 ' CD1' ' A' ' 14' ' ' TRP . 1.2 mp -103.34 42.0 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.522 0 N-CA-C 107.51 -1.293 . . . . 1.0 107.51 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -124.7 99.68 6.28 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 126.503 1.921 . . . . 1.0 107.085 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.533 1.175 0 CA-C-O 119.273 -0.737 . . . . 1.0 114.787 -176.431 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.251 0 N-CA-C 109.917 -1.273 . . . . 1.0 109.917 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 8.4 tp -54.83 -50.49 68.46 Favored 'General case' 0 N--CA 1.467 0.388 0 C-N-CA 124.586 1.154 . . . . 1.0 112.76 -169.581 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.2 t80 -63.71 -46.79 83.84 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 124.17 0.988 . . . . 1.0 110.383 -175.129 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.16 -51.03 49.25 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-N 114.032 -1.44 . . . . 1.0 111.428 171.408 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -60.97 -40.63 94.13 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 123.682 0.793 . . . . 1.0 111.835 178.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.3 mt -63.43 -63.21 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.794 0 C-N-CA 127.511 2.324 . . . . 1.0 107.082 178.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.99 -33.22 66.91 Favored 'General case' 0 CA--C 1.542 0.65 0 CA-C-O 118.999 -0.524 . . . . 1.0 112.148 179.634 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.37 -50.92 58.71 Favored Glycine 0 CA--C 1.532 1.097 0 CA-C-N 120.062 1.301 . . . . 1.0 111.339 171.431 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -53.42 -30.63 41.35 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 124.457 1.103 . . . . 1.0 112.22 173.744 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -66.93 -13.72 16.97 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.921 0 C-N-CA 126.27 1.828 . . . . 1.0 110.546 -173.645 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -112.18 1.72 16.35 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 125.054 1.342 . . . . 1.0 111.905 176.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 12.5 t30 -139.09 -48.64 0.49 Allowed 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 119.353 0.978 . . . . 1.0 112.862 -159.547 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -118.71 9.86 12.61 Favored Glycine 0 CA--C 1.527 0.833 0 C-N-CA 124.303 0.954 . . . . 1.0 111.965 178.117 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.403 ' CD1' HD11 ' A' ' 18' ' ' ILE . 65.0 t-105 -56.93 164.93 1.38 Allowed 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 126.395 1.878 . . . . 1.0 114.55 -168.372 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -150.13 91.16 1.74 Allowed 'General case' 0 N--CA 1.442 -0.869 0 C-N-CA 125.054 1.342 . . . . 1.0 111.265 -175.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 165.94 -16.13 0.09 OUTLIER Glycine 0 CA--C 1.529 0.942 0 CA-C-N 115.405 -0.816 . . . . 1.0 114.734 165.053 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 1.3 mpt? -107.69 6.78 28.04 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 124.38 1.072 . . . . 1.0 111.766 175.825 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.479 ' N ' HD12 ' A' ' 18' ' ' ILE . 1.6 mp -103.37 44.29 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.525 0 N-CA-C 106.844 -1.539 . . . . 1.0 106.844 -174.5 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 33.0 t0 -128.27 85.17 2.31 Favored 'General case' 0 CA--C 1.53 0.191 0 C-N-CA 125.925 1.69 . . . . 1.0 107.982 -179.171 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 0.998 0 C-N-CA 125.209 1.385 . . . . 1.0 110.398 -175.394 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.21 0 N-CA-C 110.155 -1.178 . . . . 1.0 110.155 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 8.7 tp -54.91 -49.05 72.22 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 124.522 1.129 . . . . 1.0 112.695 -169.147 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 12.2 t80 -63.76 -47.17 82.07 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 124.319 1.048 . . . . 1.0 110.538 -175.377 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.21 -51.11 48.96 Favored Glycine 0 CA--C 1.53 1.021 0 CA-C-N 114.072 -1.422 . . . . 1.0 111.287 171.187 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.19 -39.53 90.52 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 117.74 0.77 . . . . 1.0 111.952 179.28 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.47 -63.1 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.78 0 C-N-CA 127.654 2.381 . . . . 1.0 107.143 178.174 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.48 -29.93 64.67 Favored 'General case' 0 CA--C 1.539 0.543 0 N-CA-C 112.714 0.635 . . . . 1.0 112.714 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -66.58 -52.68 32.89 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-N 119.702 1.137 . . . . 1.0 111.206 170.094 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -52.43 -28.61 20.65 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 124.64 1.176 . . . . 1.0 112.3 174.415 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -64.83 -13.1 14.16 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.871 0 C-N-CA 125.98 1.712 . . . . 1.0 110.887 -175.568 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -126.82 6.94 6.71 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 126.357 1.863 . . . . 1.0 111.371 175.032 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 -147.69 90.61 1.87 Allowed 'General case' 0 C--N 1.341 0.196 0 O-C-N 120.956 -1.09 . . . . 1.0 109.291 -165.034 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 77.35 12.7 84.32 Favored Glycine 0 CA--C 1.532 1.124 0 CA-C-O 118.632 -1.094 . . . . 1.0 112.378 -169.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.449 ' CD1' HD11 ' A' ' 18' ' ' ILE . 55.8 t-105 -51.99 156.15 1.62 Allowed 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 125.492 1.517 . . . . 1.0 112.967 176.62 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -159.1 101.92 1.6 Allowed 'General case' 0 N--CA 1.445 -0.711 0 C-N-CA 126.241 1.816 . . . . 1.0 106.327 -179.224 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 159.5 -5.79 0.12 Allowed Glycine 0 CA--C 1.53 1.03 0 CA-C-O 118.861 -0.966 . . . . 1.0 115.254 171.373 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . 0.44 ' CB ' ' HE1' ' A' ' 14' ' ' TRP . 13.3 ttt -128.52 11.19 6.26 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 118.92 1.36 . . . . 1.0 111.947 174.095 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.449 HD11 ' CD1' ' A' ' 14' ' ' TRP . 1.7 mp -103.31 42.13 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 C-N-CA 124.977 1.311 . . . . 1.0 107.473 179.411 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 31.6 t0 -142.37 100.28 3.67 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 126.255 1.822 . . . . 1.0 106.894 -179.549 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.723 0 C-N-CA 123.86 0.743 . . . . 1.0 112.38 175.128 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.254 0 N-CA-C 110.165 -1.174 . . . . 1.0 110.165 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.5 tp -56.19 -48.63 76.01 Favored 'General case' 0 N--CA 1.468 0.449 0 C-N-CA 124.494 1.118 . . . . 1.0 112.659 -171.635 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -63.64 -45.42 90.32 Favored 'General case' 0 N--CA 1.455 -0.206 0 C-N-CA 124.18 0.992 . . . . 1.0 109.724 -178.11 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -50.74 -50.42 37.33 Favored Glycine 0 CA--C 1.532 1.13 0 CA-C-N 114.138 -1.392 . . . . 1.0 112.124 170.169 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -63.0 -41.53 99.61 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 118.143 0.972 . . . . 1.0 111.854 179.253 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.56 -63.01 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.843 0 C-N-CA 127.339 2.255 . . . . 1.0 106.695 179.663 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -54.25 -37.59 64.84 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.636 0.774 . . . . 1.0 111.814 177.332 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.34 -51.73 55.89 Favored Glycine 0 CA--C 1.531 1.049 0 CA-C-N 119.825 1.193 . . . . 1.0 111.42 173.346 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -58.46 -26.43 63.35 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 124.244 1.018 . . . . 1.0 112.712 174.031 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -68.91 -18.24 22.81 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.78 0 CA-C-N 119.776 1.171 . . . . 1.0 110.604 -172.123 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -109.53 0.73 19.35 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 125.873 1.669 . . . . 1.0 111.576 173.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 13.3 t-20 -152.05 95.84 2.12 Favored 'General case' 0 C--N 1.344 0.335 0 O-C-N 120.567 -1.333 . . . . 1.0 110.182 -159.287 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 74.94 11.16 83.92 Favored Glycine 0 CA--C 1.531 1.058 0 CA-C-O 118.583 -1.12 . . . . 1.0 112.414 -170.479 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.445 ' CD1' HD11 ' A' ' 18' ' ' ILE . 59.3 t-105 -50.25 154.96 1.08 Allowed 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 125.513 1.525 . . . . 1.0 113.105 175.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -159.22 100.63 1.54 Allowed 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 106.045 -1.835 . . . . 1.0 106.045 -178.146 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 162.51 -6.84 0.08 OUTLIER Glycine 0 CA--C 1.532 1.133 0 CA-C-O 118.762 -1.021 . . . . 1.0 115.278 173.369 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . 0.42 ' CB ' ' HE1' ' A' ' 14' ' ' TRP . 30.6 ttp -129.76 9.69 5.46 Favored 'General case' 0 CA--C 1.539 0.519 0 CA-C-N 119.128 1.464 . . . . 1.0 111.975 175.244 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.445 HD11 ' CD1' ' A' ' 14' ' ' TRP . 1.6 mp -103.29 42.6 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.506 0 N-CA-C 107.314 -1.365 . . . . 1.0 107.314 -178.02 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 25.4 t0 -130.63 95.82 3.95 Favored 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 126.102 1.761 . . . . 1.0 107.934 -174.179 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.405 0 N-CA-C 109.259 -1.536 . . . . 1.0 109.259 177.663 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.329 0 N-CA-C 110.027 -1.229 . . . . 1.0 110.027 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.5 tp -57.98 -47.65 82.36 Favored 'General case' 0 N--CA 1.466 0.365 0 C-N-CA 124.25 1.02 . . . . 1.0 112.325 -172.212 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.6 t80 -63.59 -44.75 93.13 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 124.306 1.042 . . . . 1.0 109.759 -177.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -51.63 -50.64 41.9 Favored Glycine 0 CA--C 1.533 1.191 0 CA-C-N 114.241 -1.345 . . . . 1.0 112.044 170.016 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -63.1 -40.07 96.56 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 118.369 1.084 . . . . 1.0 112.147 179.667 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.0 mt -63.58 -62.93 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.773 0 C-N-CA 127.673 2.389 . . . . 1.0 106.433 178.736 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -53.85 -32.46 53.05 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 123.599 0.76 . . . . 1.0 112.278 175.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -57.57 -53.98 40.78 Favored Glycine 0 CA--C 1.53 0.992 0 CA-C-N 119.81 1.186 . . . . 1.0 111.158 171.614 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -56.04 -28.01 55.63 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 123.657 0.783 . . . . 1.0 112.443 174.406 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -69.0 -10.27 13.16 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.889 0 C-N-CA 124.798 1.239 . . . . 1.0 110.446 -174.163 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -123.81 8.53 8.78 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 126.972 2.109 . . . . 1.0 110.946 176.452 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -156.46 92.99 1.36 Allowed 'General case' 0 C--N 1.343 0.294 0 O-C-N 120.513 -1.367 . . . . 1.0 109.285 -169.436 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 85.16 6.49 84.48 Favored Glycine 0 CA--C 1.53 0.988 0 CA-C-O 118.749 -1.028 . . . . 1.0 112.663 -172.183 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.54 ' CD1' HD11 ' A' ' 18' ' ' ILE . 55.3 t-105 -55.79 155.14 6.22 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 124.739 1.216 . . . . 1.0 112.525 176.791 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -162.16 104.06 1.13 Allowed 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 105.421 -2.066 . . . . 1.0 105.421 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 162.07 -8.59 0.1 OUTLIER Glycine 0 CA--C 1.528 0.895 0 CA-C-O 118.939 -0.923 . . . . 1.0 115.048 174.581 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 31.7 ttm -132.09 8.34 4.38 Favored 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 118.913 1.356 . . . . 1.0 112.257 174.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.54 HD11 ' CD1' ' A' ' 14' ' ' TRP . 0.7 OUTLIER -103.37 36.52 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.375 0 C-N-CA 124.695 1.198 . . . . 1.0 108.955 -179.476 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 32.4 t0 -146.09 97.74 2.99 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 125.398 1.479 . . . . 1.0 108.792 -175.023 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.789 0 CA-C-N 116.072 -0.513 . . . . 1.0 112.753 164.865 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.245 0 N-CA-C 110.211 -1.155 . . . . 1.0 110.211 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.9 tp -56.12 -48.85 75.41 Favored 'General case' 0 N--CA 1.467 0.388 0 C-N-CA 124.613 1.165 . . . . 1.0 112.604 -170.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.5 t80 -63.63 -46.05 87.45 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 124.341 1.056 . . . . 1.0 110.068 -176.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.55 -50.05 49.98 Favored Glycine 0 CA--C 1.53 1.015 0 CA-C-N 114.194 -1.367 . . . . 1.0 111.667 170.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.0 -40.94 97.36 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 118.174 0.987 . . . . 1.0 111.944 178.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.2 mt -63.58 -63.18 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.782 0 C-N-CA 127.509 2.324 . . . . 1.0 107.251 179.267 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -58.13 -29.17 65.33 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 123.508 0.723 . . . . 1.0 112.484 178.715 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.62 -54.29 29.78 Favored Glycine 0 CA--C 1.529 0.951 0 CA-C-N 119.464 1.029 . . . . 1.0 110.832 170.038 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -52.24 -28.62 19.35 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 124.413 1.085 . . . . 1.0 112.42 174.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -65.99 -11.63 12.92 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.867 0 C-N-CA 125.825 1.65 . . . . 1.0 111.016 -175.213 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -126.81 8.25 6.84 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 126.663 1.985 . . . . 1.0 110.877 174.32 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -148.1 83.53 1.51 Allowed 'General case' 0 C--O 1.234 0.274 0 O-C-N 120.817 -1.177 . . . . 1.0 108.719 -166.69 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 88.33 7.38 72.91 Favored Glycine 0 CA--C 1.531 1.054 0 CA-C-O 118.992 -0.893 . . . . 1.0 112.587 -173.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.496 ' CD1' HD11 ' A' ' 18' ' ' ILE . 55.8 t-105 -52.87 155.23 2.46 Favored 'General case' 0 N--CA 1.452 -0.336 0 C-N-CA 125.655 1.582 . . . . 1.0 113.185 175.698 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -160.35 102.65 1.4 Allowed 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 126.275 1.83 . . . . 1.0 106.124 178.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 167.92 -17.44 0.08 OUTLIER Glycine 0 CA--C 1.529 0.94 0 CA-C-O 118.842 -0.977 . . . . 1.0 114.959 170.247 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . 0.433 ' HB2' ' HE1' ' A' ' 14' ' ' TRP . 0.0 OUTLIER -126.68 19.14 7.31 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-N 118.828 1.314 . . . . 1.0 112.662 175.607 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.496 HD11 ' CD1' ' A' ' 14' ' ' TRP . 1.4 mp -103.26 43.63 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.465 0 N-CA-C 106.853 -1.536 . . . . 1.0 106.853 172.736 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -134.47 100.53 4.68 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 125.999 1.72 . . . . 1.0 107.749 -177.457 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.758 0 C-N-CA 124.925 1.25 . . . . 1.0 112.678 169.769 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.238 0 N-CA-C 109.808 -1.317 . . . . 1.0 109.808 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 14.9 tp -55.45 -51.4 67.06 Favored 'General case' 0 N--CA 1.466 0.351 0 C-N-CA 124.836 1.254 . . . . 1.0 113.068 -169.064 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.5 t80 -63.8 -46.25 86.0 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 124.155 0.982 . . . . 1.0 110.136 -176.348 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.73 -49.18 54.69 Favored Glycine 0 CA--C 1.532 1.12 0 CA-C-N 114.02 -1.446 . . . . 1.0 111.723 171.046 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.81 -40.26 96.83 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 118.059 0.93 . . . . 1.0 111.751 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.55 -63.02 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.835 0 C-N-CA 127.318 2.247 . . . . 1.0 106.969 178.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -55.93 -34.39 65.57 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 122.991 0.516 . . . . 1.0 112.141 178.296 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -61.91 -50.96 60.48 Favored Glycine 0 CA--C 1.531 1.089 0 O-C-N 120.817 -1.177 . . . . 1.0 111.328 172.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -56.81 -25.03 54.85 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 124.505 1.122 . . . . 1.0 112.58 173.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -68.43 -16.32 20.82 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.948 0 C-N-CA 124.571 1.148 . . . . 1.0 110.415 -172.779 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -110.69 1.85 18.17 Favored 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 125.752 1.621 . . . . 1.0 111.439 172.553 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -150.32 81.97 1.36 Allowed 'General case' 0 C--O 1.235 0.337 0 O-C-N 120.969 -1.082 . . . . 1.0 108.95 -160.454 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 95.41 -0.18 63.4 Favored Glycine 0 CA--C 1.53 0.988 0 CA-C-O 118.947 -0.918 . . . . 1.0 112.789 -176.18 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.532 ' CD1' HD11 ' A' ' 18' ' ' ILE . 57.5 t-105 -54.61 154.47 4.86 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 125.06 1.344 . . . . 1.0 112.661 173.257 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -158.09 116.53 3.08 Favored 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 125.729 1.612 . . . . 1.0 107.065 159.08 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 173.19 4.11 0.03 OUTLIER Glycine 0 CA--C 1.527 0.816 0 C-N-CA 128.582 2.991 . . . . 1.0 111.829 165.162 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 22.0 ttp -143.67 10.05 1.59 Allowed 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 125.173 1.389 . . . . 1.0 112.995 178.145 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.532 HD11 ' CD1' ' A' ' 14' ' ' TRP . 2.4 mp -103.14 40.73 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 CA-C-O 122.723 1.249 . . . . 1.0 107.635 172.311 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 30.2 t0 -132.5 101.44 5.33 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 126.955 2.102 . . . . 1.0 106.802 176.528 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.335 0.477 0 N-CA-C 109.927 -1.269 . . . . 1.0 109.927 -175.463 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.266 0 N-CA-C 110.112 -1.195 . . . . 1.0 110.112 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.3 tp -55.66 -49.13 73.73 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 124.656 1.182 . . . . 1.0 112.755 -170.506 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -63.63 -46.92 83.5 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 124.251 1.02 . . . . 1.0 110.134 -176.648 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.05 -50.06 46.81 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-N 114.083 -1.417 . . . . 1.0 111.61 171.16 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.26 -41.17 98.21 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 117.986 0.893 . . . . 1.0 111.928 178.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.2 mt -63.48 -63.24 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 C-N-CA 127.458 2.303 . . . . 1.0 107.196 179.606 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.87 -33.04 68.27 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 122.887 0.475 . . . . 1.0 111.98 179.014 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -61.0 -52.4 52.49 Favored Glycine 0 CA--C 1.53 1.004 0 CA-C-N 119.883 1.219 . . . . 1.0 111.09 171.671 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -54.4 -27.82 39.33 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 124.096 0.958 . . . . 1.0 112.396 173.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -68.38 -12.12 15.33 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.956 0 C-N-CA 125.199 1.399 . . . . 1.0 110.161 -174.595 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -117.11 1.77 12.57 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 125.92 1.688 . . . . 1.0 111.516 173.431 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -149.53 84.3 1.42 Allowed 'General case' 0 C--O 1.234 0.261 0 O-C-N 121.111 -0.993 . . . . 1.0 108.573 -160.167 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 87.68 6.73 76.31 Favored Glycine 0 CA--C 1.531 1.041 0 CA-C-O 118.725 -1.042 . . . . 1.0 112.613 -174.034 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.498 ' CD1' HD11 ' A' ' 18' ' ' ILE . 54.6 t-105 -53.68 152.49 5.2 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 124.878 1.271 . . . . 1.0 112.208 173.386 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -158.48 116.56 2.96 Favored 'General case' 0 N--CA 1.441 -0.924 0 C-N-CA 125.81 1.644 . . . . 1.0 107.042 159.147 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.407 ' H ' ' H ' ' A' ' 17' ' ' MET . . . 172.4 5.28 0.03 OUTLIER Glycine 0 CA--C 1.528 0.882 0 C-N-CA 129.248 3.308 . . . . 1.0 111.747 168.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . 0.414 ' CB ' ' HE1' ' A' ' 14' ' ' TRP . 23.2 ttm -147.91 10.77 0.93 Allowed 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 125.054 1.341 . . . . 1.0 113.329 178.868 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.498 HD11 ' CD1' ' A' ' 14' ' ' TRP . 3.1 mp -103.14 44.07 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.745 0 N-CA-C 106.581 -1.637 . . . . 1.0 106.581 172.225 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 17.6 t0 -123.4 96.61 5.05 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 127.458 2.303 . . . . 1.0 106.238 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.749 0 N-CA-C 109.527 -1.429 . . . . 1.0 109.527 -168.123 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.313 0 N-CA-C 110.478 -1.049 . . . . 1.0 110.478 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.4 tp -55.83 -48.19 75.91 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 124.528 1.131 . . . . 1.0 112.578 -170.543 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -63.65 -45.51 89.85 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 124.567 1.147 . . . . 1.0 110.123 -176.424 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.01 -50.89 49.33 Favored Glycine 0 CA--C 1.531 1.087 0 CA-C-N 113.973 -1.467 . . . . 1.0 111.595 170.302 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.8 -38.6 91.3 Favored 'General case' 0 CA--C 1.535 0.396 0 CA-C-N 118.126 0.963 . . . . 1.0 112.072 179.22 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.7 mt -63.58 -62.96 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 C-N-CA 127.516 2.326 . . . . 1.0 106.717 178.376 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.66 -34.21 69.13 Favored 'General case' 0 CA--C 1.541 0.635 0 CA-C-O 119.134 -0.46 . . . . 1.0 111.793 179.124 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -60.0 -50.21 70.16 Favored Glycine 0 CA--C 1.532 1.14 0 CA-C-N 120.049 1.295 . . . . 1.0 111.235 172.36 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -54.75 -31.06 58.04 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 124.242 1.017 . . . . 1.0 112.143 173.845 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -68.21 -11.83 14.87 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.822 0 C-N-CA 126.463 1.905 . . . . 1.0 111.112 -172.189 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -121.1 6.65 10.28 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 125.788 1.635 . . . . 1.0 111.348 176.714 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 27.1 t-20 -138.84 -45.87 0.48 Allowed 'General case' 0 N--CA 1.466 0.336 0 O-C-N 121.312 -0.867 . . . . 1.0 113.29 -161.665 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.24 14.49 8.29 Favored Glycine 0 CA--C 1.528 0.863 0 C-N-CA 124.687 1.137 . . . . 1.0 111.477 175.806 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.589 ' CD1' HD11 ' A' ' 18' ' ' ILE . 57.7 t-105 -60.13 163.05 5.17 Favored 'General case' 0 N--CA 1.447 -0.582 0 C-N-CA 126.281 1.832 . . . . 1.0 113.845 -168.017 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -150.06 95.48 2.29 Favored 'General case' 0 N--CA 1.445 -0.715 0 C-N-CA 125.271 1.429 . . . . 1.0 108.127 177.131 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 166.72 -5.0 0.05 OUTLIER Glycine 0 CA--C 1.534 1.27 0 N-CA-C 117.085 1.594 . . . . 1.0 117.085 171.562 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . 0.477 ' H ' HD12 ' A' ' 18' ' ' ILE . 4.0 ppp? -130.68 9.68 5.05 Favored 'General case' 0 N--CA 1.475 0.786 0 CA-C-N 119.541 1.67 . . . . 1.0 113.628 167.831 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.589 HD11 ' CD1' ' A' ' 14' ' ' TRP . 0.5 OUTLIER -103.3 42.29 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 N-CA-C 107.543 -1.28 . . . . 1.0 107.543 -176.615 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 11.3 p-10 -113.38 -0.97 14.33 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 126.172 1.789 . . . . 1.0 112.899 -160.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.085 0 N-CA-C 110.426 -1.07 . . . . 1.0 110.426 166.19 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.225 0 N-CA-C 110.131 -1.188 . . . . 1.0 110.131 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.1 tp -55.04 -49.13 72.34 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 124.625 1.17 . . . . 1.0 112.582 -170.778 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -63.77 -46.75 83.83 Favored 'General case' 0 C--N 1.331 -0.199 0 C-N-CA 124.325 1.05 . . . . 1.0 110.327 -176.316 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.52 -49.3 57.84 Favored Glycine 0 CA--C 1.531 1.071 0 CA-C-N 114.168 -1.378 . . . . 1.0 111.48 171.703 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.58 -39.78 94.79 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-N 117.989 0.895 . . . . 1.0 111.932 178.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.6 mt -63.75 -63.05 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.801 0 C-N-CA 127.524 2.33 . . . . 1.0 106.866 178.578 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -57.44 -31.63 66.09 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 122.972 0.509 . . . . 1.0 112.256 179.009 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.72 -51.55 52.95 Favored Glycine 0 CA--C 1.53 1.0 0 CA-C-N 119.954 1.252 . . . . 1.0 111.018 171.09 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -54.12 -26.68 28.7 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 124.072 0.949 . . . . 1.0 112.36 173.671 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -67.76 -10.04 11.72 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.878 0 C-N-CA 125.175 1.39 . . . . 1.0 110.59 -175.372 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -127.16 6.76 6.48 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 126.524 1.93 . . . . 1.0 111.376 173.788 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 13.1 t-20 -148.51 93.36 2.13 Favored 'General case' 0 C--N 1.342 0.239 0 O-C-N 120.81 -1.181 . . . . 1.0 109.691 -164.384 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 76.93 10.84 85.99 Favored Glycine 0 CA--C 1.533 1.187 0 CA-C-O 118.979 -0.901 . . . . 1.0 112.199 -167.623 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.5 ' CD1' HD11 ' A' ' 18' ' ' ILE . 53.2 t-105 -53.82 161.09 1.22 Allowed 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 126.06 1.744 . . . . 1.0 113.228 176.877 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -152.49 98.08 2.33 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 125.579 1.552 . . . . 1.0 107.754 177.391 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.411 ' H ' HD12 ' A' ' 18' ' ' ILE . . . 161.3 -4.44 0.09 OUTLIER Glycine 0 CA--C 1.531 1.074 0 N-CA-C 116.29 1.276 . . . . 1.0 116.29 170.026 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 4.3 ppp? -116.65 -0.9 12.25 Favored 'General case' 0 N--CA 1.47 0.551 0 CA-C-N 119.17 1.485 . . . . 1.0 112.695 169.451 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.5 HD11 ' CD1' ' A' ' 14' ' ' TRP . 1.4 mp -103.03 34.88 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.69 0 CA-C-O 123.281 1.515 . . . . 1.0 107.54 -168.076 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 24.1 t0 -91.38 93.1 8.87 Favored 'General case' 0 N--CA 1.454 -0.257 0 C-N-CA 125.8 1.64 . . . . 1.0 109.146 -171.376 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.962 0 C-N-CA 125.094 1.331 . . . . 1.0 112.952 174.435 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.173 0 N-CA-C 110.186 -1.165 . . . . 1.0 110.186 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.7 tp -55.84 -50.25 71.08 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 124.89 1.276 . . . . 1.0 112.963 -170.225 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.2 t80 -63.53 -47.93 79.62 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 124.077 0.951 . . . . 1.0 110.241 -176.806 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -50.89 -50.46 38.05 Favored Glycine 0 CA--C 1.53 0.969 0 CA-C-N 114.087 -1.415 . . . . 1.0 111.485 171.338 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.01 -43.23 99.19 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 117.896 0.848 . . . . 1.0 111.722 178.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.4 mt -63.51 -63.31 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.673 0 C-N-CA 127.246 2.218 . . . . 1.0 107.55 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -60.73 -27.85 68.23 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 123.579 0.752 . . . . 1.0 112.524 -179.226 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.55 -55.16 21.95 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 110.655 -0.978 . . . . 1.0 110.655 169.697 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -51.22 -31.41 20.46 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 124.657 1.183 . . . . 1.0 112.297 176.124 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -60.07 -17.53 14.03 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.737 0 C-N-CA 126.631 1.973 . . . . 1.0 111.615 -174.263 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -129.58 9.84 5.56 Favored 'General case' 0 CA--C 1.545 0.767 0 C-N-CA 125.942 1.697 . . . . 1.0 110.391 177.36 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -147.6 78.91 1.47 Allowed 'General case' 0 C--O 1.234 0.279 0 C-N-CA 124.869 1.268 . . . . 1.0 108.905 -170.055 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 98.96 -3.16 58.48 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-O 119.198 -0.779 . . . . 1.0 112.875 -177.65 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.608 ' CD1' HD12 ' A' ' 18' ' ' ILE . 24.6 t-105 -55.17 155.76 4.59 Favored 'General case' 0 N--CA 1.456 -0.174 0 C-N-CA 124.795 1.238 . . . . 1.0 112.321 168.362 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -157.01 116.23 3.38 Favored 'General case' 0 N--CA 1.428 -1.572 0 C-N-CA 124.875 1.27 . . . . 1.0 108.156 158.798 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -160.61 -102.68 0.18 Allowed Glycine 0 CA--C 1.524 0.598 0 C-N-CA 125.557 1.551 . . . . 1.0 109.487 169.639 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 4.8 mpp? -71.03 6.75 1.43 Allowed 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 124.718 1.207 . . . . 1.0 113.242 -177.659 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.608 HD12 ' CD1' ' A' ' 14' ' ' TRP . 48.6 mt -104.03 56.9 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.3 0 N-CA-C 105.769 -1.937 . . . . 1.0 105.769 176.22 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -133.1 102.14 5.48 Favored 'General case' 0 N--CA 1.453 -0.276 0 C-N-CA 125.596 1.558 . . . . 1.0 107.646 179.225 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.595 0 C-N-CA 125.096 1.331 . . . . 1.0 110.725 175.75 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.306 0 N-CA-C 110.225 -1.15 . . . . 1.0 110.225 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.1 tp -56.86 -49.18 76.24 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 124.57 1.148 . . . . 1.0 112.596 -171.268 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -63.65 -45.52 89.83 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 124.45 1.1 . . . . 1.0 110.128 -176.706 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.98 -50.16 56.07 Favored Glycine 0 CA--C 1.532 1.115 0 CA-C-N 114.031 -1.44 . . . . 1.0 111.497 171.097 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.08 -38.31 88.36 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 118.044 0.922 . . . . 1.0 112.095 179.145 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.9 mt -63.58 -63.22 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.694 0 C-N-CA 127.855 2.462 . . . . 1.0 107.299 176.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.8 -26.53 58.12 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 113.062 0.764 . . . . 1.0 113.062 177.773 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -67.32 -56.02 13.48 Favored Glycine 0 CA--C 1.531 1.073 0 CA-C-N 119.312 0.96 . . . . 1.0 111.066 168.35 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -47.98 -34.41 9.24 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 125.687 1.595 . . . . 1.0 112.193 175.058 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -57.29 -19.98 11.97 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.771 0 C-N-CA 127.336 2.254 . . . . 1.0 111.629 -175.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -132.15 15.09 4.66 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 126.783 2.033 . . . . 1.0 111.275 -178.355 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 21.4 t-20 -137.31 -33.45 0.74 Allowed 'General case' 0 N--CA 1.467 0.405 0 O-C-N 121.352 -0.842 . . . . 1.0 113.236 -170.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -139.42 9.21 3.2 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-O 119.017 -0.88 . . . . 1.0 112.53 174.647 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.675 ' CD1' HD12 ' A' ' 18' ' ' ILE . 35.3 t-105 -62.51 145.35 54.49 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 118.152 0.976 . . . . 1.0 113.271 -173.01 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 48.0 mt-10 -155.11 114.47 3.66 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 105.32 -2.104 . . . . 1.0 105.32 158.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -167.06 -24.79 0.02 OUTLIER Glycine 0 CA--C 1.53 0.982 0 N-CA-C 115.603 1.001 . . . . 1.0 115.603 168.738 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -133.74 -0.41 3.16 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 118.669 1.235 . . . . 1.0 112.962 172.235 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.675 HD12 ' CD1' ' A' ' 14' ' ' TRP . 59.8 mt -104.1 53.19 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.26 0 N-CA-C 105.147 -2.168 . . . . 1.0 105.147 -176.221 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 22.8 t0 -138.78 97.17 3.27 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 126.539 1.936 . . . . 1.0 106.683 -174.519 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.122 0 C-N-CA 123.898 0.761 . . . . 1.0 114.399 178.617 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.371 0 N-CA-C 109.89 -1.284 . . . . 1.0 109.89 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.3 tp -56.28 -48.58 76.34 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 124.419 1.088 . . . . 1.0 112.594 -170.552 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.1 t80 -63.7 -47.23 82.02 Favored 'General case' 0 N--CA 1.455 -0.206 0 C-N-CA 124.401 1.08 . . . . 1.0 110.105 -176.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -51.73 -50.61 42.61 Favored Glycine 0 CA--C 1.531 1.068 0 CA-C-N 114.178 -1.374 . . . . 1.0 111.538 171.156 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.18 -40.51 96.29 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 117.966 0.883 . . . . 1.0 112.031 179.197 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.9 mt -63.59 -63.18 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.704 0 C-N-CA 127.662 2.385 . . . . 1.0 107.061 178.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -58.84 -28.42 66.05 Favored 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 123.432 0.693 . . . . 1.0 112.513 179.261 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.1 -54.84 25.13 Favored Glycine 0 CA--C 1.528 0.894 0 CA-C-N 119.331 0.969 . . . . 1.0 110.762 169.782 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -51.92 -29.83 21.83 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 124.582 1.153 . . . . 1.0 112.478 175.443 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -61.98 -17.41 17.56 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.876 0 C-N-CA 126.055 1.742 . . . . 1.0 110.916 -175.432 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -123.17 6.45 9.16 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 127.04 2.136 . . . . 1.0 110.634 176.663 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -148.22 80.59 1.47 Allowed 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.596 1.159 . . . . 1.0 108.882 -167.265 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 96.29 -5.54 65.42 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 124.029 0.823 . . . . 1.0 113.049 -179.203 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.525 ' CD1' HD12 ' A' ' 18' ' ' ILE . 3.7 t-105 -60.03 155.24 17.34 Favored 'General case' 0 N--CA 1.456 -0.158 0 CA-C-N 118.027 0.913 . . . . 1.0 112.083 166.701 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -158.74 115.98 2.81 Favored 'General case' 0 N--CA 1.428 -1.534 0 C-N-CA 125.515 1.526 . . . . 1.0 107.784 158.708 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -168.79 -26.07 0.02 OUTLIER Glycine 0 CA--C 1.53 1.013 0 N-CA-C 115.57 0.988 . . . . 1.0 115.57 165.372 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 93.0 mtp -132.76 4.13 3.85 Favored 'General case' 0 N--CA 1.473 0.71 0 CA-C-N 118.947 1.374 . . . . 1.0 112.661 176.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.525 HD12 ' CD1' ' A' ' 14' ' ' TRP . 66.4 mt -104.18 54.05 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 N-CA-C 105.303 -2.11 . . . . 1.0 105.303 178.482 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 21.7 t0 -144.7 97.07 2.97 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 126.097 1.759 . . . . 1.0 107.617 -176.164 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.84 0 N-CA-C 110.598 -1.001 . . . . 1.0 110.598 177.351 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.309 0 N-CA-C 110.294 -1.122 . . . . 1.0 110.294 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.4 tp -56.33 -47.39 78.89 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 124.506 1.123 . . . . 1.0 112.454 -171.779 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 7.8 t80 -63.55 -45.45 90.48 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 124.54 1.136 . . . . 1.0 110.06 -176.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.69 -51.9 41.55 Favored Glycine 0 CA--C 1.531 1.059 0 CA-C-N 114.096 -1.411 . . . . 1.0 111.474 170.197 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.48 -38.43 87.24 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 118.061 0.931 . . . . 1.0 112.175 179.611 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 12.8 mt -63.65 -62.99 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.706 0 C-N-CA 127.721 2.408 . . . . 1.0 106.963 177.38 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.65 -27.4 58.47 Favored 'General case' 0 CA--C 1.541 0.597 0 N-CA-C 113.077 0.769 . . . . 1.0 113.077 177.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -67.75 -55.15 15.28 Favored Glycine 0 CA--C 1.53 0.971 0 CA-C-N 119.748 1.158 . . . . 1.0 110.797 169.078 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -49.14 -30.05 6.19 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 125.096 1.359 . . . . 1.0 112.568 174.799 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -59.6 -20.9 19.74 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.848 0 C-N-CA 126.409 1.884 . . . . 1.0 111.074 -177.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -121.64 4.57 10.09 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 126.454 1.902 . . . . 1.0 111.048 175.111 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -141.34 76.87 1.57 Allowed 'General case' 0 C--N 1.339 0.13 0 O-C-N 120.363 -1.461 . . . . 1.0 107.971 -166.453 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 93.54 4.27 64.09 Favored Glycine 0 CA--C 1.528 0.898 0 CA-C-O 118.434 -1.203 . . . . 1.0 113.364 -179.029 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.471 ' CD1' HD12 ' A' ' 18' ' ' ILE . 11.9 t-105 -53.82 148.64 9.86 Favored 'General case' 0 C--N 1.34 0.162 0 CA-C-N 118.925 1.362 . . . . 1.0 112.466 170.121 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -166.34 116.32 0.96 Allowed 'General case' 0 N--CA 1.441 -0.917 0 C-N-CA 125.077 1.351 . . . . 1.0 108.476 158.285 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -168.39 8.24 0.05 OUTLIER Glycine 0 CA--C 1.53 0.971 0 C-N-CA 126.26 1.886 . . . . 1.0 115.2 163.466 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 9.1 ttp -167.92 7.78 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.411 1.484 . . . . 1.0 113.189 -174.208 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.471 HD12 ' CD1' ' A' ' 14' ' ' TRP . 41.1 mt -123.12 43.01 0.68 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 N-CA-C 104.485 -2.413 . . . . 1.0 104.485 -179.068 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 10.4 p-10 -98.84 -5.35 31.21 Favored 'General case' 0 N--CA 1.462 0.17 0 C-N-CA 128.011 2.525 . . . . 1.0 113.948 -158.814 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.706 0 C-N-CA 125.176 1.37 . . . . 1.0 109.843 178.566 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.25 0 N-CA-C 110.382 -1.087 . . . . 1.0 110.382 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 15.0 tp -55.48 -48.77 74.03 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 124.822 1.249 . . . . 1.0 112.673 -172.574 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -63.44 -45.41 91.03 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 124.469 1.108 . . . . 1.0 110.01 -177.394 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.67 -49.86 51.52 Favored Glycine 0 CA--C 1.531 1.061 0 CA-C-N 114.126 -1.397 . . . . 1.0 111.796 170.211 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -63.6 -39.29 94.01 Favored 'General case' 0 CA--C 1.537 0.46 0 CA-C-N 118.298 1.049 . . . . 1.0 112.038 179.451 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.4 mt -63.39 -63.17 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.826 0 C-N-CA 127.586 2.354 . . . . 1.0 106.915 177.797 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -55.34 -32.63 62.68 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.033 0.533 . . . . 1.0 112.252 177.234 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -61.99 -52.24 51.54 Favored Glycine 0 CA--C 1.531 1.053 0 CA-C-N 119.879 1.218 . . . . 1.0 111.039 171.805 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -54.53 -26.84 34.25 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 124.196 0.998 . . . . 1.0 112.42 173.391 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -70.15 -9.41 12.4 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.043 0 C-N-CA 125.103 1.361 . . . . 1.0 109.653 -175.67 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -118.19 1.36 11.9 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 125.71 1.604 . . . . 1.0 111.468 171.738 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -151.96 81.19 1.27 Allowed 'General case' 0 C--O 1.234 0.261 0 O-C-N 121.072 -1.018 . . . . 1.0 108.707 -161.519 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 99.01 0.82 57.23 Favored Glycine 0 CA--C 1.531 1.075 0 CA-C-O 119.065 -0.853 . . . . 1.0 112.572 -173.366 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.762 ' CD1' HD13 ' A' ' 18' ' ' ILE . 62.4 t-105 -53.06 155.09 2.66 Favored 'General case' 0 N--CA 1.452 -0.356 0 C-N-CA 125.65 1.58 . . . . 1.0 112.728 174.576 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -141.79 -115.68 0.12 Allowed 'General case' 0 N--CA 1.442 -0.85 0 N-CA-C 105.047 -2.205 . . . . 1.0 105.047 -176.509 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 58.64 -75.58 0.01 OUTLIER Glycine 0 CA--C 1.531 1.086 0 C-N-CA 126.183 1.849 . . . . 1.0 113.437 -177.509 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 28.1 ttt -102.34 -10.6 19.34 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 125.35 1.46 . . . . 1.0 112.503 173.005 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.762 HD13 ' CD1' ' A' ' 14' ' ' TRP . 3.3 mp -103.3 41.68 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 C-N-CA 128.178 2.591 . . . . 1.0 106.126 176.749 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 42.6 t0 -76.19 96.41 3.9 Favored 'General case' 0 C--O 1.234 0.249 0 C-N-CA 125.129 1.372 . . . . 1.0 109.026 176.643 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.245 0 CA-C-O 118.174 -1.348 . . . . 1.0 114.535 177.158 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.271 0 N-CA-C 110.135 -1.186 . . . . 1.0 110.135 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.6 tp -56.65 -49.04 76.19 Favored 'General case' 0 N--CA 1.468 0.425 0 C-N-CA 124.51 1.124 . . . . 1.0 112.635 -170.478 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -63.71 -45.27 90.72 Favored 'General case' 0 C--O 1.225 -0.203 0 C-N-CA 124.358 1.063 . . . . 1.0 110.031 -176.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -52.83 -50.23 51.01 Favored Glycine 0 CA--C 1.532 1.145 0 CA-C-N 113.976 -1.465 . . . . 1.0 111.724 170.5 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -62.86 -39.05 93.2 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 118.258 1.029 . . . . 1.0 112.048 179.315 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.0 mt -63.73 -62.94 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 C-N-CA 127.384 2.274 . . . . 1.0 106.827 177.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -56.82 -31.74 65.03 Favored 'General case' 0 CA--C 1.542 0.644 0 N-CA-C 112.387 0.514 . . . . 1.0 112.387 178.326 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.66 -49.86 61.96 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-N 119.846 1.203 . . . . 1.0 111.329 172.018 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -54.24 -26.88 31.12 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 123.929 0.892 . . . . 1.0 112.241 172.478 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -68.84 -10.71 13.7 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.061 0 C-N-CA 124.878 1.271 . . . . 1.0 109.88 -174.523 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -118.71 2.51 11.68 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 126.027 1.731 . . . . 1.0 111.47 172.02 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -149.12 82.23 1.43 Allowed 'General case' 0 C--O 1.235 0.303 0 O-C-N 120.995 -1.066 . . . . 1.0 109.029 -164.167 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 97.23 -1.97 60.97 Favored Glycine 0 CA--C 1.532 1.094 0 CA-C-O 118.98 -0.9 . . . . 1.0 112.719 -175.783 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.853 ' CD1' HD13 ' A' ' 18' ' ' ILE . 56.1 t-105 -50.75 150.16 3.0 Favored 'General case' 0 C--O 1.233 0.202 0 C-N-CA 125.738 1.615 . . . . 1.0 113.055 173.326 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -123.94 -105.73 0.35 Allowed 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 126.827 2.051 . . . . 1.0 107.873 177.621 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 63.37 -68.91 0.03 OUTLIER Glycine 0 CA--C 1.534 1.24 0 CA-C-N 121.868 2.122 . . . . 1.0 114.683 174.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 67.5 mtt -123.56 -3.98 8.28 Favored 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 126.56 1.944 . . . . 1.0 112.937 172.627 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.853 HD13 ' CD1' ' A' ' 14' ' ' TRP . 3.2 mp -103.59 47.12 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 C-N-CA 128.327 2.651 . . . . 1.0 105.442 174.594 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 22.1 t0 -139.13 102.01 4.41 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 126.718 2.007 . . . . 1.0 106.532 173.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.748 0 N-CA-C 109.729 -1.348 . . . . 1.0 109.729 -171.765 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.289 0 N-CA-C 110.132 -1.187 . . . . 1.0 110.132 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.9 tp -55.39 -48.28 74.57 Favored 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 124.424 1.09 . . . . 1.0 112.737 -169.374 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -63.47 -47.1 83.19 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 124.453 1.101 . . . . 1.0 110.659 -174.78 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.56 -51.55 47.47 Favored Glycine 0 CA--C 1.531 1.042 0 CA-C-N 113.918 -1.492 . . . . 1.0 111.026 170.701 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -61.91 -37.08 83.28 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 117.806 0.803 . . . . 1.0 112.489 179.506 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 13.1 mt -63.53 -63.13 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 C-N-CA 127.771 2.429 . . . . 1.0 106.931 177.031 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -58.12 -27.79 64.06 Favored 'General case' 0 CA--C 1.539 0.547 0 N-CA-C 112.708 0.632 . . . . 1.0 112.708 179.417 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -67.48 -53.54 24.28 Favored Glycine 0 CA--C 1.531 1.055 0 CA-C-N 119.391 0.996 . . . . 1.0 111.302 169.502 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -51.44 -28.38 12.89 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 124.896 1.278 . . . . 1.0 112.397 174.338 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -65.98 -9.59 8.8 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.936 0 C-N-CA 126.161 1.784 . . . . 1.0 110.876 -175.858 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -130.13 8.9 5.2 Favored 'General case' 0 CA--C 1.545 0.751 0 C-N-CA 126.723 2.009 . . . . 1.0 110.811 173.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -148.41 81.77 1.47 Allowed 'General case' 0 C--O 1.234 0.287 0 O-C-N 120.826 -1.171 . . . . 1.0 108.466 -166.47 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 91.89 7.26 64.58 Favored Glycine 0 CA--C 1.531 1.047 0 CA-C-O 119.023 -0.876 . . . . 1.0 112.393 -171.318 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.653 ' CD1' HD13 ' A' ' 18' ' ' ILE . 60.4 t-105 -59.22 156.78 11.73 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 124.756 1.222 . . . . 1.0 112.098 175.684 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -140.02 -107.11 0.16 Allowed 'General case' 0 N--CA 1.449 -0.475 0 CA-C-N 115.433 -0.803 . . . . 1.0 108.883 167.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 65.79 -59.74 0.13 Allowed Glycine 0 CA--C 1.534 1.234 0 C-N-CA 126.839 2.162 . . . . 1.0 114.41 177.235 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 12.8 tmm? -128.81 -11.21 4.89 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 127.108 2.163 . . . . 1.0 112.666 175.537 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.653 HD13 ' CD1' ' A' ' 14' ' ' TRP . 2.5 mp -114.41 44.26 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.438 0 C-N-CA 128.687 2.795 . . . . 1.0 107.553 174.607 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -68.62 66.56 0.13 Allowed 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 128.792 2.837 . . . . 1.0 112.499 -176.353 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.073 0 C-N-CA 125.971 1.748 . . . . 1.0 114.758 -179.152 . . . . . . . . 0 0 . 1 stop_ save_